Programme book

XXth EVER CONGRESS

EVER 2017

NICE

SEPTEMBER 27-30

www.ever.be

Final version on 24/08/2017
Word from the president ................................................................................................................................... 3
About EVER .................................................................................................................................................. 4
Composition of the board 2017 .................................................................................................................... 6
Congress information ...................................................................................................................................... 9
Grants and prizes .......................................................................................................................................... 12
Floorplan ...................................................................................................................................................... 14
Partners of EVER ........................................................................................................................................ 16
About the programme book .......................................................................................................................... 18
Scientific sections 2017 ............................................................................................................................... 19
Industry Sponsored Symposium .................................................................................................................. 20
Courses ......................................................................................................................................................... 21

**Scientific Programme**

**Wednesday, September 27**

Noon session .................................................................................................................................................. 24
First afternoon session .................................................................................................................................... 29
Opening Ceremony ......................................................................................................................................... 33
Second afternoon session ............................................................................................................................ 34
European Ophthalmology Heritage Lecture by Alan C BIRD .................................................................... 39
Keynote Lecture: Carol SHIELDS............................................................................................................... 41

**Thursday, September 28**

First morning session ..................................................................................................................................... 44
EVER-Acta Lecture ...................................................................................................................................... 48
Second morning session ............................................................................................................................... 49
Lunchtime session ........................................................................................................................................ 53
Keynote Lecture by Shomi BHATTACHARVA ............................................................................................ 54
First afternoon session ............................................................................................................................... 55
Poster session 1............................................................................................................................................. 59
Second afternoon session ............................................................................................................................ 67
Evening session ............................................................................................................................................ 71

**Friday, September 29**

First morning session................................................................................................................................... 74
Keynote Lecture by Caroline KLAVER ....................................................................................................... 78
Second morning session ............................................................................................................................... 79
General Assembly ......................................................................................................................................... 83
First afternoon session ................................................................................................................................... 84
Poster session 2.............................................................................................................................................. 88
Section Business Meetings .......................................................................................................................... 95
Second afternoon session ............................................................................................................................. 96
Evening session - Chibret lecture ................................................................................................................ 100
EVER 20th Anniversary ............................................................................................................................... 101

**Saturday, September 30**

First morning session.................................................................................................................................. 104
Ophthalmic Research Lecture by Hendrik SCHOLL ................................................................................. 107
Poster session 3............................................................................................................................................ 108
Prize Award Ceremony & Closing Remarks .............................................................................................. 115
First afternoon session ............................................................................................................................... 116

Presenting First Authors .............................................................................................................................. 129
All Authors .................................................................................................................................................... 135
Authors by country ....................................................................................................................................... 145
Sponsors ......................................................................................................................................................... 146
Sight is our most precious sense, in fact, more than 80% of what we know is based on what we’ve seen. Any loss of sight has the power to devastate every aspect of a person’s life – until they develop new coping skills and strategies to deal with their family, work and social lives. At Allergan, we don’t want anyone’s life to be devastated by visual loss. That’s why we support research and development to protect sight, especially where patient needs are high and unmet.

We’re impatient for the day that everyone’s vision lasts a lifetime


Date of preparation: September 2017 FR/0428/2017
Word from the President

Dear EVER members, colleagues and friends,

I am honored and privileged to be President for EVER 2017. EVER flourishes because of you, EVER members and delegates. I am pleased to be able to serve and lead EVER, harnessing the energy and will of its members.

EVER remains the European meeting for scientific and clinical-scientific dialogue across our ophthalmic repertoire. It combines this with an increasing educational program and through links with other societies where EVER has an ever increasing presence.

Together with EVER support and mentorship through Woman for EVER program, young ophthalmic scientist programs makes EVER a vibrant community with much promise for the future. 2017 will continue in the EVER tradition, a culture for dissemination of great science, bringing highlights of top speakers and maintaining the social ambiance and fun afforded through the hospitality and ambiance of Nice.

Andrew DICK
President EVER 2017
The European Association for Vision and Eye Research, EVER, is a non-profit organisation. The aims of the association are to encourage research and the dissemination of knowledge concerning the eye and vision by means of meetings, publications and exchange of information. EVER is the leading ophthalmological research association in Europe which covers all areas of ophthalmology and the visual sciences. It provides an umbrella for other ophthalmological societies to meet during its annual congress and is an excellent place for networking.

Membership

EVER currently has members from 50 countries all over the world and represented by 11 scientific sections. Membership is open to individuals of any nationality, engaging in or with an interest in ophthalmic and vision research. Applications for membership - available on www.ever.be - may be submitted at any time, membership is on calendar year basis and starts on January 1. Every member must select one of the 11 scientific sections that best represents his or her primary area of interest.

The benefits of EVER membership are:
- significantly reduced registration fees for annual meeting
- submission of abstracts at annual meeting
- organizing Special Interest Symposia (SIS) and Courses
- free electronic subscription to the EVER journal, Acta Ophthalmologica (IF 3.157)
- voting rights for the election of the Board Members
- travel supports and poster prizes
- quarterly E-Newsletter

Elections 2017

Cast your vote for the elections of
- Secretary General
- Chair of section COS
- Chair of section Glaucoma

They will be elected by online voting. Voting will close on Thursday, September 28, midnight. The result of the elections will be announced at the General Assembly on Friday, September 29, 12:30 - 13:30.

Website: www.ever.be

On this website, you can
- obtain up-to-date information about the scientific programme and the EVER 2017 meeting and view the status (session, hour, place) of your presentation
- pay on-line and print your invoice
- access general information about EVER
- access Acta Ophthalmologica, the EVER journal
- cast your vote for officers
- print CME certificate after each congress you attended

Speakers’ affiliation to scientific sections

<table>
<thead>
<tr>
<th>Section</th>
<th>Retina / Vitreous</th>
<th>Glaucoma</th>
<th>Cornea / Ocular Surface</th>
<th>Anatomy / Cell Biology</th>
<th>Immunology / Microbiology</th>
<th>Neuro-ophthalmology / Strabismology / Paediatric / History</th>
<th>Molecular Biology / Genetics / Epidemiology</th>
<th>Physiology / Biochemistry / Pharmacology</th>
<th>Pathology / Oncology</th>
<th>Electrophysiology, physiological Optics, Vision Sciences</th>
<th>Lens / Cataract</th>
</tr>
</thead>
<tbody>
<tr>
<td>RV</td>
<td>17%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>G</td>
<td>14%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>COS</td>
<td>12%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ACB</td>
<td>9%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>M</td>
<td>9%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NSPH</td>
<td>9%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MBGE</td>
<td>8%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BUP</td>
<td>8%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PDP</td>
<td>7%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EOVS</td>
<td>4%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LC</td>
<td>4%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
EVER - European Association for Vision and Eye Research

www.ever.be

EVER is the leading ophthalmological research association in Europe which covers all areas of ophthalmology and the visual sciences. One of the main activities of EVER is the organizing of a high quality research meeting every year at a location chosen for its access and its agreeable autumn climate. EVER collaborates closely with other societies and encourages them to convene annually with EVER.

EVER - EVER Foundation

www.ever-f.eu

In 2010, the EVER Foundation was created to raise money to organize EVER Research Fellowships to offer to young ophthalmologists or young vision scientists, especially from Eastern Europe or from developing countries outside Europe, the opportunity to gain experience in laboratory techniques and scientific research in leading European Departments for Vision and Eye Research. The duration of the fellowship is limited to 6 months.

Fellowships 2016:
1. Dr. Mahajan DEEPTI, India - host institute: Vision Lab, Cardiff Centre for Vision Sciences, Cardiff University, UK
2. Dr. Narine ADZHEMIAN, Russia - host institute: Medical University of Vienna, Austria

Fellowships 2015:
1. Dr. Sepehr FEIZI, Iran - host institute: Queens Medical Centre, Nottingham, UK
2. Dr. Sabina SAPETA, Poland - host institute: Medical University of Vienna, Austria

Fellowships 2014:
1. Dr. Ganne PRATYUSHA, India - host institute: Vision Lab, Cardiff Centre for Vision Sciences, Cardiff University, UK
2. Dr. Mohamed Shafik Mohamed ELALFY, Egypt - host institute: Queens Medical Centre, Nottingham, UK

Fellowships 2013:
1. Dr. Reka ALBERT, Hungary - host institute: Queens Medical Centre, Nottingham, UK
2. Dr. Minika JASIELSKA, Poland - host institute: Department of Experimental Ophthalmology at the Charite University Medicine in Berlin, Germany

Acta Ophthalmologica

eu.wiley.com

Acta Ophthalmologica is the official scientific publication of the European Association for Vision and Eye Research (EVER) and of the five Nordic ophthalmological societies. Acta Ophthalmologica publishes clinical and experimental original articles, reviews, editorials, educational photo essays (Diagnosis and Therapy in Ophthalmology), case reports and case series, letters to the editor and doctoral theses. (IF 3.157)
COMPOSITION OF THE BOARD, 2017

Executive committee

Andrew DICK
President

Catherine CREUZOT
Secretary General

Steffen HEEGAARD
Treasurer

Aki KAWASAKI
Past President

Francesca CORDEIRO
Programme Secretary

Alain BRON
President Elect

Thomas FUCHSLUGER
Vice President Elect

Gerhard GARHOFER
Vice President

Marcela VOTRUBA
EVER liaison

EVER office by Mecodi

Marlene VERLAECKT
Executive Officer

Lies VAN EYCKEN
Executive Assistant

Mieke AKKERS
Executive Assistant

Kapucijnenvoer 33, 3000 Leuven, Belgium - ever@ever.be
www.mecodi.eu

Website and onsite support

COVR - IT solutions for scientific and medical associations
www.covr.be
Section chairs

Kai KAARNIRANTA
Anatomy / Cell Biology

Thomas FUCHSLUGER
Cornea / Ocular Surface

Miguel CASTELO-BRANCO
Electrophysiology, physiological
Optics, Vision Sciences

Alain BRON
Glaucoma

Piergiorgio NERI
Immunology / Microbiology

Rafael BARRAQUER
Lens / Cataract

Jochen GRAW
Molecular Biology / Genetics / Epidemiology

Dominique BREMOND-GIGNAC
Neuro-ophthalmology / Strabismology / Paediatric / History

Frédéric MOURIAUX
Pathology / Oncology

Manuel Vidal Sanz
Physiology / Biochemistry /

Peter WIEDEMANN
Retina / Vitreous Pharmacology

Pharmacology

EVER representatives in Acta Board

Aki KAWASAKI  Steffen HEEGAARD

Senior advisory committee

Jean-Jacques DE LAEY  Graham HOLDER
Jost JONAS  Einar STEFANSSON

Representatives

Bozena ROMANOWSKA-DIXON  Stephanie BAILLIF
Representative East Europe  Local representative France
Venue

EVER 2017 will be held at the Acropolis Convention Center in Nice, France
⇒ www.nice-acropolis.com

The scientific programme of the EVER congress starts on Wednesday, September 27 at 11:30 and concludes on Saturday, September 30 at 14:30.
Registration

Everyone attending the scientific sessions - whether or not an EVER member - must register and pay the registration fee. Onsite registration starts on Wednesday, September 27 at 9:00.

Please note that:
- being or becoming an EVER member – or having an abstract accepted – does not imply that you are registered
- if you register as a member-in-training, you need to prove your traineeship with a document signed by the Head of your Department
- if you register as an Eye-care, Technician or Nurse, you need to prove your status

Registration fees on-site

<table>
<thead>
<tr>
<th></th>
<th>EUR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Member / Course invited speakers</td>
<td>546</td>
</tr>
<tr>
<td>Member-in-training</td>
<td>275</td>
</tr>
<tr>
<td>Non-member</td>
<td>960</td>
</tr>
<tr>
<td>Non-member-in-training</td>
<td>440</td>
</tr>
<tr>
<td>Eye-Care / Technician / Nurse</td>
<td>220</td>
</tr>
</tbody>
</table>

EVER 20th Anniversary

- Friday, 18:15 - 18:45 Chibret lecture in room Hermes
- Friday 19:00 - 22:00 Walking dinner in the Exhibition area, Acropolis Convention Center

The EVER 20th Anniversary walking dinner is open for all participants and exhibitors.

Coffee / tea / refreshments

Included in the registration fee are the coffee / tea and soft drinks offered throughout the whole meeting. In addition coffee & croissants will be served early morning.

Photographs

It is strictly forbidden to take photographs or videos of the presentations in all lecture halls. Please respect this rule.

No-shows

Please note that any first author, whose paper or poster has been accepted, will be prohibited from presenting papers at EVER for the next two years if a valid reason is not sent to the EVER office in writing.

CME credits

Continued Medical Education credits

An application has been made to the UEMS EACCME® for CME accreditation of the EVER 2017 congress.

Internet access

Wi-Fi internet access is available in the Convention Center. Wifi login code: ever2017

Liability

The organisers cannot accept liability for personal accidents, loss of or damage to private property of participants and accompanying persons either during, or directly arising from the Meeting. Participants must make their own arrangements with respect to health and travel insurance.
DOWNLOAD THE EVER 2017 CONGRESS APP NOW

TO ENHANCE YOUR CONGRESS EXPERIENCE

All congress information in a nutshell:

Information about EVER - Browse sessions by day, type, section, ... - Visit the exhibitors and sponsors - My congress bag: create your personal agenda - Receive the latest news - Make notes - Rate sessions - etc.
Publication of the abstracts

The abstracts of the EVER 2017 congress are published on-line in a special issue of Acta Ophthalmologica, the EVER journal. Access for members only through EVER homepage.

Section Business Meetings

Friday, September 29 from 15:45 to 16:15

EVER Section Business Meetings of the scientific sections

- ACB ............................................. Gallieni 4
- COS ............................................ Rhodes 2
- EOVS ......................................... Rhodes 1
- G ................................................ Rhodes 1
- IM ............................................. Gallieni 1 & 2
- LC .............................................. Hermes
- MBGE ......................................... Gallieni 1 & 2
- NSHP ............................................ Rhodes 2
- PO ............................................. Rhodes 3
- PBP ............................................. Rhodes 3
- RV .............................................. Hermes

The sections

- LC
- RV

will nominate at least 2 candidates for the succession of their representatives in the Board of EVER for elections in 2018. 
Agenda see page 95

EVER General Assembly

Friday, 12:30 - 13:30 in room Hermes
Agenda see page 83

Prize award ceremony and Closing remarks

Saturday, 12:00 - 13:00 in room Hermes
Agenda see page 115

Women 4 EVER

Friday, September 29 from 11:00 to 12:30 in Gallieni 5

Women 4 EVER wishes to assist women in developing tools for career advancement and to foster gender equality in ophthalmology and visual science. We encourage mentorship, collaboration, and communication. In this informal and open session, we invite all interested members of EVER to come and meet colleagues, share experiences and ask for advice. It is also a venue where ideas about gender-based studies in ophthalmology may be developed. See page 82.

Coffee with Profs

Thursday, September 28 from 16:00 to 17:00 in poster area

In an initiative to encourage dialogue amongst speakers and EVER members, we have organised a session called “Coffee with Profs”. This will be a table of 6-8 “guests” at a table headed by one of the EVER speakers: Alfredo Sadun, Michael Belkin, a.o. The idea is to provide a casual yet personal venue where colleagues, in particular the younger faction, can share comments and ideas with an expert. 
See page 66.
Please sign in at the registration desk.

YOS for EVER

Young Ophthalmologist/Scientist

Thursday, September 28 from 17:00 to 18:30 in Gallieni 4

YOS is a well-recognized acronym for “young ophthalmologist” and as not only ophthalmologists attend EVER, YOS stands for “young ophthalmologist/scientist”. YOS for EVER represents the trainee and young specialist group within EVER. This is a networking assembly of students, residents, post-docs and junior scientists to focus on objectives and goals relevant to the early stages of career development. Such topics include board examinations, information exchange, research and/or educational programs, fellowship and job opportunities. The 2017 inaugural symposium will be organized by Gauti Jóhannesson, a young ophthalmologist/scientist and member of the organization committee for YOS sessions at the Nordic Ophthalmologic Congress. All interested parties are encouraged to attend as guidelines and objectives and representatives for this new subgroup will be discussed at this first meeting. Immediately following the symposium, there will be a reception with light food and beverages on site. See page 70.
We are pleased to announce that the following 14 members have received an EVER section Travel Support of 500 EUR each:

- **ACB - RANTA-AHO Sofia - Finland**
  T004 - Effects of HSP90 inhibitor TAS-116 on the inflammasome activation in ARPE-19 cells

- **COS - SMEDOWSKI Adrian - Poland**
  S026 - Confocal characterization of recurrent corneal erosion syndrome suspects

- **COS - JEPPESEN Helene - Denmark**
  1543 - Ocular Chronic Graft-Versus-Host Disease after allogeneic Haematopoietic Stem Cell Transplantation in Denmark (1971-2011): - Incidence and Risk Factors in Adults

- **EOVS - MAHAJAN Deepti - India**
  T061 - Can the retina be used to diagnose and plot the progression of Alzheimer’s disease?

- **G - ABBASI Mojdeh - Australia**
  4122 - Effects of Caveolin-1 ablation in the inner retina under healthy and experimental glaucoma conditions

- **G - LIM Suho - South-Korea**
  S040 - Comparative study of retinal nerve fiber layer and ganglion cell complex thickness between Korean patients with unilateral exfoliation syndrome and normal control

- **IM - HERETH Esther - France**
  3181 - Ocular inflammatory diseases in ebola survivors

- **LC - CHAMMAS Jimmy - France**
  S078 - Robotic surgery - a new way to perform cataract surgery

- **MBGE - VELISSARIS Stavros - United Kingdom**
  2684 - Characteristics, socioeconomic status and ethnic variations of primary idiopathic macular hole repair in vitreoretinal centers in the United Kingdom

- **NSPH - ROUX Lauriane - France**
  2673 - In vitro modeling of aniridia-related PAX6 haploinsufficiency by the use of CRISPR/Cas9 on limbal epithelial cells

- **PBP - SANCHEZ RAMON Ariadne - Spain**
  F088 - Influence of metabolic control in patients with refractory diabetic macular edema treated with Ozurdex

- **PO - CABRÉ ESTIVILL Eduard - Spain**
  S083 - Protein kinase inhibitors for targeting tumor-initiating cells in uveal melanoma

- **RV - CHOTARD Geraldine - France**
  F052 - Ocular manifestations associated with takayasu arteritis: a multimodal imaging study

- **RV - JENKINS Kevin Sean - Australia**
  F039 - Ophthalmoscopic and video OCT methods to detect spontaneous venous pulsation in individuals with apparently normal intracranial pressure: the rebirth of the SVP?

The Travel Support certificates will be handed over during the Prize Award Ceremony on Saturday, 12:00 - 13:00 in room Hermes.
EVER Poster Prizes

Poster Prizes will be awarded for the best posters across all sections.

The winners will be chosen by the poster moderators and will be announced in the Prize Award Ceremony on Saturday, 12:00 - 13:00 in room Hermes. No prize will be given after the congress. The winners will be waived registration to the EVER congress 2018.

Best paper for presentation

Certificate to be given at each free paper session of ‘best paper’ without money.
FLOORPLAN ACROPOLIS CONVENTION CENTER, 2nd FLOOR

Floorplan
EXHIBITION AREA

Exhibitors

- 108 - AOP
- 111 - Diagnosys UK Ltd
- 100 - Heidelberg Engineering
- 105 - Horus Pharma
- 109 - Novartis Pharma
- 110 - Topcon
- 102 - Thea Pharma
- 107 - Metrovision
- 103 - Wisepress

Poster area

Registration area
ARVO - Association for Research in Vision and Ophthalmology

www.arvo.org

In many senses the counterpart of EVER in North America, the purposes of ARVO are to encourage and assist research, training, publication, and dissemination of knowledge in vision and ophthalmology. Since 2005, EVER and ARVO are collaborating in many fields, including an ARVO symposium held every year during EVER and an EVER symposium scheduled during ARVO.

See page 75

EUROPEAN BOARD OF OPHTHALMOLOGY

EBO - European Board of Ophthalmology
ebo-online.org

The European Board was founded in 1992 to guarantee the highest standards of care in ophthalmology in the countries of the European Union by ensuring that the training is raised to the best possible level. It makes recommendations regarding the standards and syllabus for training ophthalmologists, assesses the content and quality of training by site visits and the annual EBO Diploma Examination, facilitates the exchange of trainees and teachers, and promotes CME in ophthalmology. EBO works under the Section of Ophthalmology of the European Union of Medical Specialists (UEMS). Since 2007, EBO has organized review courses open to all delegates during the EVER congress.

See pages 25, 30

EUROPEAN UNIVERSITY PROFESSORS OF OPHTHALMOLOGY

EUPO - European University Professors of Ophthalmology
www.eupo.eu

EUPO is the organizer of the annual structured subspecialty course for residents in training in Europe since 1988. Most of the ophthalmology curriculum is covered over a 4 year period to allow residents to get an overview of theoretical knowledge during their residency rotation. EUPO courses are held in different places in Europe. The EUPO 2018 course on Retina is organised in conjunction with the EVER congress in Nice, France.

See page 75

EUROPEAN FLUORESCEIN ANGIOGRAPHY CLUB

FAN - European Fluorescein Angiography Club
www.fan-int.org

The FAN Club started as a friendly reunion of pioneers of Medical Retina, in the early days of fluorescein angiography and laseroagulation of the retina. The FAN received a semi-official status, being invited to organize a session of Medical Retina Case Presentations during large meetings in Ophthalmology. The Club runs itself without official status, there is no membership fee, and no registration fee for the meetings. Upcoming meetings are decided within the group, trying to change the location from country to country, and offering all members the opportunity to organize at least once a full day reunion in their hospital. Since 2012, FAN has organised joint meetings open to all delegates during the EVER congress.

See page 96
FRO - Belgian Fund for Research in Ophthalmology

www.fro-online.org

The aim of the FRO association is to stimulate research in ophthalmology and in visual function by awarding grants to research projects carried out under order of Belgian institutions. The FRO candidates have presented their research work to an international jury during the EVER congress since 2002.

See pages 106, 119

GOA - Groupe Ophtalmo Allergo

In ocular surface pathologies the cooperation between clinical ophthalmology and allergology created the GOA. The GOA allowed the development of clinical research in ocular allergic disease. Vernal keratoconjunctivitis and atopic keratoconjunctivitis create severe ocular impairment that must be recognized and treated.

See page 81

OOG - The Ophthalmic Oncology Group

www.oog.eu

OOG is an independent scientific workgroup devoted to basic and clinical ophthalmic oncology. It has convened with EVER since 1998. The aims of the OOG are to improve the practice of ophthalmic oncology in Europe, develop internet-based databases to share scientific information, organise multicenter studies and quality control studies, and meetings and other activities with the aim of improving the treatment of eye tumours and knowledge about them. OOG encourages all EVER delegates to take part in its sessions.

See pages 97, 105, 117

Optic Nerve Meeting

www.optic-nerve-online.com

Intended for basic scientists and clinicians to address important topics in translational research, including scientists in interdisciplinary areas such as neurology, neurodegenerations and autoimmunity.

Next Optic Nerve Meeting: Obergurgl, Austria, December 12-14, 2017

See page 84
ABOUT THE PROGRAMME BOOK

Sessions

<table>
<thead>
<tr>
<th>BM</th>
<th>Business Meeting</th>
</tr>
</thead>
<tbody>
<tr>
<td>C</td>
<td>Course</td>
</tr>
<tr>
<td>CIS</td>
<td>Industry Sponsored Symposium</td>
</tr>
<tr>
<td>FP</td>
<td>Free Paper session</td>
</tr>
<tr>
<td>GA</td>
<td>General Assembly</td>
</tr>
<tr>
<td>JM</td>
<td>Joint Meeting</td>
</tr>
<tr>
<td>KN</td>
<td>Keynote lecture</td>
</tr>
<tr>
<td>SIS</td>
<td>Special Interest Symposium</td>
</tr>
<tr>
<td>SOC</td>
<td>Social</td>
</tr>
<tr>
<td>POS</td>
<td>Poster session</td>
</tr>
<tr>
<td>PS</td>
<td>Plenary session</td>
</tr>
</tbody>
</table>

Symbols

- EVER section travel support recipient
- Rapid fire presentation
- Conflict of interest disclosed

Scientific sections

- ACB = Anatomy / Cell Biology
- COS = Cornea / Ocular Surface
- EOVS = Electrophysiology, Physiological Optics, Vision Sciences
- G = Glaucoma
- IM = Immunology / Microbiology
- LC = Lens and Cataract
- MBGE = Molecular Biology / Genetics / Epidemiology
- NSPH = Neuro-ophthalmology / Strabismology / Paediatric Ophthalmology / History of Ophthalmology
- PBP = Physiology / Biochemistry / Pharmacology
- PO = Pathology / Oncology
- RV = Retina / Vitreous Section programme secretaries
Programme Secretary, Francesca M CORDEIRO

2017 Section programme secretaries

<table>
<thead>
<tr>
<th>Section</th>
<th>Description</th>
<th>Secretary</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACB</td>
<td>Anatomy/Cell Biology</td>
<td>Goran PETROVSKI</td>
</tr>
<tr>
<td>COS</td>
<td>Cornea/Ocular Surface</td>
<td>Thomas FUCHSLUGER</td>
</tr>
<tr>
<td>EOVS</td>
<td>Electrophysiology, Physiological Optics, Vision Sciences</td>
<td>Franziska RAUSCHER</td>
</tr>
<tr>
<td>G</td>
<td>Glaucoma</td>
<td>Eduardo NORMANDO</td>
</tr>
<tr>
<td>IM</td>
<td>Immunology/Microbiology</td>
<td>Joachim VAN CALSTER</td>
</tr>
<tr>
<td>LC</td>
<td>Lens and Cataract</td>
<td>Stefan LÖFGREN</td>
</tr>
<tr>
<td>MBGE</td>
<td>Molecular Biology/Genetics/Epidemiology</td>
<td>Petra LISKOA</td>
</tr>
<tr>
<td>NSPH</td>
<td>Neuro-ophthalmology/Strabismus/Paediatric Ophthalmology/History of Ophthalmology</td>
<td>Patrick YU-WAI-MAN</td>
</tr>
<tr>
<td>PBP</td>
<td>Physiology/Biochemistry/Pharmacology</td>
<td>Neville OSBORNE</td>
</tr>
<tr>
<td>PO</td>
<td>Pathology/Oncology</td>
<td>Alexandre MOULIN</td>
</tr>
<tr>
<td>RV</td>
<td>Retina/Vitreous</td>
<td>Anita LEYS</td>
</tr>
</tbody>
</table>
Courses throughout the EVER 2017 congress:

Wednesday, September 27

<table>
<thead>
<tr>
<th>Time</th>
<th>Room</th>
<th>Speaker</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:30</td>
<td>Rhodes 2</td>
<td>IM</td>
<td>EBO course: Intraocular inflammation and infection (part I)</td>
</tr>
<tr>
<td>11:30</td>
<td>Rhodes 4</td>
<td>ACB</td>
<td>Why and how to perform proteomics?</td>
</tr>
<tr>
<td>11:30</td>
<td>Gallieni 4</td>
<td>EOVS</td>
<td>Basic principles of state-of-the-art ophthalmic instrumentation</td>
</tr>
<tr>
<td>14:00</td>
<td>Rhodes 2</td>
<td>IM</td>
<td>EBO course: Intraocular inflammation and infection (part II)</td>
</tr>
<tr>
<td>14:00</td>
<td>Rhodes 3</td>
<td>LC/RV/COS</td>
<td>Flat-mount techniques of eye tissues</td>
</tr>
<tr>
<td>16:50</td>
<td>Rhodes 1</td>
<td>G</td>
<td>Glaucoma HotTopics Course in association with EVICR.net</td>
</tr>
<tr>
<td>16:50</td>
<td>Gallieni 4</td>
<td>ACB</td>
<td>Imaging in retinal disease models and differential diagnosis</td>
</tr>
</tbody>
</table>

Thursday, September 28

<table>
<thead>
<tr>
<th>Time</th>
<th>Room</th>
<th>Speaker</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30</td>
<td>Rhodes 4</td>
<td>PO</td>
<td>Ophthalmic pathology: new and old insights</td>
</tr>
<tr>
<td>14:30</td>
<td>Rhodes 4</td>
<td>PO</td>
<td>Tumors and pseudo-tumors of the iris: diagnosis and management</td>
</tr>
<tr>
<td>17:00</td>
<td>Rhodes 4</td>
<td>COS</td>
<td>An update on corneal infectious diseases</td>
</tr>
<tr>
<td>17:00</td>
<td>Gallieni 4</td>
<td>G</td>
<td>YOS - The ABC of fellowship opportunities - what to expect, where to go and how to pay for it?</td>
</tr>
</tbody>
</table>

Friday, September 29

<table>
<thead>
<tr>
<th>Time</th>
<th>Room</th>
<th>Speaker</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30</td>
<td>Rhodes 4</td>
<td>EOVS/MBGE</td>
<td>Structure and function in retinal disease; the role of iscev standard electrophysiology</td>
</tr>
<tr>
<td>16:20</td>
<td>Gallieni 1+2</td>
<td>PBP</td>
<td>Noninvasive morphological and functional imaging in the eye</td>
</tr>
</tbody>
</table>

Saturday, September 30

<table>
<thead>
<tr>
<th>Time</th>
<th>Room</th>
<th>Speaker</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00</td>
<td>Hermes</td>
<td>RV</td>
<td>OCT-angiography for the evaluation and management of macular pathologies</td>
</tr>
</tbody>
</table>
EVER 2017
WEDNESDAY
SEPT 27
WEDNESDAY, SEPT 27 - NOON SESSION

11:30 - 13:00 | HERMES
RV - Anti-VEGF, surgery, toxic maculopathy

**1111**
11:30
SOUIED E, POURNARAS C
Ranibizumab in patients with neovascular age-related macular degeneration: results from the real-world LUMINOUS™ study

**1112**
11:42
MCCLOSKEY C, Mongan AM, Chetty S, McAteer D, Quinn S - Sligo
Aflibercept in neovascular age related macular degeneration previously refractory to standard intravitreal therapy: An Irish perspective to compare against international trends

**1113**
11:54
Internal limiting membrane peeling in retinal detachment complicated by grade B proliferative vitreoretinopathy

**1114**
12:06
ESPOSTI G, Esposti PL, Fruschelli M, Hadjistilianou T - Siena
Photostimulation with subthreshold yellow micropulsed laser for chronic residual subfoveal rhegmatogenous retinal detachment after surgery

**1115**
12:12
Evaluation of efficacy and safety of dexamethasone intravitreal implants between vitrectomized and non-vitrectomized eyes in a real-life study

**1116**
12:18
MURPHY R, James M, Cullinane A - Dublin
Popper associated maculopathy – Case report and literary synthesis

11:30 - 13:00 | RHODES 1
G - Advances in glaucoma diagnosis

**1121**
11:30
NORMANDO EM, CORDEIRO MF
Automated gonioscopy photography for iridocorneal angle grading

**1122**
11:42
SODERBERG P, Malmberg F, Sandberg-Melin C - Uppsala
Subject specific angular waist of the optic nerve head nerve fiber layer allows follow up detection of local nerve fiber bundle loss

**1123**
11:54
Advanced vascular exams improve the accuracy of conventional parameters in distinguishing normal tension from primary open angle glaucoma

**1124**
12:06
EDAWAJI B, Proudlock F, Gottlob I - Leicester
Changes of anterior chamber morphometry with age in children using hand-held spectral domain optical coherence tomography

**1126**
12:24
PANTALON A, Chisellita D, Feraru C - Iasi
Screening for glaucoma progression by using non-parametric tests

**1127**
12:30
BONO V, Normando EM, Davis B, Cordeiro MF - Avellino
Prospective comparison of global visual field indices and cluster progression in glaucoma and their relationship to structural changes

**1128**
12:36
EDAWAJI B, Shah S, Proudlock F, Gottlob I - Leicester
Reproducibility of angle metrics in children using hand-held spectral domain optical coherence tomography: intra-observer and inter-observer variability
The aim of this course is to review major topics of intraocular inflammation and infection. MCQs will be proposed during the course to evaluate the basic knowledge of the participants. The test will be associated with 6 consecutive general presentations for the understanding of different uveitis features. The course will be interactive allowing general discussion and the participation of the audience. MCQs will be discussed during each presentation. At the end of this course, participants will be prepared for the MCQ part of the EBO examination in uveitis.

**BODAGHI B, HERBORT JR. CP**

<table>
<thead>
<tr>
<th>Course Code</th>
<th>Time</th>
<th>Title</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>1131</td>
<td>11:30</td>
<td>Pathophysiology of uveitis</td>
<td>DICK A - Bristol</td>
</tr>
<tr>
<td>1132</td>
<td>11:45</td>
<td>Classification of uveitis</td>
<td>MARKOMICHELAKIS N - Athens</td>
</tr>
<tr>
<td>1133</td>
<td>12:00</td>
<td>Signs and symptoms of uveitis</td>
<td>NERI P, Calamita R, Pelliccioni P, Gorgoni F, Lassandro N, Pirani V - Agugliano</td>
</tr>
<tr>
<td>1134</td>
<td>12:15</td>
<td>Laboratory work-up and specialized investigations</td>
<td>KHAIRALLAH M, Khochtali S, Jelliti B - Monastir</td>
</tr>
<tr>
<td>1135</td>
<td>12:30</td>
<td>Imaging in uveitis: modalities and applications</td>
<td>HERBORT CP - Lausanne</td>
</tr>
<tr>
<td>1136</td>
<td>12:45</td>
<td>Therapeutic management of uveitis</td>
<td>DICK A - Bristol</td>
</tr>
</tbody>
</table>

**SIS**

Advancement of technology creates more opportunities to study both structure and physiology of the retina through imaging. This special interest symposium will discuss various aspects of physiological imaging. Blood flow measurements with three technologies will be covered: OCT, laser speckle flowgraphy and adaptive optics. The SIS will also include discussion of analysis of retinal vessel diameters and retinal vessel oximetry.

**HARDARSON S, HEITMAR R**

| Course Code | Time  | Title                                                                                     | Speakers                                                                    |
|-------------|-------|-------------------------------------------------------------------------------------------|                                                                            |
| 1141        | 11:30 | Measurement of retinal blood flow using Doppler OCT in diabetic retinopathy                | BEKT - Aarhus C                                                            |
| 1142        | 11:48 | Retinal oximetry in central retinal vein occlusion                                        | JEPPESEN SK, BEKT - Aarhus C                                               |
| 1143        | 12:06 | Retinal microvascular imaging with adaptive optics                                         | KALITZEOS A - London                                                       |
| 1144        | 12:24 | Static vessel parameters in health and disease                                            | HEITMAR R - Birmingham                                                     |
Proteomics is a powerful tool to analyze complex mechanisms in cells and tissues. It can be used for discovery of proteomic biomarkers. They can predict risk of disease, most suitable therapeutic options, complications of the diseases or therapies. Biomarkers can reflect the severity of the disease or act as end points for clinical studies. The idea of this course is give practical advice why, when and how to perform proteomic analyses and how to select the most suitable technology for experimental or clinical studies.

**UUSITALO H, BEUERMAN R**

<table>
<thead>
<tr>
<th>1151</th>
<th>11:30</th>
<th>Using biomarkers in clinical trials in ophthalmology</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td><strong>BEUERMAN R - Singapore</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>1152</th>
<th>11:52</th>
<th>Executing clinical proteomic studies using mass spectrometry</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td><strong>JYLHA A - Tampere</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>1153</th>
<th>12:14</th>
<th>Bioinformatic analysis of experimental and clinical proteomic data</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td><strong>NATTINEN J - Tampere</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>1154</th>
<th>12:36</th>
<th>Practical examples of proteomic studies</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td><strong>UUSITALO H - Tampere</strong></td>
</tr>
</tbody>
</table>

During embryonic development of the eye, transcription factors and signaling molecules play important roles in the coordination of the process and the differentiation of the various cell types into the complex system of an eye. Errors in these processes lead to congenital diseases affecting the cornea, the lens, the retina, the optic nerve and in many cases the entire eye. The speakers of this SIS will discuss the cellular and molecular principles of vertebrate eye development using different model organisms, but also including human data.

**GRAW J, CVEKL A**

<table>
<thead>
<tr>
<th>1161</th>
<th>11:30</th>
<th>Neural retina identity is specified by lens-derived BMP signals</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td><strong>GUNHAGA L, Pandit T, Patthey C, Jidigam V - Umeå</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>1162</th>
<th>11:48</th>
<th>The role of Meis genes is lens and retina development</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td><strong>KOZMIK Z, Antosova B - Prague</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>1163</th>
<th>12:06</th>
<th>Neural crest FGF signaling controls lacrimal gland development</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td><strong>Garg A, ZHANG X - New York</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>1164</th>
<th>12:24</th>
<th>Genes and regulation of eye development</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td><strong>SEMINA E, Sorokina E, Muheisen S, Hendee K, Weh E, Reis L - Iowa City</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>1165</th>
<th>12:42</th>
<th>Transcriptional dynamics, denucleation, and gene regulation in embryonic lens development</th>
</tr>
</thead>
</table>
This course is aimed at providing an overview of the basic principles of various state-of-the-art ophthalmic instruments such as scanning laser ophthalmoscopy, optical coherence tomography, as well as adaptive optics. The goal is to illuminate for the clinician and scientist the underlying optical concepts and principles of various devices, even when not familiar with the particular technology employed within the instrument.

IRSCH K, BERNARDES R

1171  11:30  Scanning laser ophthalmoscopy – basic optical principles  
      IRSCH K - Paris

1172  11:45  Optical coherence tomography – basic optical principles  
      IRSCH K - Paris

1173  12:10  Optical coherence tomography – machine learning  
      BERNARDES R, Castelo-Branco M - Coimbra

1174  12:35  Adaptive optics – basic optical principles  
      IRSCH K - Paris
BIRD AC, BHATTACHARYA SS

1181  11:30  Omega-3 fatty acids supplementation: therapeutic potential in a mouse model of Stargardt's disease

1182  11:40  Vision improvement in dry and wet Age-Related Macular Degeneration (AMD) patients after treatment with new corneal CPV procedure for light redirections onto the retina
       SERDAREVIC O, Tasindi E, Dekaris I, Berry M - Goshen

1183  11:50  Optical coherence tomography angiography in occlusive retinal vasculitis

1184  12:00  Choroidal thickness assessed by swept-source optical coherence tomography in patients with diabetes

1185  12:10  Bilateral quantification of vascular density in diabetic patients using optical coherence tomography angiography

1186  12:20  Differential diagnosis of cystoid macular edema by optic disc thickness in optical coherence tomography
       CARDIGOS J, Crisostomo S, Basilio A, Costa L, Carvalho B, Vieira L, Flores R - Lisbon

1187  12:30  Macular thickness after intraocular pressure reduction following trabeculectomy
       DRUKTEINIENE E, Strelkauskait E, Kaziauskien A, Asoklis R, Schmetterer L - Vilnius

1188  12:40  27-Gauge vitrectomy – the smaller the better?
       FALKNER-RADLER C, Bukaty E, Krebs I - Vienna

1189  12:50  Bidirectional cross talk between uveal melanoma cells and hepatic myofibroblasts promotes inflammation-induced chemokines expression
       BABCHIA N, Landreville S, Clement B, Coulouarn C, Mouriaux F - Rennes

1190  13:00  Intracanal hybrid neurofibroma - schwannoma of the orbit
       VERHELST E, Lauwers N, Siozopoulou V, De Keizer RWJ, De Groot V - Antwerpen

1191  13:10  Alternated intra-arterial and intravitreal chemotherapy: successes and failures of advanced intraocular retinoblastoma treated without systemic chemotherapy
       DE FRANCESCO S, Hadjistilianou T, Borri M - Siena

1192  13:20  Nanostructured hydroxyapatite used as an augmenting material to expand the orbit
       POPA CHERECHEANU A, Istrate S, Ianuc R, Popescu M, Bastian A, Ciuluvica R - Bucharest

1193  13:30  The advantages of serological tests of blood and tears for the diagnosis and the follow up of corneal rickettsiosis
       BENABDERRAHIM K, Feki J, Khairallah M - Medenine
RV - OCT-angiography for the evaluation and management of macular pathologies

OCT angiography (OCT-A) as a new non-invasive imaging technology that enables the monitoring of the macular retinal and choroidal circulation.

OCT-A allows a detailed detection either of the macular retinal capillaries plexus as well as the subretinal choroidal neovascularisation. The correlation of OCT-A with OCT longitudinal or “en face” sections resulted to a better understanding of the pathologic features of the macular degenerative or vascular pathologies. OCT-A became a useful imaging modality in the evaluation and management of macular hemodynamic changes observed during the evolution of the retinal ischemic micronagiopathies, age related maculopathies related to a subretinal neovascularisation as well as the vitreoretinal interface surgical pathologies.

The aim of this course is to present the most recent findings for the evaluation of macular pathologies and to have an interactive session.

COSCAS G , POURNARAS C

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>1311</td>
<td>14:00 Principles and techniques; pearls and pitfalls</td>
<td>LUPIDI M , Coscas G , Coscas F - Perugia</td>
</tr>
<tr>
<td>1312</td>
<td>14:12 OCT-A et critères d’activité</td>
<td>COSCAS G , Lupidi M , Coscas F - Creteil</td>
</tr>
<tr>
<td>1313</td>
<td>14:24 OCT-A and VRO</td>
<td>COSCAS F , Coscas G , Souied EH - Creteil</td>
</tr>
<tr>
<td>1314</td>
<td>14:36 OCT-A A in CSC and in MacTel type 2</td>
<td>MAUGET-FAYSSE M , Wolff B , Vasseur V , De Bats F - Paris</td>
</tr>
<tr>
<td>1315</td>
<td>14:48 OCT-A in ocular oncology</td>
<td>ZOGRAFOS L - Lausanne</td>
</tr>
<tr>
<td>1316</td>
<td>15:00 OCT-A: Diagnosis and management of surgical macular pathologies</td>
<td>POURNARAS C - Genève</td>
</tr>
<tr>
<td>1317</td>
<td>15:12 OCT-A and Diabetic maculopathy; automated assessment</td>
<td>LUPIDI M , Cagini C , Coscas F , Coscas G - Perugia</td>
</tr>
</tbody>
</table>

G - Glaucoma neuroprotection - feasibility and application

This SIS which is also organised through the auspices of the European Glaucoma Society Special Interest Group hopes to update the glaucoma community on what is happening in terms of neuroprotection in glaucoma.

It will address the following questions:
- Can we use neuroprotection in glaucoma?
- What proof do we currently have?
- Is it feasible?
- If we can, which patients would benefit?

CORDEIRO MF , LEVIN L

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>1321</td>
<td>14:00 Doctor is there anything else that I can do for my glaucoma?: Alternative therapy for glaucoma, what is the evidence?</td>
<td>SUNARIC MEGEYAND G - Geneva</td>
</tr>
<tr>
<td>1322</td>
<td>14:30 Do we need to treat?</td>
<td>MEIER-GIBBONS F - Rapperswil</td>
</tr>
<tr>
<td>1323</td>
<td>15:00 Is it feasible to treat?</td>
<td>LEVIN L - Montreal</td>
</tr>
</tbody>
</table>
The first part on general aspects of uveitis will be followed by case presentations in different basic or more challenging situations. Important points will be discussed during each practical situation. The course will be interactive allowing general discussion and the participation of the audience. It will be intermediate and present entities that are frequently observed in routine. At the end of this course, participants will be prepared for the viva voce part of the EBO examination in uveitis.

**BODAGHI B, HERBORT JR. CP**

- **1331** 14:00 B27-associated uveitis, Fuchs uveitis
  - WILLERMAIN F - Bruxelles
- **1332** 14:18 Infectious posterior uveitis
  - MARKOMICHELAKIS N - Athens
- **1333** 14:36 Behçet’s disease, VKH, sarcoidosis
  - KHAIRALLAH M, KSIAA I, JELLITI B - Monastir
- **1334** 14:54 Choroiditis (non-infectious)
  - HERBORT CP - Lausanne
- **1335** 15:12 Retinal vasculitis
  - BODAGHI B - Paris

This is a cross-sectional course inviting participants from the Cornea/Ocular surface, Lens/Cataract and Retina/Vitreous Sections. The course aims at describing various techniques in flat-mounting ocular tissues. Flat-mounting is a necessity for many subsequent analytic techniques involving optics, and the globular shape of the eye introduces technical challenges when a flat-mount is performed.

**LOFGREN S, THURET G**

- **1341** 14:00 Flat-mount preparation of cornea
  - THURET G, He Z - Saint Etienne
- **1342** 14:30 Flat-mount preparation of lens epithelium
  - LOFGREN S - Stockholm
- **1343** 15:00 Flat-mount of retina, including preparation of choroid and iris
  - ANDRE H - Stockholm
**WEDNESDAY, SEPT 27 - FIRST AFTERNOON SESSION**

### MBGE - Grand rounds in human and mouse ophthalmic genetics

This SIS will provide a forum to discuss clinical and molecular cases with peers and leaders from the field of ophthalmic genetics, with the specific aim to stimulate interaction between human and mouse ophthalmic geneticists. The format is simple and is comparable to that of the Grand Rounds in departments of ophthalmology around the World. All EVER participants are invited to come and discuss cases during this session. As such, the format will be similar to the FAN Club meeting.

**LEROY B , GRAW J**

<table>
<thead>
<tr>
<th>Case</th>
<th>Time</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mouse case</td>
<td>14:00</td>
<td>ROUX M , Amiot C , Maréchal D , Hérault Y - Illkirch</td>
</tr>
<tr>
<td>Human case</td>
<td>14:18</td>
<td>LISKOVA P - Prague</td>
</tr>
<tr>
<td>Deficiency in the expression of Vps13C is associated with altered retinal and lens development in mice</td>
<td>14:36</td>
<td>AMARIE O , Rathkolb B , Fuchs H , Galilus-Durner V , Hab de Angelis M , Graw J - Neuherberg</td>
</tr>
<tr>
<td>Human case</td>
<td>14:54</td>
<td>LEROY BP , Hamel C , Bocquet B , Manes G , Meunier I - Montpellier</td>
</tr>
</tbody>
</table>

### PBP - Insults related to a cause for retinal disease processes

Neural signals from the rods and cones undergo processing by other cell-types of the retina. The output takes the form of action potentials in retinal ganglion cells whose axons form the optic nerve. Several important features of visual perception can be traced to the retinal encoding and processing of light. In retinal diseases, specific retinal cell-types are affected that results in diseases like glaucoma, AMD or diabetic retinopathy. Basic science studies suggest that the cause for individual cell-types initially being affected that result in a defined disease might be due to genetics or specific insults such as raised IOP, light, inflammation, autoimmunity or oxidative stress. The aim of this SIS is to provide information as to why this is the likely case.

**OSBORNE N , VIDAL-SANZ M**

<table>
<thead>
<tr>
<th>Case</th>
<th>Time</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inflammation in relation to retinal diseases</td>
<td>14:00</td>
<td>DICK A - Bristol</td>
</tr>
<tr>
<td>Autoimmunity in relation to retinal diseases like glaucoma</td>
<td>14:18</td>
<td>GRUS F - Mainz</td>
</tr>
<tr>
<td>Insult dependent oxidative-induced cell death</td>
<td>15:12</td>
<td>OSBORNE N - Oxford</td>
</tr>
</tbody>
</table>
14:00 - 15:30 | GALLIENI 4
ACB - Anatomy and cell biology of the eye - from retina to cornea and back

PETROVSKI G, KAUPPINEN A

1371 14:00 Phenotype of human corneal stroma-derived cells obtained by different isolation techniques from various corneal regions

1372 14:12 The role of p62/SQSTM1 in IL-1-mediated cytokine production in retinal pigment epithelial cells
KAUPPINEN A, Korhonen E, Piippo N, Hytti M, Kaarniranta K - Kuopio

1373 14:24 Mitochondrial impairment regulates inflammasome activation in human retinal pigment epithelial cells
KORHONEN E, Piippo N, Hytti M, Kaarniranta K, Kauppinen A - Kuopio

1374 14:36 National diabetic retina screening programme: Identifying non-diabetic eye disease
MURPHY R, Keegan D - Dublin

1375 rf 14:48 Loss of Nrf-2 and PGC1-alpha genes changes macromorphology of the eye and evokes microstructural and pigmentation pattern changes of the retinal pigmented epithelium

1376 rf 14:54 Effects of HSP90 inhibitor TAS-116 on the inflammasome activation in ARPE-19 cells

1377 rf 15:00 The supportive role of interferon- in retinal differentiation of mesenchymal stem cells

1378 rf 15:06 Remote ischemia affects the diameter of larger retinal vessels in normal persons
EL DABAGHY, Petersen L, Pedersen M, Bek T - Aarhus C

14:00 - 15:30 | GALLIENI 5
Roundtable Innovations in imaging part I

CREUZOT C, SOUIED E

1381 14:00 When OCT angio can help us: from diagnosis to follow-up
SOUIED E - Creteil

1382 14:18 OCT A from anatomy to imaging, vascular remodeling in macular diseases
MIERE A - Creteil

1383 14:36 OCT angiography in diabetic retinopathy: what for?
KOROBELNIK JF - Bordeaux

1384 14:54 Adaptive optics: the optical Stiles-Crawford effect in the clinics
PAQUES M - Paris

1385 15:12 Diabetic retinopathy screening and deep learning
LAMARD M - Brest
15:45

WELCOME BY
THE EVER PRESIDENT 2017

Andrew DICK - Bristol

16:00

EVER LECTURE DELIVERED
BY THE PAST PRESIDENT:
THE PUPIL: A MARKER OF VISUAL
AND NON-VISUAL LIGHT SENSITIVITY

Aki KAWASAKI - Lausanne
WEDNESDAY, SEPT 27 - SECOND AFTERNOON SESSION

**AMBRESIN A, POURNARAS C**

1511  16:50  Fluorescence lifetimes of drusen in age-related macular degeneration  
*DYSLI C, Fink R, Wolf S, Zinkernagel MS - Bern*

1512  17:02  Deep learning to screen for referable diabetic retinopathy  
*DE BOEVER P, Malik R, Affifi N, Elen B - Mol*

1513  17:14  Macular changes in patients with multiple sclerosis – A texture analysis of optical coherence tomography data  
*BERNASDES R, Silva G, Batista S, Sousa L, Castelo Branco M - Coimbra*

1514  17:26  Structural Bscan OCT correlation with OCT angiography biomarkers of activity in neovascular age related macular degeneration  
*AMBRESIN A, Mantel I, Bergin C, Naso S - Lausanne*

1515  17:38  Cross-sectional static retinal vessel analysis in routine optometric practice  
*FRENCH C, Heitmar R - Birmingham*

1516  17:44  Ophthalmoscopical and video OCT methods to detect spontaneous venous pulsation in individuals with apparently normal intracranial pressure: the rebirth of the SVP?  
*JENKINS KS, Layton CJ, Adams MKM - Brisbane*

1517  17:50  Inner retina changes in hydroxychloroquine patients  
*BARATA A, Leal I, Sousa F, Teixeira F, Pinto F - Lisboa*

1518  17:56  Idiopathic retinal vasculitis, arteriolar macroaneurysms and neuroretinitis (IRVAN): Case series of three patients with multimodal imaging.  
*YU JEAT C, Logeswaran A, Damato E - Birmingham*

**CORDEIRO MF**

1521  16:50  Summary of main clinical trials  
*NORMANDO EM - London*

1522  17:12  Evidence for successful treatment in glaucoma: who to treat and when?  
*GANDOLFI S - Parma*

1523  17:34  The three P’s of testing new drugs in glaucoma: Pilot, POC and Pivotal  
*LEVIN L - Montreal*

1524  17:56  Outcomes and endpoints in glaucoma  
*CORDEIRO MF - London*
IM - Top mistakes in uveitis and how to avoid them: a case-based approach

Misunderstanding laboratory evaluation
- False positive rate in quantiferon TB test
- The importance of urinalysis (TINU)
- Misinterpreting the updated syphilis algorithm
- Multiple positive tests can lead to multiple diagnoses

Mistaking infection for inflammation
- Peripheral punctate lesions in sarcoidosis and syphilis
- Inflammatory “masquerades” of herpetic viruses
- Dealing with intravitreal steroids in an infected eye

Forgetting malignancies
- Atypical presentations of intraocular lymphoma

Over-interpreting white dots
- Placoid syphilis
- Punctate inner choroidopathy vs multifocal choroiditis
- Relentless and persistent placoid chorioretinopathies

Choosing the wrong imaging modalities
- When to get fluorescein angiography in anterior uveitis
- When fundus autofluorescence alone can evaluate inflammatory activity
- Underestimating indocyanine green angiography

Fear of the correct treatment dose
- Underdosing valacyclovir
- Underdosing immunosuppressive therapy

PICI F, LOWDER C

1531 16:50 Misunderstanding laboratory evaluation
NERI P, Pirani V, Cesari C - Agugliano

1532 17:05 Mistaking infection for inflammation
ALBINI T - Miami

1533 17:20 Forgetting malignancies
SEN HN - Bethesda MD

1534 17:35 Over-interpreting white dots
SRIVASTAVA S - Cleveland

1535 17:50 Choosing the wrong imaging modalities
PICI F - Abu Dhabi

1536 18:05 Fear of the correct treatment dose
LOWDER C - Cleveland
### WEDNESDAY, SEPT 27 - SECOND AFTERNOON SESSION

**16:50 - 18:20 | RHODES 3**

**COS - Dry eye & corneal transplantation**

**JEPESEN H, KESTELYN P**

1541 16:50 Sicca syndrome - disease continuum. Anatomical, functional and systemic assessment


1542 17:02 Estimating basal rear osmolarity in normal and dry eye subjects

WILLSHIRE C, Buckley R, Bron A - Cambridge


1544 17:26 Preclinical validation of an innovative corneal bioreactor versus organ culture for long term storage: a randomized controled study


1545 *rf 17:38 Efficacy of a RAR selective agonist eye drop formulation on improvement of tear production and corneal fluorescein staining in the BTX-B mouse model of dry eye disease

LEMIERE I, Harvey M, Grogan D, Desjardins C - Montreal

1546 *rf 17:44 Graft blues: case report


---

**16:50 - 18:20 | RHODES 4**

**ACB - From retinal biochemistry and angiogenesis to dry eye disease**

**KAUPPINEN A, ANDRE H**

1551 16:50 Modulation of Muller cell membrane organization by 24S-hydroxycholesterol


1552 17:02 Plasmalogens and cell-cell communication between retinal glial cells


1553 17:14 Gene therapy strategies for hypoxia-inducible angiogenesis in ocular neovascularization


1554 17:26 A holistic dynamic concept on dry eye disease identifies several different interacting self-enforcing vicious circles of disease progression

KNOP E, Knop N - Berlin

1555 *rf 17:38 A novel in vivo model of puncture-induced iris neovascularization

LOCRI F, Beaujean O, Aronsson M, Kvanta A, André H - Stockholm

1556 *rf 17:44 Modulation of the rod outer segment aerobic metabolism diminishes the production of radicals due to light absorption

PANFOLI I, Calzia D, Degan P, Caicci F, Manni L, Traverso C E - Genova

1557 *rf 17:50 Protective effects of sulforaphane on STZ-induced diabetic retinopathy via activation of Nrf2/HO-1 antioxidant pathway and inhibition of NADPH oxidase

HE M, Luan L, Zhang Y, Nan Y - Beijing

1558 *rf 17:56 The 8-fold quadrant dissection method for ex vivo human interventional retinal experimentation

MURALI A, Ramlogan-Steel C, Andrzejewski S, Dhungel B, Steel J, Layton C - Brisbane
### PBP - Retinal physiology, biochemistry and pharmacology

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Title</th>
<th>Authors and Affiliations</th>
</tr>
</thead>
<tbody>
<tr>
<td>1651</td>
<td>16:50</td>
<td>Biological model of Zebrafish - a new research trend in ophthalmology, for an antiangiogenic treatment</td>
<td>DANIELUK K, Swiech-Zubilewicz A, Oseka M, Mackiewicz J - Lublin</td>
</tr>
<tr>
<td>1562</td>
<td>17:02</td>
<td>Importance of cellular factors in the retention of melanin-binding drugs in pigmented ocular tissues</td>
<td>RIMPELA AK, Urtti A - Helsinki</td>
</tr>
<tr>
<td>1563</td>
<td>17:14</td>
<td>Optic nerve cupping and lamina cribrosa sclerae depth as a resultant of translaminar pressure difference</td>
<td>CZAK W, Piróg - Mulak M, Nowakowski J, Misiuk - Hojło M - Wroclaw</td>
</tr>
<tr>
<td>1564</td>
<td>17:26</td>
<td>Alzheimer's disease: can the retina be a window to the brain?</td>
<td>NEVES AC, Chiquita S, Carecho R, Campos E, Moreira P, Baptista F, Ambrósio F - Coimbra</td>
</tr>
<tr>
<td>1565</td>
<td>17:32</td>
<td>Electrical direct current stimulation affects retinal vessel diameter and vasodilation in healthy subjects</td>
<td>FREITAG S, Klee S, Haueisen J - Ilmenau</td>
</tr>
</tbody>
</table>

### ACB - Imaging in retinal disease models and differential diagnosis

This course aim to help scientists and clinicians better understand the principles of, and the main trends in modern scanning and imaging modalities used in ophthalmology. It is intended to ease the communication between basic scientists and clinicians in the field of modern imaging. Potential of microscopic imaging, spectral imaging, fluorescence and optical coherent imaging are discussed in retinal disease models and differential diagnoses.

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Title</th>
<th>Authors and Affiliations</th>
</tr>
</thead>
<tbody>
<tr>
<td>1572</td>
<td>17:08</td>
<td>Different light spectra to better visualize retinal detail</td>
<td>UUSITALO H, Leusu L, Hauta-Kasari M - Tampere</td>
</tr>
<tr>
<td>1573</td>
<td>17:26</td>
<td>Old and new retinal imaging techniques in research and differential diagnosis of retinal diseases</td>
<td>PETROVSKI G - Szeged</td>
</tr>
<tr>
<td>1574</td>
<td>17:44</td>
<td>What is the meaning of autofluorescence in retinal diseases?</td>
<td>KAARNIRANTA K - Kuopio</td>
</tr>
<tr>
<td>1575</td>
<td>18:02</td>
<td>Histological analysis with OCT</td>
<td>PATERNO J - Kuopio</td>
</tr>
</tbody>
</table>

---

**FP**

**WEDNESDAY, SEPT 27 - SECOND AFTERNOON SESSION**

**16:50 - 18:20 | GALLIENI 1+2**

### ACB - Imaging in retinal disease models and differential diagnosis

This course aim to help scientists and clinicians better understand the principles of, and the main trends in modern scanning and imaging modalities used in ophthalmology. It is intended to ease the communication between basic scientists and clinicians in the field of modern imaging. Potential of microscopic imaging, spectral imaging, fluorescence and optical coherent imaging are discussed in retinal disease models and differential diagnoses.

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Title</th>
<th>Authors and Affiliations</th>
</tr>
</thead>
<tbody>
<tr>
<td>1572</td>
<td>17:08</td>
<td>Different light spectra to better visualize retinal detail</td>
<td>UUSITALO H, Leusu L, Hauta-Kasari M - Tampere</td>
</tr>
<tr>
<td>1573</td>
<td>17:26</td>
<td>Old and new retinal imaging techniques in research and differential diagnosis of retinal diseases</td>
<td>PETROVSKI G - Szeged</td>
</tr>
<tr>
<td>1574</td>
<td>17:44</td>
<td>What is the meaning of autofluorescence in retinal diseases?</td>
<td>KAARNIRANTA K - Kuopio</td>
</tr>
<tr>
<td>1575</td>
<td>18:02</td>
<td>Histological analysis with OCT</td>
<td>PATERNO J - Kuopio</td>
</tr>
</tbody>
</table>
**Roundtable Innovations in imaging part II**

A platform for Industry & Academy

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>1581</td>
<td>16:50</td>
<td>Retina assessment: Imaging or function?</td>
<td>Schmetterer L - Vienna</td>
<td></td>
</tr>
<tr>
<td>1582</td>
<td>17:08</td>
<td>3D surgery: new tool or just a toy?</td>
<td>Creuzot C - Dijon</td>
<td></td>
</tr>
<tr>
<td>1583</td>
<td>17:26</td>
<td>Glaucoma: structure assessment and imaging</td>
<td>Bron A - Dijon</td>
<td></td>
</tr>
<tr>
<td>1584</td>
<td>17:44</td>
<td>OCTA Predictive factors of CNV re treatment</td>
<td>Coscas F - Creteil</td>
<td></td>
</tr>
<tr>
<td>1585</td>
<td>18:02</td>
<td>Corneal nerves: from imaging to disease</td>
<td>Rousseau A - Le Kremlin Bicêtre</td>
<td></td>
</tr>
</tbody>
</table>
18:30 - 19:00 | HERMES

European Ophthalmology Heritage Lecture by Alan C BIRD

**EVOLUTION OF OUR UNDERSTANDING AND MANAGEMENT OF MONOGENETIC RETINAL DISORDER**

*Alan C BIRD - London*

HERMES

18:30 Introduction by Andrew DICK

18:35 **Evolution of our understanding and management of monogenetic retinal disorders**

Night blindness as a hallmark of many monogenetic retinal disorders has been known for over a thousand years. Indirect evidence implies that this was due to vitamin A deficiency in some of these early descriptions. In the 18th century it was recognised that it may be seen in families implying a genetic origin of disease. A secure diagnosis of retinitis pigmentosa became possible with the invention of the ophthalmoscope in the mid-19th century and by 1908 Nettleship synthesised reports of over 1,000 reported cases. He generated an accurate clinical description of the disorders and there was little revision of his conclusions until the 1970’s apart from early electrophysiological studies. Thereafter, there has been highly productive research that has led to identifying the causes, and pathogenetic mechanisms involved in disease, followed by early attempts at intervention. It is likely that over the next 10 years successful treatment will become available in disorders that were ill understood 40 years ago.

19:00 Award presentation of the EVER Certificate of Honour

**Biography of Prof. Alan C BIRD:**

Alan C. Bird, Chief Scientist for The MacTel Project, is a Professor and Consultant at the Institute of Ophthalmology at the Moorfields Eye Hospital in London, UK. Since joining Moorfields in 1969, Dr. Bird has held numerous positions. For the past several years, Dr. Bird’s his main area of interest is retina. Under his direction, The Medical Retinal Service now holds 24 clinics each week, and has 7 Consultants. A productive multidisciplinary research team developed for the investigation of monogenic retinal disorders and age-related macular disease. Investigative techniques included molecular genetics, electrophysiology, psychophysics, specialised imaging and morphology. Along with his colleagues, Dr. Bird as established research programs in inflammatory eye disease, and retinal vascular diseases. Dr. Bird has done extensive international work in Africa on river blindness and in Jamaica on retinal changes in sickle cell disease. Dr. Bird has received a number of awards in recognition of his work.
19:00 - 19:30 | HERMES

Keynote Lecture by Carol SHIELDS

UVEAL MELANOMA: MILLIMETERS, PERSONALIZED PROGNOSIS, AND NEW THERAPIES

Carol SHIELDS - Philadelphia

19:00 Introduction by Frédéric MOURIAUX and Steffen HEEGAARD

19:05 Uveal melanoma: millimeters, personalized prognosis, and new therapies

The management of uveal melanoma is going through tremendous transition into the realm of early detection, personalized prognostication and potentially new systemic and local therapies. In this Keynote Lecture, we will discuss four topics relevant to current melanoma management including (1) the importance of detection of small melanoma where thickness is approximately 3 mm or less, (2) optical coherence tomography angiography (OCTA) of melanoma before and after plaque radiotherapy, (3) DNA analysis of >1000 cases of uveal melanoma and the ability to personally prognosticate each patient based on cytogenetic profile, and (4) new systemic and local therapies.

19:30 Award presentation of the EVER Certificate of Honour

Biography of Dr. Carol SHIELDS:

Dr. Carol Shields completed her residency in ophthalmology at Wills Eye Hospital in Philadelphia in 1987 and subsequently did fellowship training in ocular oncology, oculoplastic surgery, and ophthalmic pathology. She is currently Co-Director of the Oncology Service, Wills Eye Hospital, and Professor of Ophthalmology at Thomas Jefferson University in Philadelphia.

She has authored or coauthored 12 textbooks, over 1500 articles in major peer-reviewed journals, over 300 textbook chapters, given over 700 lectureships, and has received numerous professional awards. The 7 most prestigious awards include:

- The Byron Kanaley Award (1979) given to the top student-athlete at the University of Notre Dame. She was the first woman ever to receive this award.
- The Donders Award (2003) given by the Netherlands Ophthalmological Society every 5 years to an ophthalmologist worldwide who has contributed extensively to the field of ophthalmology. She was the first woman ever to receive this award.
- Honorary Doctorate of Science Degree from the University of Notre Dame (2005) and the Catholic University (2011) bestowed at the graduation ceremonies from each University. She was the first woman graduate of Notre Dame to receive this award.
- The American Academy of Ophthalmology Life Achievement Honor Award (2011) for significant contributions to the field of ophthalmology.
- Induction into the Academic All-American Hall of Fame (2011) for lifetime success in athleticism and career.
- President of the International Society of Ocular Oncology (2013-2015) – This is the largest international society of clinicians and basic scientists interested in ocular tumors. She was the first elected President of this society.
- Ophthalmology Power List - Nominated by peers as one of the top 100 leaders in the field of ophthalmology and published in The Ophthalmologist. There have only been 2 “Top 100” power lists in 2014 and 2016 and she was on both.

Dr. Carol Shields is a member of numerous ocular oncology, pathology, and retina societies and has delivered 47 named lectures in America and abroad. She has been active in the American Academy of Ophthalmology. She serves on the editorial/advisory board of 27 journals including JAMA Ophthalmology, Retina, Journal of Pediatric Ophthalmology and Strabismus, Ophthalmic Plastic and Reconstructive Surgery, and International Journal of Clinical Oncology.

She practices Ocular Oncology on a full time basis with her husband, Dr. Jerry Shields and associates on the Oncology Service at Wills Eye Hospital. Each year the Oncology Service manages approximately 500 patients with uveal melanoma, 120 patients with retinoblastoma, and numerous other intraocular, orbital, and adnexal tumors from the United States and abroad. She and her husband Jerry are the parents of 7 children, ranging in age from 16 to 28 years.
OCT angiography (OCT-A) as a new non-invasive imaging technology that enables the monitoring of the macular retinal and choroidal circulation.

OCT-A allows a detailed detection either of the macular retinal capillaries plexus as well as the subretinal choroidal neovascularisation.

The correlation of OCT-A with OCT longitudinal or “en face” sections resulted to a better understanding of the pathologic features of the macular degenerative or vascular pathologies. OCT-A became a useful imaging modality in the evaluation and management of macular hemodynamic changes observed during the evolution of the retinal ischemic micronangiopathies, age related maculopathies related to a subretinal neovascularisation and the vitreoretinal interface surgical pathologies.

POURNARAS C, ZOGRAFOS L

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Topic</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>2111</td>
<td>8:30</td>
<td>Acute retinal ischemia</td>
<td>AMBRESIN A - Lausanne</td>
</tr>
<tr>
<td>2112</td>
<td>8:45</td>
<td>OCT-A: guided treatment of diabetic retinopathy</td>
<td>COSCAS G, Lupidi M, Coscas F - Creteil</td>
</tr>
<tr>
<td>2113</td>
<td>9:00</td>
<td>OCT-A based management and treatment of RVO</td>
<td>COSCAS F, Coscas G, Souied EH - Creteil</td>
</tr>
<tr>
<td>2114</td>
<td>9:15</td>
<td>OCT-A evaluation and treatment of the macular surgical pathologies</td>
<td>POURNARAS C - Genève</td>
</tr>
<tr>
<td>2115</td>
<td>9:30</td>
<td>Irradiation induced retinopathy: OCT-A in the management and treatment</td>
<td>ZOGRAFOS L - Lausanne</td>
</tr>
<tr>
<td>2116</td>
<td>9:45</td>
<td>AMD type I and II: OCT-A based management and treatment</td>
<td>LUMBROSO B - Rome</td>
</tr>
</tbody>
</table>

Primary glaucoma surgeries, whether minimally invasive or trabeculectomy, are usually effective in lowering intraocular pressure. However, in a proportion of cases the initial procedure is ineffective or the procedure fails; in this eventuality comprehensive glaucoma specialists need to be skilled in a number of other surgical strategies. This special interest symposium will address a variety of the more complex and innovative glaucoma treatment options for such refractory cases, in a series of lectures delivered by glaucoma sub-specialists working in busy glaucoma referral centres.

BLOOM P, CRAWLEY L

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Topic</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>2121</td>
<td>8:30</td>
<td>Tube surgery techniques</td>
<td>GANDOLFI S - Parma</td>
</tr>
<tr>
<td>2122</td>
<td>8:52</td>
<td>Tube surgery in scary eyes!</td>
<td>AHMED F - London</td>
</tr>
<tr>
<td>2123</td>
<td>9:14</td>
<td>Pars plana &amp; ciliary sulcus drainage tubes</td>
<td>BLOOM P - London</td>
</tr>
<tr>
<td>2124</td>
<td>9:36</td>
<td>ECP - limbal &amp; pars plana techniques</td>
<td>BLOOM P - London</td>
</tr>
</tbody>
</table>
THURSDAY, SEPT 28 - FIRST MORNING SESSION

8:30 - 10:00 | RHODES 2
IM - SOIE : Quantitative measurement methods for the management of uveitis and for the design of trials are to be privileged

In the last 25 years, uveitis represented one of the fields in ophthalmology where the evolution was tremendously fast. Ophthalmologists not only gained access to more effective, more targeted and better tolerated treatments, but in parallel precise and quantitative measurement techniques developed, allowing the specialists to evaluate the balance between safety and efficacy of therapies and adjust such interventions with a higher degree of precision. Precise measurement of intraocular inflammation became possible for most inflammatory diseases, thanks to new technologies such as laser flare photometry and indocyanine green angiography. Furthermore, the introduction of new softwares for optical coherence tomography can allow the measurement of anterior chamber and vitreous involvement in uveitis. In addition, in very severe cases, the anterior chamber tap and the vitreous biopsy can provide important data which can be not only important for the visual prognosis but can even lead to the correct diagnosis in uncertain cases, such as for vitreo-retinal lymphoma. The aim of this SIS is to bring new concepts on diagnostic techniques in uveitis and discuss the possible perspectives of the evolution of such methods. In addition, we will highlight the impact of these tools in the clinical practice.

NERI P, HERBORT JR. CP

2131 8:30 Ocular angiography: dual FA/ICGA scoring of posterior uveitis
HERBORT CP - Lausanne

2132 8:52 Ocular fluid analysis to pin down the cause of inflammation
NERI P, Gorgoni F, Pirani V, Pelliccioni P, Nicolai M - Agugliano

2133 9:14 The place of OCT-angiography in uveitis
KHAIRALLAH M, Khochtei S, Abroug N - Monastir

2134 9:36 The potential impact of new OCT technology for the measurement of ocular inflammation
PICI F - Cleveland

8:30 - 10:00 | RHODES 3
PBP/RV - Novel therapeutics and drug delivery approaches for eye diseases

A number of innovations in drug development as well as drug delivery are dramatically expanding the therapeutic options for treating diseases of the eye, particularly those affecting the back of the eye. The purpose of this session is to introduce recent innovations in therapeutic agents, biomaterials, delivery systems, and routes of delivery intended for improving treatment of eye diseases. The specific topics to be discussed include new protein drugs; development of biocompatible and bioresorbable materials for sustained intraocular drug delivery; manufacturing and characterization of ophthalmic implants for sustained drug delivery; mathematical models to explain ocular pharmacokinetics and drug effects; and suprachoroidal drug delivery, which is enabling targeted, sustained drug delivery for posterior as well as anterior segment diseases.

KOMPELLA UB, RITTENHOUSE K

2141 8:30 New protein drugs for retinal diseases: Attributes, efficacy, and safety
BEHAR-COHEN F - Paris

2142 8:48 New biomaterials and ocular drug delivery
SHEARDOWN H, Muirhead B, Zhang J - Hamilton

2143 9:06 Biodegradable implants for sustained drug release: Manufacturing considerations, drug stability, and drug release
KOMPPELLA UB - Aurora

2144 9:24 Ocular pharmacokinetics and pharmacodynamics
URTII A, Del Amo E, Pelkonen L, Rimpelä A K, Kidron H, Reinisalo M - Helsinki

2145 9:42 Iontophoretic targeting of drug delivery in the eye via the suprachoroidal space
JUNG JH, Chiang B, Prausnitz M - Atlanta
Ophthalmic pathology: new and old insights: do we still need wet tissue to investigate by old techniques. Which biopsies are still necessary and how do newer techniques change our diagnostic modalities? Newer diagnostic modalities as OCT, ultrasound, confocal microscopy, high-definition MRI-CT can provide the clinician with a very high change of correct diagnosis. Pcr and new genetic techniques pinpoint to the exact mutation and disease process. In more and more diseases a therapy of radiotherapy or chemotherapy can be delivered without surgery or with minimal invasive techniques. Nevertheless in most cancer cases and strange inflammations a wet biopsy with tissue processing is still necessary. By newer techniques in surgery and laboratory smaller biopsies are used in the advantage of the patient. This course will highlight clinical-pathologic correlations and stress on the advancements and the consequences for clinician and laboratory in disease processes in the eye.

VAN GINDERDEUREN R, HEEGAARD S

2151  8:30  Tips and tricks in grossing & processing specimens
      MOULIN A - Lausanne

2152  8:45  Overview of conjunctival and eyelid tumours
      VAN GINDERDEUREN R - Leuven

2153  9:00  Overview of adult and paediatric orbital pathology
      HEEGAARD S - Copenhagen

2154  9:15  Anterior to posterior “tour” of ocular disease processes
      VAN GINDERDEUREN R - Leuven

2155  9:30  Molecular techniques in ocular pathology
      MOULIN A - Lausanne

2156  9:45  Comparative ocular pathology and animal models used in eye research
      HEEGAARD S - Copenhagen

---

EOVS - The role of pre-receptoral filters of short wavelength light in the eye with emphasis on macular pigment

We propose a SIS on the role of pre-receptoral filters of short wavelength light in the eye with emphasis on macular pigment. We believe this is timely following recent interest in the effects carotenoids can have on various aspects of human vision (e.g. visual acuity, scattered light, functional contrast sensitivity, red/green and yellow/blue colour vision and rod and cone mediated flicker sensitivity). Carotenoids, including beta-carotene, lycopene, lutein, zeaxanthin and meso-zeaxanthin are regarded as effective antioxidants. In addition to ‘optical’ effects that link directly to spatial distribution of carotenoids in the retina e.g. scattered light and spectrally selective absorption of short wavelength light, other health benefits such as enhanced immune function and reduction in risk of some eye diseases have also been reported and may play a role in mediating observed improvements in visual performance. The aim of the SIS is to examine the latest research findings on the optical and health-related benefits of carotenoids in human vision with emphasis on colour vision and rod/cone rapid flicker sensitivity. This will be of interest to ophthalmologists, psychologists, optometrists, vision scientists and nutritionists.

CTORI I, HUNTJENS B

2161  8:30  A review of the nature & role of pre-receptoral, wavelength-selective, ocular filters in vertebrates
      DOUGLAS R - London

2162  8:50  A review of motion photometry in the assessment of macular pigment distribution profiles
      obtained over two decades; applications and insights
      ROBSON A, Moreland J - London

2163  9:05  Does ethnicity and foveal morphology play a role in the spatial distribution of macular pigment?
      CTORI I, Huntjens B - London

2164  9:20  Is macular pigment spatial profile a clinical biomarker in children of AMD parents?

2165  9:35  Pre-receptoral filters in the eye and their effect on vision
      BARBUR J - London
RPE is a key player in maintaining the integrity of retina via their multiple functions e.g. in phagocytosis, secretion of growth factors, epithelial barrier and transport and visual cycle. Impairment of these vital functions are common cause of retinal diseases e.g. AMD. Special Interest Symposium “RPE in function” is focusing in demonstration of novel characteristics of these functions and their development during differentiation by means of molecular biology, electrophysiology and proteomics. In the development of replacement therapies or personalized disease models based on RPE cell differentiation from iPSC or hESC, the evaluation of the stage of differentiation could be functionally determined by using these analyses.

### UUSITALO H, KAARNIRANTA K

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Time</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>2171</td>
<td>Circadian regulation of outer segments phagocytosis by RPE cells: more complexity than meets the eye</td>
<td>8:30</td>
<td>NANDROT E - Paris</td>
</tr>
<tr>
<td>2172</td>
<td>Novel roles for voltage sensitive ion channels in retinal pigment epithelium and phagocytosis</td>
<td>8:52</td>
<td>NYMARK S, Johansson JK, Skottman H, Ihalainen TO - Pirkkala</td>
</tr>
</tbody>
</table>

### MBGE - Ophthalmic epidemiology

Ophthalmic epidemiology contributes to the understanding of the distribution of eye diseases and the association of those diseases with risk indicators and potential causal risk factors. This SIS brings together experts of various fields of ophthalmic epidemiology to discuss causative factors including genetics from different points of view.

### GRAW J, MCCARTY C

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Time</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>2181</td>
<td>Ophthalmic ophthalmology</td>
<td>8:30</td>
<td>MCCARTY C - Duluth</td>
</tr>
<tr>
<td>2182</td>
<td>A genome-wide association study suggests that the NADPH Oxidase 4 (NOX4) gene is associated with severe diabetic retinopathy in a Scottish diabetic population</td>
<td>9:00</td>
<td>MENG W, Hebert H, Palmer C - Dundee</td>
</tr>
<tr>
<td>2183</td>
<td>Ophthalmic ophthalmology</td>
<td>9:30</td>
<td>KLAVER C - CA Rotterdam</td>
</tr>
</tbody>
</table>
10:20 - 10:50 | HERMES
EVER-Acta Lecture by Leopold SCHMETTERER

OCULAR IMAGING:
WHAT WE SEE AND
WHAT WE WOULD LIKE TO SEE

Leopold SCHMETTERER - Singapore
HERMES

10:20 Introduction by Einar STEFANSSON

10:25 Ocular imaging: What we see and what we would like to see
Imaging is a highly innovative field in ophthalmology. Optical coherence tomography (OCT) has gained widespread clinical importance for both, the anterior and the posterior segment of the eye and is routinely used in diagnosis, follow up and treatment monitoring. While OCT has continuously improved in performance the question is what comes next: higher resolution, faster data acquisition, functional imaging, molecular contrast? In the present talk a perspective is given in terms of clinical needs. Unsolved challenges in terms of screening, diagnosis, follow up and treatment monitoring will be discussed and potential ways to overcome these issues will be provided.

10:50 Award presentation of the EVER Certificate of Honour

Biography of Prof. Leopold SCHMETTERER:
Prof Schmetterer is Professor of Ophthalmology and head of ocular imaging at Singapore Eye Research Institute. His interests span a wide range of ocular imaging from development of novel technologies to applications in preclinical research and clinical settings. Prof Schmetterer is also interested in clinical trials and is involved in many studies in retina, glaucoma, cornea and dry eye. He has published more than 280 peer reviewed publications, was invited for more than 200 lectures including more than 15 keynote lectures and has been awarded more than 15 million Euro in research grant funding. He is a member of the Editorial Boards of Acta Ophthalmologica, Journal of Ocular Pharmacology and Therapeutics, Current Eye Research and five other journals.
**VAN CALSTER J , AMBRESIN A**

**2311 11:00** Interventions to increase attendance for diabetic retinopathy screening: a systematic review and meta-analysis  

**2312 11:12** A systematic review of the associations between dietary intake and diabetic retinopathy  
WONG M , Man R , Gupta P , Fenwick E , Li L J , Lamoureux E - Singapore

**2313 11:24** Towards a shared care model for stable diabetic retinopathy patients: a feasibility trial in Singapore  

**2314 11:36** Cost-effectiveness of intravitreal therapy with both anti-VEGF and Dexamethasone implant in patients with Diabetic Macular Edema  
D’AMICO RICCI G , Bouzios D , Boscia F , Lupino M , Pinna A - Sassari

**2315 11:42** Topical betamethasone sodium phosphate, tetracycline hydrochloride and nonsteroidal anti-inflammatory drugs in the treatment of diabetic macular edema: a case report  
D’AMICO RICCI G , Bouzios D , Boscia F , Pinna A - Sassari

**2316 11:48** Vitrectomy with fibrovascular membrane delamination for proliferative diabetic retinopathy with or without preoperative Avastin  
GARNAVOU-XIROU C , Papavasileiou E , Velissaris S , McHugh D , Jackson T L - London

**11:00 - 12:30 | RHODES 1**

**G - Ocular manifestation of neurodegenerative diseases**

Neurodegenerative disorders such as Alzheimer Disease, Parkinson Disease and Multiple Sclerosis present ocular manifestations which could precede general signs and symptoms. This correlation between the eye and the brain has been confirmed by recent advances in imaging technologies.

Hardware and software improvements have given the possibility of examining structures previously inaccessible. The assessments of these structures could lead to novel diagnostic and therapeutic approaches.

The first objective of this SIS is to generate a multidisciplinary discussion between ophthalmologists and non-eye experts; novel synergic approaches to neurodegenerative conditions will be discussed.

The second objective is to explore the current application of retinal imaging in neurodegenerative diseases.

**NORMANDO EM , BARBONI P**

**2321 11:00** Leber’s hereditary optic neuropathy: the ophthalmologist point of view  
BARBONI P - Bologna

**2322 11:18** Leber’s hereditary optic neuropathy: the neurologist point of view  
CARELLI V , La Morgia C - Bologna

**2323 11:36** Fluorescence lifetime imaging ophthalmoscopy  
DYSLI C , Wolf S , Zinkernagel MS - Bern

**2324 11:54** AD in the eye  

**2325 12:12** MS and optic neuritis  
NORMANDO EM - London
THURSDAY, SEPT 28 - SECOND MORNING SESSION

11:00 - 12:30 | RHODES 2
IM - New insights in Uveitis 1

BODAGHI B, KESTELYN P
2331 11:00 Activation of retinal microglia and accumulation of sub-retinal fluid after systemic challenge with Lipopolysaccharide in mice
KOKONA D, Ebneret A, Zinkernagel M - Bern

2332 11:12 Chronic exposure to TNF impairs RPE barrier and immunosuppressive functions

2333 11:24 Uveitic macular edema: efficacy and safety of subconjunctival triamcinolone injections
VERMUSO L, Gueudry J, Ngo C, Portmann A, Muraine M - Rouen

2334 11:36 INFLIXIMAB and ADALIMUMAB in uveitic macular edema
LEJOYEUX R, Diwo E, Vallet H, Bodaghi B, Le Hoang P, Fardeau C - Paris

2335 11:42 Results from the SAKURA program: central retinal thickness changes with intravitreal sirolimus in subjects with non-infectious uveitis of the posterior segment and macular edema at baseline
BODAGHI B, White S - Paris

11:00 - 12:30 | RHODES 3
PO - Controversies in ophthalmic oncology

This symposium will allow a debate and a confrontation of different opinions in ophthalmic oncology:
Should we perform an intraocular biopsy when we treat a uveal melanoma with radiotherapy? Some of us do it as a routine procedure to offer a better prognostication to their patients but other are against this procedure which can cause tumor dissemination and does not improve survival as we do not have efficient adjuvant therapy.

Can we perform endoresection surgery without any previous radiation therapy? Bertil Damato uses this technique but most ophthalmic oncologist prefers to use radiation before endoresection to prevent tumor dissemination.

How should we treat iris melanoma? Surgery has been used for a long time but proton beam is now the preferred treatment in many centers.

Finally what should we do when a patient has a suspicious naevus: observe all of them, or treat? Dermatologists have reduced melanoma mortality by removing all suspicious naevi should we do this as well?

Experts in ophthalmic oncology will give arguments pro and against for each of these clinical situations

DESJARDINS L, CAUJOLLE JP
2341 11:00 uveal melanoma biopsy or not (pro)
SHIELDS C - Philadelphia

2342 11:11 Uveal melanoma biopsy or not (against)
CAUJOLLE JP - Nice

2343 11:22 Endoresection of uveal melanoma without radiotherapy
DAMATO B - San Francisco

2344 11:33 Endoresection after proton beam
CASSOUX N - Paris

2345 11:44 Surgery of iris melanoma
MOURIAUX F - Rennes

2346 11:55 Radiotherapy of iris melanoma
LUMBROSO L - Paris

2347 12:06 Suspicious naevi: treat
DESJARDINS L, Cassoux N, LumbrosoLeRouic L, Levy C, Dendale R - Paris

2348 12:17 Suspicious naevi: observe
ZOGRAFOS L - Lausanne
Retinal imaging is a highly dynamic field with enormous achievements over the recent years. OCT angiography is a functional extension of OCT that allows for the non-invasive visualization of the ocular microvasculature. An important aspect of the technique is the potential to visualize choroidal neovascularization secondary to diseases such as age-related macular degeneration and pathological myopia. The technique has, however, also been used to visualize perfusion changes in a wide variety of diseases such as diabetic retinopathy, glaucoma and non-arteritic ischemic optic neuropathy. Whereas OCT has found its way to clinical practice already soon after its introduction adaptive optics imaging is still at the stage of research and is available only at a few centers. In the present SIS we will discuss whether adaptive optics will make it into widespread clinical use in the next years. Another issue that has attracted much attention is the possibility to use imaging as endpoint in clinical trials. This topic will be discussed with a focus on geographic atrophy.

**SCHMETTERER L, GARHOFER G**

2351  11:00  OCT angiography in retinal disease  
SOUIED E - Creteil

2352  11:15  OCT angiography in ONH disease  
SCHMETTERER L - Vienna

2353  11:30  AO Imaging - will it become a clinical tool?  
PAQUES M - Paris

2354  11:45  Imaging endpoints in clinical trials  
GARHOFER G - Vienna

2355  12:00  Ultrawidefield OCT  
KOLB JP, Klee J, Klein T, Kufner W, Neubauer A, Huber R - Lubeck

2356  12:15  Updates on retinal imaging technology for screening and diagnosis  
WONG T, Schmetterer L - Melbourne

**SIS**

11:00 - 12:30 | RHODES 4

PBP/RV - Update on retinal imaging

**SIS**

11:00 - 12:30 | GALLIENI 1+2

NSPH - Update in pediatric retina and low vision

Retinal dystrophies in children are degenerative diseases of the retina that have marked clinical and genetic heterogeneity. These disorders include a low vision in children that should be early diagnosed with a complete work-up. The low vision has to be rehabilitated in order to keep the best quality of life of the children and parents. The review also provides insight to recent advances in clinical features, genomic molecular diagnosis and prevention of retinal dystrophies.

**BREMONT-GIGNAC D, ROBERT M**

2361  11:00  Targeted NGS: an effective approach for molecular diagnosis of hereditary vitreoretinopathies  

2362  11:22  Update in low vision reeducation  
ATILLA H - Ankara

2363  11:44  Update in vitreoretinal diseases in children  
ROTHSCHILD P - Paris

2364  12:06  New insights on the anatomy and function of the retina in sickle cell disease  
Scleral Contact Lenses have evolved into a high-tech and versatile tool for the treatment in many different scenarios of ocular surface dysfunction and disease. They are custom made from novel materials according to the ocular surface topography of an individual patient and are much easier to fit and to wear than the historic scleral glass lenses. Sclerals are thus an ideal medical tool in the hands of the clinician for optical restoration of irregular corneas, in keratoconus, in severe dry eye disease and as a measure to improve or even heal corneal recurrent erosions, ulcers, opacities and scars without the need to undergo surgery or even keratoplasty. The aim of the present SIS is to evaluate and discuss the chances and limits of Scleral Contact Lenses in relation to surgical approaches.

**KNOP E, MEKKI MB**

<table>
<thead>
<tr>
<th>2371</th>
<th>11:00</th>
<th>What makes ocular surface anatomy attractive for a scleral lens?</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>KNOP E - Berlin</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2372</th>
<th>11:18</th>
<th>Scleral lens as lifeline for dissatisfied patients after refractive reshaping corneal surgery</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>MEKKI MB, Yahiaoui S, Titah O, Belaoudmou R - Algiers</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2373</th>
<th>11:36</th>
<th>Sclerals contact lenses in daily practise – When is it bowl and when knife?</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>ROSENBLATT M - Chicago</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2374</th>
<th>11:54</th>
<th>Scleral lenses - What we don’t (but should) know</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>NAU A - Boston</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2375</th>
<th>12:12</th>
<th>SURGERY: When do I still prefer surgery instead of Sclerals?</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>ROSENBLATT M - Chicago</td>
</tr>
</tbody>
</table>

**STACHS O, SZENTMARY N**

<table>
<thead>
<tr>
<th>2381</th>
<th>11:00</th>
<th>Rostock Cornea Module 2.0 - a versatile extension for anterior segment imaging</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>STACHS O, Sperlich K, Bohn S, Stolz H, Guthoff R - Rostock</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2382</th>
<th>11:12</th>
<th>Comparison of four technics of surface roughness assessment of corneal lamellar cuts</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>2383</th>
<th>11:24</th>
<th>Revisiting corneal collagen crosslinking (CXL) safety: Evaluation of the effect of ultraviolet-A (UVA) radiation on the retina with multifocal electroretinogram (mf-ERG) and optical coherence tomography (OCT)</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>2384</th>
<th>11:36</th>
<th>Long term outcome of Intrastromal corneal ring segment in keratoconus</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>KANG M J, Lee J H, Choi M H, Joo C K - Seoul</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2385</th>
<th>11:48</th>
<th>Two photon microscopic findings of sonoporation-assisted enhancement of corneal penetration of fluoroquinolone antibiotics</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>2386</th>
<th>11:54</th>
<th>Hydrops: Not that bad!</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>MEKKI MB, Said Y, Okba T, Taibi A - Algiers</td>
</tr>
</tbody>
</table>
### Lunchtime CIS - Demodex under the spotlight

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>2431</td>
<td>12:40</td>
<td>Prevalence and clinical practice in management across Europe</td>
<td>KAYA S - Vienna</td>
<td>RHODES 2</td>
</tr>
<tr>
<td>2432</td>
<td>13:00</td>
<td>Detection of Demodex in the clinical setting</td>
<td>MARKOMICHELAKIS N - Athens</td>
<td></td>
</tr>
<tr>
<td>2433</td>
<td>13:20</td>
<td>Presentations of case management</td>
<td>OZCAN AA - Adana</td>
<td></td>
</tr>
</tbody>
</table>
13:50 Introduction by Francesca M. CORDEIRO

13:55 The genetics revolution as seen through the eye

Up to the early 1980s, a molecular understanding of the disease process for retinal dystrophies such as retinitis pigmentosa (RP) was almost nil. Given the complex nature of the retina, it was clear that significant clinical variability would exist but no clues that could explain the disease. Fortunately at this time molecular biology techniques were maturing that started the new genetics revolution and the field of ophthalmology saw the greatest progress in understanding the molecular basis of inherited retinopathies. A “reverse genetics” approach laid the foundation for the eventual isolation of the first gene for RP, namely ‘rhodopsin’ in 1989. Family based studies became the driving force that began unraveling the immense genetic heterogeneity defining retinal dystrophies. RP affects 1 in 3000 people worldwide. Initially the rod photoreceptor cells are affected leading to night-blindness and constriction of the visual field. In later stages cone cells may also die often resulting in total blindness. RP can be inherited as an autosomal dominant or autosomal recessive or X-linked trait. So far over 60 retina-specific as well as ubiquitously expressed genes have been implicated, describing a wide variety of functions including enzymes, structural proteins, transcription factors and splicing factors. Taken together that include RP, cone-rod dystrophy, cone dystrophy and a variety of macular dystrophies, well over 250 genes have been identified so far (RetNet, http://www.sph.uth.tmc.edu/Retnet/), underpinning a real advance in our knowledge of retinal dystrophies. This knowledge is steadily leading the way to developing exciting new genetic therapies for these incurable diseases.

14:20 Award presentation of the EVER Certificate of Honour

Biography of Prof. Shomi BHATTACHARYA:

Shomi Bhattacharya graduated in Chemistry from University of Mumbai in 1969 and then came to UK in 1970. He completed his M.Sc. in 1971 followed by Ph.D. from University of Newcastle upon Tyne in 1977. In 1980 he joined University of Edinburgh where in 1984 identified the first genetic locus for retinitis pigmentosa (RP). In 1986 he started his own research group and in 1987 he returned to Newcastle where he was appointed as head of Molecular Genetics in the department of Human Genetics.

In 1992 he joined the Institute of Ophthalmology in London as Sembal Professor of Experimental Ophthalmology. Shomi retired in January 2016 and is now an Emeritus Professor of Ophthalmology at UCL. He is currently appointed as a Distinguished Researcher & Principal Investigator at the Andalusian Centre of Molecular Biology & Regenerative Medicine (CABIMER) in Seville, Spain. He was Director of CABIMER from 2008 to 2016.

Prof Bhattacharya received the Paul Kayser International Award of Merit in 1986 followed by the Alcon Research Institute Award in 1991. He was elected Fellow of the Academy of Medical Sciences (FMedSci) in 2001 and Fellow of the Royal Society of Edinburgh (FRSE) in 2006. He was awarded the Chair of Excellence in France in 2007 where he holds a Full Professor appointment at the Institut de la Vision, Paris.

His major research interests are in gene mapping and gene identification of inherited eye diseases. His notable achievements have been in gene identification for retinal degeneration (NRL, PRPF31, 3 & 8, CRB1, APL1, TOPORS, EYS, GCAP1, CRX and RetGC1), cataract (connexins 46 & 50, alpha-B crystallin and MIP) and dominant optic atrophy (OPA1). Established proof of principle of gene based therapy by the rescue of the rds mouse. His current research includes disease modeling in vitro in cell lines generated through iPSC technology and cell therapy. During the course of his academic career he has published over 375 peer-reviewed papers, two books, 15 book chapters and supervised 40 Ph.D. students.
The development of topically applied agents for retinal diseases is a potentially paradigm shift in treatments of many diseases. Multiple approaches have been tried, and agents are now in clinical trial for age related macular degeneration, diabetic retinopathy and other conditions. However, a clear understanding of the properties required to deliver agents from the ocular surface to the retina are still not clearly laid out, and proof of concept for therapeutic agents is still awaited. This session will explore the latest advances in understanding how agents can be designed to penetrate to the retina, and highlight some of the pitfalls with drug design that could hinder effective drug delivery.

**BATES D**

**2611**  
14:30 Topical delivery for retinal angiogenesis - an overview of clinical developments  
*BATES D - Nottingham*

**2612**  
15:00 Optimisation of novel small molecule inhibitors of SRPK1-mediated VEGF-A splicing through modelling of permeability properties required for trans-scleral eye drop delivery  

**2613**  
15:30 Nanoparticle delivery for diabetic macular edema  
*STEFANSSON E - Reykjavik*

---

Surgical training in the field of Ophthalmology is a complex process for both trainers and trainees. It requires a fine balance between allowing younger generations to acquire technical skills and the ethical requirements to provide the patient with the best possible medical treatment. Centers throughout the world have been developing strategies to minimize both the steepness of the learning curve and the rate of surgical complications. One such strategy is simulated training. By allowing the trainee to test protocols, manual procedures and routines in a risk-free environment, the concept has been implemented in several areas of knowledge where the risks of malperforming are unacceptable (such as in the airline industry). In the field of Ophthalmology, this strategy has had several approaches, from virtual training to wet-lab facilities.

We expect from our SIS to have a shared experience between centers and to provide a discussion on the role simulated surgery can play in filling in the gap of the perceived lack of surgical training.

**ABEGAO PINTO L , SUNARIC MEGEVAND G**

**2621**  
14:30 Simulation in flight safety - what can we learn from the airline industry?  
*DOW I - London*

**2622**  
14:48 SOS - Simulated Ocular Surgery website and applications  
*MCNAUGHT A - Cheltenham*

**2623**  
15:06 Real-life Experience with glaucoma surgical training using SOS eyes  
*MERCIECA K - Manchester*

**2624**  
15:24 The Royal College of Ophthalmologists and Surgical Training Evolution in the UK  
*SPENCER F - Manchester*

**2625**  
15:42 Simulation in Mainland Europe - the present and future  
*ABEGAO PINTO L - Lisbon*
14:30 - 16:00 | RHODES 2

IM - The new era of non-infectious uveitis treatment: from old concepts to new perspectives

**PICHI F, ALBINI T**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2631</td>
<td>14:30 Local steroidal treatments: what’s new</td>
<td>LOWDER C - Cleveland</td>
</tr>
<tr>
<td>2632</td>
<td>14:52 New intraocular therapies for non-infectious uveitis</td>
<td>ALBINI T - Miami</td>
</tr>
<tr>
<td>2633</td>
<td>15:14 Traditional immunesuppressive therapy: is there something we should know further?</td>
<td>PICHI F - Cleveland</td>
</tr>
<tr>
<td>2634</td>
<td>15:36 Biologic therapy: let the Copernican revolution begin!</td>
<td>NERI P, Gorgoni F, Gennari G, Cesari C - Agugliano</td>
</tr>
</tbody>
</table>

14:30 - 16:00 | RHODES 3

EOVS/MBGE - Doctor, I don’t like bright lights

A discussion of the investigation and management of the patient with photophobia.

**HOLDER G, LEROY BP**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2641</td>
<td>14:30 The first consultation</td>
<td>DE ZAETYUJD J - Ghent</td>
</tr>
<tr>
<td>2642</td>
<td>14:52 Photophobia in retinal disease</td>
<td>LEROY BP - Ghent</td>
</tr>
<tr>
<td>2643</td>
<td>15:14 Photophobia in neuro-ophthalmic disorders</td>
<td>KAWASAKI A - Lausanne</td>
</tr>
<tr>
<td>2644</td>
<td>15:36 The role of electrophysiology</td>
<td>HOLDER G - London</td>
</tr>
</tbody>
</table>
**Diagnosis and management of iris tumors and pseudo-tumors in selected cases may be challenging.**

The aim of this course is to describe the clinical presentation of the most frequent iris tumors and pseudo-tumors and to describe all possible therapeutic approaches as well as the management of secondary glaucoma which may be associated to the melanocytic tumors of the irido-ciliary complex.

**ZOGRAFOS L, DESJARDINS L**

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2651</td>
<td>14:30</td>
<td>Tumors and pseudo-tumors of the iris: classification and imaging techniques</td>
<td>ZOGRAFOS L - Lausanne</td>
</tr>
<tr>
<td>2652</td>
<td>14:48</td>
<td>Nevus, melanocytoma and melanoma: differential diagnosis</td>
<td>SHIELDS C - Philadelphia</td>
</tr>
<tr>
<td>2653</td>
<td>15:06</td>
<td>Circumscribed irido-ciliary melanoma: surgery versus irradiation</td>
<td>DESJARDINS L, Cassoux N, LumbrosoloRouic L, Dendale R - Paris</td>
</tr>
<tr>
<td>2654</td>
<td>15:24</td>
<td>Diffuse iris melanoma: proton beam irradiation</td>
<td>SCHALENBOURG A - Lausanne</td>
</tr>
<tr>
<td>2655</td>
<td>15:42</td>
<td>Pediatric tumors of the iris</td>
<td>HADJISTILIANOUT - Sienna</td>
</tr>
</tbody>
</table>

**Corneal dystrophies refer to a group of corneal diseases and that are genetically determined.**

Our understanding of corneal phenotype has improved with improving anterior segment imaging and early genotype-phenotype correlations. Primary corneal disease includes endothelial dystrophies, corneal dermoids, cornea plana, and kerato-irido-lenticular dysgenesis (also known as Peters anomaly, types 1 and 2). Other secondary developmental corneal diseases may include Axenfeld-Rieger syndrome, Aniridia, and primary congenital glaucoma, with specific genotype. The new molecular information is challenging the traditional thinking that was usually guided by the histopathological findings. Other secondary causes are acquired and include infection, trauma, and metabolic disorders. The new molecular information is challenging the traditional thinking that was usually guided by the histopathological findings. An overview of the innovating diagnosis and treatment are summarized.

**BREMOND-GIGNAC D, ATILLA H**

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2662</td>
<td>14:52</td>
<td>Update in CHED</td>
<td>BREMOND-GIGNAC D - Paris</td>
</tr>
<tr>
<td>2663</td>
<td>15:14</td>
<td>Peters anomaly new insights</td>
<td>ATILLA H - Ankara</td>
</tr>
<tr>
<td>2664</td>
<td>15:36</td>
<td>Aqueous humor cytokines report in congenital cataract</td>
<td>SAUER A - Strasbourg</td>
</tr>
</tbody>
</table>
THURSDAY, SEPT 28 - FIRST AFTERNOON SESSION

14:30 - 16:00 | GALLIENI 4
NSPH - Neuro-ophthalmology

YU-WAI-MAN P, SADUN A


2672 14:42 Red light provides partial protection against retinal ganglion cell degeneration in a mouse model of dominant optic atrophy through the activation of NFkB VOTRUBA M, Beirne K, Rozanowska M - Cardiff

2673 14:54 In vitro modeling of aniridia-related PAX6 haploinsufficiency by the use of CRISPR/Cas9 on limbal epithelial cells ROUX L, Concordet J P, Ferrigno O, Aberdam D - Paris


2675 15:18 Attitudes of parents toward eye care in children under 7 years old in the Republic of Ireland CONWAY M, Subramanian A, O Donoghue E, Donaldson L - London

2676 15:30 MabThera use and efficacy in patients with active moderate to severe Graves’ Orbitopathy: a multicentre retrospective study of 40 cases LEBRANCHU P, Deltour J B, Cariou B, Vabres B, D’Assigny M, Drui D - Nantes

14:30 - 16:00 | GALLIENI 5
MBGE - Retinal disorders and their treatment

LISKOVA P, DAVIDSON A

2681 14:30 Mutation detection of Pakistani families with autosomal recessive retinal dystrophies RAVESH Z, Wissinger B, Ansar M - Tehran

2682 14:42 A novel NR2E3 gene mutation in autosomal recessive retinitis pigmentosa with cystic maculopathy MAHAJAN D, Votruba M - Shimla, Himachal Pradesh

2683 14:54 Gene therapy targeting of choroidal disease and AAV transcytosis through the outer blood retina barrier epithelium LAYTON C, Dhungel B, Andrzejewski S, Jayachandran A, Murali A, Ramlogan-Steel C, Steel J - Greenslopes


2686 rf 15:30 X-linked juvenile retinoschisis: different mutations – same phenotype STRUPAITE R, Ambroziaityt L, Cimbalistien L, Ašoklis R, Utkus A - Vilnius

POSTER SESSION 1
THURSDAY, SEPT 28

16:00 - 17:00 | POSTER AREA

ACB: Anatomy/Cell Biology

Poster T001-T020

PETROVSKI G, KAARNIRANTA K

T001
Nature-inspired Nrf2 activators in retinal pigment epithelial cells: a source for therapeutics in age-related
macular degeneration
AMADIO M, Serafini MM, Marchesi N, Catanzaro M, Fagiani F, Simoni E, Pascale A, Rosini M, Lanni C - Pavia

T002
Nrf-2 and PGC1-alpha deletion affects ultrastructural changes in retinal pigmented epithelium associated
with the changes of oxidative stress and autophagy markers expression pattern in compound null mice

T003
Nrf-2 and PGC1-alpha deletion affects ultrastructural changes in retinal pigmented epithelium associated
with the changes of oxidative stress and autophagy markers expression pattern in compound null mice

T004
Effects of HSP90 inhibitor TAS-116 on the inflammasome activation in ARPE-19 cells

T005
Autophagy induction decreases protein aggregation in response to polyphenolic pinosylvin and heat shock
exposures in ARPE-19 cells
AMIRKAVEI M, Koskela A, Koskelainen A, Kaarniranta K - Kuopio

T006
Loss of Nrf-2 and PGC1-alpha genes changes macromorphology of the eye and evokes microstructural and
pigmentation pattern changes of the retinal pigmented epithelium

T007
Serum adiponectin associates with aging rather than neovascular AMD
PATERNO JJ, Kauppinen A, Kaarniranta K - Kuopio

T008
Modulation of the rod outer segment aerobic metabolism diminishes the production of radicals due to light
absorption
PANFOLI I, Calzia D, Degan P, Caicci F, Manni L, Traverso CE - Genova

T009
Protective effects of sulforaphane on STZ-induced diabetic retinopathy via activation of Nrf2/HO-1
antioxidant pathway and inhibition of NADPH oxidase
HE M, Luan L, Zhang Y, Nan Y - Beijing

T010
Differential hypoxic response of human choroidal and retinal endothelial cells proposes tissue heterogeneity
of ocular angiogenesis
ANDRE H, Mammadzada P, Gudmundsson J, Kvanta A - Stockholm

T011
Human ex vivo model of iris angiogenesis
ANDRE H, Pesce N, Plastino F, Kvanta A - Stockholm

T012
A novel in vivo model of puncture-induced iris neovascularization

T013
The supportive role of interferon- in retinal differentiation of mesenchymal stem cells

T014
Can optical coherence tomography be used in lacrimal gland imaging?
MRAZOVA D, Juri Mandic J, Ivkic PK, Mandic K, Jukić T - Zagreb

T015
The 8-fold quadrant dissection method for ex vivo human interventional retinal experimentation
MURALI A, Ramlogan-Steel C, Andrzejewski S, Dhungel B, Steel J, Layton C - Brisbane
The investigation of the distribution of nerves, blood vessels and immune cells on the fresh human corneal surface using optimized protocols for immunostaining of flat mounted whole cornea

Remote ischemia affects the diameter of larger retinal vessels in normal persons
EL DABAGHY, Petersen L, Pedersen M, Bek T - Aarhus C

An educational information platform on the ocular surface and dry eye disease - OSCB-Berlin.org
KNOP E, Knop N - Berlin

A holistic dynamic concept on the pathophysiology in dry eye disease
KNOP E, Knop N - Berlin

Macrogilal retinal cells show a bilateral early activation in a mouse model of unilateral laser-induced experimental glaucoma
KARANJIA R, CARELLI V

**T021**
Assessment of the visual acuity, contrast sensitivity, color vision and visual integration in the Alzheimer’s Disease progression according to the scale GDS

**T022**
Thickness mapping of individual retinal layers and sectors by Spectralis SD-OCT in Autosomal Dominant Optic Atrophy
CORAJEVIC N, Larsen M, Rönnbäck C - Copenhagen N

**T023**
Optical coherence tomography in cerebral amyloidosis

**T024**
Changes in visual function and retinal structure in patients with manic-depressive illness or bipolar disorder

**T025**
Macular thickness changes using spectral-domain optical coherence tomography automated layer segmentation in multiple sclerosis
BARATA A, Leal I, Sousa F, Teixeira F, Henriques J, Pinto F - Lisboa

**T026**
Reduction in subfoveal choroidal thickness and peripapillary retinal thickness after high-dose melphalan therapy followed by autologous peripheral blood stem cell transplantation in a patient with POEMS syndrome
HIROTAKAY, Toshiyuki O, Takayuki B, Shuichi Y - Chiba

**T027**
Retinal nerve fibre layer thickness associates with cognitive impairment and physical disability in multiple sclerosis

**T028**
Swept-Source OCT utilised to compare the choroidal thickness of the peripapillary area between patients with Parkinson’s disease and healthy subjects
OBIS J, Garcia-Martin E, Satue M, Rodrigo MJ, Cipres M, Vilades E, Orduna E - Zaragoza

**T029**
Neuro-retinal changes evaluation in multiple sclerosis patients: 10 years follow-up

**T030**
Choroidal changes in patients with multiple sclerosis
Rodrigo MJ, Garcia-Martin E, Orduna E, Obis J, Cipres M, VILADES E, Satue M - Zaragoza

**T031**
Reproducibility of the measurements taken with swept source optical coherence tomography

**T032**
Choroidal thickness measurements around the optic disc in healthy subjects using Swept-Source optical coherence device
CIPRES ALASTUEY M, Garcia Martín E, Bambó Rubio MP, Vilades Palomar E, Rodrigo Sanjuan MJ, Satué Palacián M, Orduna Hospital E, Obis Alfaro J - Zaragoza

**T033**
Optical coherence tomography outcomes in patients with Friedreich ataxia

**T034**
Visual impairment in combined pathology: multiple sclerosis and pituitary adenoma
IOYLEVA E, Makarenko I - Moscow
KARANJIA R, CARELLIV

T035  Correlation between electrophysiological test and visual dysfunction in multiple sclerosis patients
VILDADES PALOMAR E, Orduna Hospital E, Ciprés M, Obis J, Rodrigo SanJuan MJ, Satué Palacian M, Garcia-Martin E - Zaragoza

T036  Multifocal electroretinogram and optical coherence tomography to evaluate parafoveal fixation
VILDADES PALOMAR E, Orduna Hospital E, Ciprés M, Obis J, Rodrigo SanJuan MJ, Satué M, Garcia-Martin E - Zaragoza

T037  Visual function in multiple sclerosis patients treated with Fingolimod during two years of follow-up
CIPRES ALASTUEY M, Garcia Martin E, Bambó Rubio MP, Vilades Palomar E, Satué Palacian M, Obis Alfaro J, Rodrigo Sanjuan MJ, Orduna Hospital E - Zaragoza

T038  Cabin pressure aboard commercial aircraft and non-arteritic ischemic optic neuropathy

T039  Differences in onset between eyes in patients with Leber’s Hereditary Optic Neuropathy (LHON)

T040  Clinical experience with idebenone in the treatment of patients harboring rare mutations related to Leber’s Hereditary Optic Neuropathy (LHON)

T041  Idebenone is effective and well tolerated in Leber’s Hereditary Optic Neuropathy (LHON): Long-term results of real world clinical practice
LLORIA X, Catarino C, Silva M, Klopstock T - Liestal

T042  Optical coherence tomography angiography of the peripapillary retina and optic nerve head in Wolfram syndrome
HASSAIRI A, Falhoul Y, Matri K, Regai E, Chebil A, El Matri L - Tunis

T043  Ophtara centers of expertise in France: Fostering collaborative research and patient care for rare eye diseases
BREMOND-GIGNAC D, Mincheva Z, De Vergnes N, Valleix S, Robert M, SENSGENE Network Team T, OPHTARA Network Team T - Paris

T044  Microperimetry by optic nerve atrophy
IOYLEVA E, Krivosheeva M - Moscow

T045  Clinical applications of a visual field perimeter with binocular video imaging
CHARLIER J - Perenchies

T046  Comparative investigation of compression optic neuropathy of Graves orbitopathy(GO) as emergency orbital decompression
TAGAMI M, Kusuhara S, Azumi A - Kobe

T047  Prediction of ophthalmological problems in 6.5 year-old prematurely born children

T048  Comparison of traditional training and push-pull training for the binocular visual function in anisometropic amblyopia
FU J, Hong J, Zhao B - Beijing

T049  Visual status of patient with syndrome of Moebius
BUSHUYEVA N, Romanenko D, Dukhayer S - Odessa

T050  Magnetic resonance imaging features in moebius syndrome: a pilot study
Poster T021-T060

KARANJIA R, CARELLIV

T051 Clinical features of strabismus and nystagmus in bilateral congenital cataract
LEE S J, Sung Soo H, Jung Min P - Busan

T052 Treatment with prism glasses for overcorrection after surgery for exotropia in children
CHANG HR - Seoul

T053 Comparison between over-glasses patching and conventional patching for children with moderate amblyopia: a prospective randomized clinical trial
KIM SJ, Lee SU, Jeon HS, Jung JH, Choi HY - Changwon-si

T054 A method for a rapid objective measurement of eye deviation angle in both strabismus and phoria
YEHEZKEL O, Spierer A, Oz D, Yam R, Belkin M - Airport City

T055 Redistribution within retinal layers of the central fovea in preterms with developmental arrest
SJOSTRAND J, Popovic Z - Mölndal

T056 Enhanced visual attentional modulation in patients with inherited peripheral retinal degeneration in the absence of cortical degeneration
Ferreira S, Andreia P, Quendera B, Silva E, Reis A, CASTELO-BRANCO M - Coimbra

T057 Slit lamp assessment of relative afferent pupillary defect
MEKKI M B - Algiers

T058 Case of IgG4-related eye disease accompanied by compressive optic neuropathy
TAKEISHI M, Oshitari T, Ota S, Chiba A, Yamamoto S - Chiba

T059 Spectral-domain optical coherence tomography of optic nerve after closed eye injury
IOYLEVA E, Zelentsov K, Zelentsov S, Duginov A, Ankundinov A - Moscow

T060 An intraocular foreign body detection using swept-source OCT
Can the retina be used to diagnose and plot the progression of Alzheimer’s disease?
MAHAJAN D, Votruba M - Shimla, Himachal Pradesh

The proportion of microsaccadic overshoot and the influence of accommodation on the quantitative measures of microsaccades in fourteen normal test persons
VISBY E, Møller F - Vejle

Correlations of retinal thickness with frequency-doubling technology perimetry in older healthy subjects

Timing of changes in the entropy of the electroretinogram with glaucoma
SAROSSY M, Aliahmad B, Kumar D - Moonee Ponds

Across-frequency impairment in seeing a temporal gap
HIROSE N, Okuda Y, Mori S - Fukuoka

Changes in the electromyography of the lateral and medial muscles after the electrostimulation treatment of lateral muscles in children with convergent concomitant strabismus
BOYCHUK I, Mazur V - Odessa

The time course of contrast sensitivity recovery after a pigment bleaching is delayed in subjects with abdominal obesity

AMD drusenoid deposits “L” lipid type: morphology, volume, evolution analysis with morphology-structural software
GONZALEZ C - Toulouse

AMD drusenoid deposits “P”, protein-cellular type: volume, morphology, evolution analysis with morphology-structural software
GONZALEZ C - Toulouse
**Poster T070-T090**

**WILLERMAIN F, DICK A**

**T070**

Effect of microglia suppression on branch retinal vein occlusion in mice

JOVANOVIC J, Ebnet A, Kokona D, Zinkernagel MS - Bern

**T071**

Panton-Valentine leukocidin enhances glial reaction and microglial apoptosis through retinal ganglion and amacrine cell binding


**T072**

Inflammatory markers but not symptoms are a strong predictor of temporal artery biopsy outcome – the Portsmouth experience

MEREDITH PR, Sepetis A, Balendra S, Jawed M, Lockwood A J, Maclean H - Portsmouth

**T073**

The effect of autoimmune retinopathy on retinal vessel oxygen saturation in patients with and without clinical features of retinitis pigmentosa

WAIZEL M, Türksever C, Rickmann A, Todorova MG - Basel

**T074**

Unilateral retinal vasculopathy in systemic lupus erythematosus


**T075**

Fuchs’ uveitis masquerading as a Behçet related anterior uveitis

CLAEYS M, Sys C, Leroy BP, De Schryver I - Ghent

**T076**

Towards a new therapy concept for acute microbial keratides, including Acanthamoebae

STORSBERG J, Schmidt C, Plog C, Höfer P, Klöpzig S, Rehfeldt S, Sel S - Potsdam

**T077**

Efficacy of tumour necrosis factor inhibitors in peripheral ulcerative keratitis in Granulomatosis with polyangiitis

VERLY E, De Kock J, Leroy B P, Sys C, De Schryver I - Gent

**T078**

Orbital lymphoma presenting as a recurrence of posterior scleritis after treatment with adalimumab


**T079**

Adalimumab as an alternative treatment in Serpiginous Choroiditis


**T080**

INFliximAB and ADAlIMUMAB in uveitic macular edema

LEJOYEUR R, Diwo E, Vallet H, Bodaghi B, Le Hoang P, Fardeau C - Paris

**T081**

Immunosuppression for uveal effusion syndrome – a report of two cases

STANISZEWSKI B, Forrester J V, Kuffova L - Aberdeen

**T082**

A case of recurrent bilateral optic oedema in tubulo-interstitial nephritis and uveitis syndrome treated with plasmapheresis


**T083**

Post-marketing surveillance study of the safety of dexamethasone intravitreal implant (DEX) in patients with retinal vein occlusion (RVO) or noninfectious posterior segment uveitis (NIPSU)

THURSDAY, SEPT 28 - POSTER SESSION 1

16:00 - 17:00 | POSTER AREA

IM: Immunology/Microbiology

**WILLERMAIN F, DICK A**

**T084**  Portuguese prescription patterns of topical antibiotics in Ophthalmology: a yearlong analysis
   **SOUSA DC, Leal I, Nascimento N, Abegão Pinto L, Marques-Neves C - Lisboa**

**T085**  Intravitreal ranibizumab treatment in choroidal neovascularization secondary to ocular toxoplasmosis in children

**T086**  Inflammatory choroidal neovascularization imaged by optical coherence tomography – angiography
   **DIWO E, Coscas F, Massamba N, Bodaghi B - Paris**

**T087**  Superficial and deep retinal foveal avascular zone OCT-A findings of non-infectious anterior and posterior uveitis compared to healthy controls
   **WAIZEL M, Todorova MG, Terrada C, Massamba N, LeHoang P, Bodaghi B - Basel**

**T088**  Macular study on SD-OCT in sarcoidosis uveitis at active and sequelae phases
   **BOULADI M, Nafaa F, Bouraoui R, Limaiem R, Chaker N, Mghaieth F, El Matri L - Tunis**

**T089**  Use of wide-field fluorescein angiography in the diagnosis and management of sarcoidosis uveitis

**T090**  A new model of fundus autofluorescence time evolution in multiple evanescent white dot syndrome
   **SOJKA-LESZCZYNSKA P, Leszczy ski B, Kubicka-Trz ska A, Romanowska-Dixon B - Kraków**

**Coffee with the Profs**

In an initiative to encourage dialogue amongst speakers and EVER members, we have organised a session called “Coffee with Profs”. This will be a table of 6-8 “guests” at a table headed by one of the EVER speakers: **Alfredo Sadun, Michael Belkin, a.o.** The idea is to provide a casual yet personal venue where colleagues, in particular the younger faction, can share comments and ideas with an expert.
### HERMES

**RV - Macular interface surgery**

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Title</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2711</td>
<td>17:00</td>
<td>ERM management</td>
<td>TRANOS P - Thessaloniki</td>
</tr>
<tr>
<td>2712</td>
<td>17:12</td>
<td>Partial thickness Macular holes and pharmaceutical treatment of FTMH</td>
<td>POURNARAS JA - Lausanne</td>
</tr>
<tr>
<td>2713</td>
<td>17:24</td>
<td>Surgical techniques for failed/difficult macular holes</td>
<td>OZDEK SO - Ankara</td>
</tr>
<tr>
<td>2714</td>
<td>17:36</td>
<td>Retinal re-modelling following ILM flap technique for FTMH</td>
<td>STAPPLERT, Hussain R, Heimann H, Wong D - Liverpool</td>
</tr>
<tr>
<td>2715</td>
<td>17:48</td>
<td>Pathophysiology of macular interface</td>
<td>KALEMAKI M - Heraklion</td>
</tr>
<tr>
<td>2716</td>
<td>18:00</td>
<td>New technologies in the investigation of macular interface disorders</td>
<td>TSAKPINIS D, Pappas G - Thessaloniki</td>
</tr>
<tr>
<td>2717</td>
<td>18:12</td>
<td>Non-surgical treatment of idiopathic macular hole (IMH)</td>
<td>XIROU T - Glyfada</td>
</tr>
</tbody>
</table>

### RHODES 1

**G - Innovations in glaucoma surgery**

This section will aim to give an update in the exciting and innovative field of glaucoma surgery, with a focus on minimally invasive glaucoma surgery.

**RATNARAJAN G, KERR N**

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Title</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2721</td>
<td>17:00</td>
<td>Schlemm canal stenting</td>
<td>KERR N - Victoria</td>
</tr>
<tr>
<td>2722</td>
<td>17:18</td>
<td>Supra-choroidal outflow</td>
<td>SHAARAWY T - Lausanne</td>
</tr>
<tr>
<td>2723</td>
<td>17:36</td>
<td>Newer goniotomy devices</td>
<td>VARMA D - Oakville</td>
</tr>
<tr>
<td>2724</td>
<td>17:54</td>
<td>Sub-conjunctival drainage</td>
<td>RATNARAJAN G - East Grinstead</td>
</tr>
<tr>
<td>2725</td>
<td>18:12</td>
<td>Non-penetrating glaucoma surgery</td>
<td>MERMOUD C - Genève</td>
</tr>
</tbody>
</table>
Molecularly targeted agents are commonly used in oncology practice, and many new targeted agents are currently being tested in clinical trials. Many of the molecules targeted by anticancer agents are also expressed in ocular tissues, causing frequent and potentially severe ocular adverse events. Ophthalmologists should have high indexes of suspicion to diagnose and treat these complications promptly. The aim of this SIS is to discuss the proposed pathogenesis, monitoring guidelines, and management recommendations. Special attention will be given to the clinical and molecular features of MEKi-related retinopathy.

ANGI M, NERI P

2731 17:00  Why the eye? Current understanding on the pathogenesis of ocular toxicities  
NERI P, Nicolai M, Bisceglia P - Agugliano

2732 17:22  What to look for? Monitoring guidelines  
ANGI M - Milan

2733 17:44  What to do? Management recommendations  
DAMATO EM - Birmingham

2734 18:06  MEKi-related retinopathy  
JAGER MJ, Van Dijk EHC, Van Herpen CML, Marinkovic M, Luyten GP, Kapiteijn EH, Boon CJ - Oegstgeest

The prevalence of refractive error in Europe and the world has become a major research topic. Here it is important to discuss the definition and mechanisms of emmetropisation. Biometry of the human eye is key for understanding such processes, feeding into patient diagnosis and treatment. This symposium will present evidence on biometric and optical changes with age and their differences with gender. As such biometry is the backbone of our understanding of "normal," a specific emphasis of the Symposium is placed on life-long lens changes. Myopia has become a major public health concern, with prevalence rates rising in several countries, most notably in urban East Asia. The etiology for the development of myopia is diverse, including genetics and environmental factors such as near work versus outdoor activity. This Special Interest Symposium will give an overview about the refractive development from childhood to adulthood, highlighting the unresolved questions which will define future research.

MICHAEL R, RAUSCHER F

2741 17:00  The epidemiology of refraction  
OHLENHOF A - Tübingen

2742 17:18  What do we really mean by emmetropisation  
MORGAN I - Ainslie

2743 17:36  Changes in normal ocular biometry and optics with age  
ROZEMA J - Edegem

2744 17:54  Age related changes of the crystalline lens  
NAVARRO R - Madrid

2745 18:12  Myopia - biological mechanisms and unresolved questions  
SCHAEFFEL F - Tübingen
Acanthamoeba keratitis, infectious crystalline keratopathy, fungal keratitis and atypical mycobacterial keratitis have emerged as important types of infectious keratitis. These corneal infections have often been associated with contact lens wear, with corneal surgery such as radial keratotomy or penetrating keratoplasty and with the uncontrolled use of topical steroids. The clinical setting of each of these infections is important in alerting the clinician to the possible diagnosis. There have been improvements in rapid diagnostic techniques for such infections in the last years. Treatment has also improved, but remains a difficult problem, especially for Acanthamoeba. In this course, we’ll give you an overview of recent developments in the clinical and histopathologic methods for diagnosis and treatment options of these corneal infections. We will also see how new techniques such as Amniotic Membrane Transplantation and Crosslinking can help the clinician, when facing severe cases.

GICQUEL J, DUA HS

2751  17:00  Corneal bacterial infections: A practical approach  
       GICQUEL JJ - Saint Jean d’Angély

2752  17:22  Herpes and Zoster infections update  
       LABETOUSLE M - Le Kremlin Bicêtre

2753  17:44  The particularities of corneal infectious diseases in children  
       BREMOND-GIGNAC D - Paris

2754  18:06  New emerging treatments in severe corneal infectious diseases  
       DUA HS - Nottingham

Due to the delicate and sensitive structures of the eye, inflammation and wound healing are playing an essential role in ophthalmology. They are complex interacting processes involved in the pathogenesis of many eye diseases, trauma and ocular surgery. In the maintenance of the fine homeostasis of ocular surfaces, cornea, conjunctiva and lacrimal glands are interacting via nervous system, growth factors and cytokines regulating several mechanisms like tear fluid secretion, cell differentiation, tissue regeneration, inflammation and wound healing. Tear proteomics is a novel approach to study the mechanisms involved in disease processes and to find clinically relevant biomarkers for diagnostics and for the development of novel therapeutic interventions in clinical studies.

UUSITALO H, BEUERMAN R

2761  17:00  Principles of wound healing - knowledge transfer to cornea  
       JARVINENT - Tampere

2762  17:22  Inflammatory biomarkers of the tear proteome in anterior segment disease  
       BEUERMAN R, Zhou L - Singapore

2763  17:44  Cornea and lacrimal gland synergy, a corner stone for a healthy vision  
       MICHON F - Helsinki

2764  18:06  Proteomics as a tool for stem cell research in the anterior segment of eye  
       MIKHAILOVA A - Tampere
This course will include four short lectures covering the ins and outs of clinical/research fellowships in Europe and how they can be seen from different angles, followed by interactive small group discussions, where interested attendees can see their questions answered by someone who has been or is currently doing a fellowship. The lectures will cover the fellowship as a whole, starting from the search process, going through funding and applying, understanding what hosts expect from the fellow, and finally how to make the most out of the experience. This session will end with a short wrap up and will be followed by a YOS Café Soirée, where participants can then mingle and get to know each other over some drinks and food.

JOHANNESSON G

17:00 - 18:30 | GALLIENI 4

YOS - The ABC of fellowship opportunities - what to expect, where to go and how to pay for it?

This course will include four short lectures covering the ins and outs of clinical/research fellowships in Europe and how they can be seen from different angles, followed by interactive small group discussions, where interested attendees can see their questions answered by someone who has been or is currently doing a fellowship. The lectures will cover the fellowship as a whole, starting from the search process, going through funding and applying, understanding what hosts expect from the fellow, and finally how to make the most out of the experience. This session will end with a short wrap up and will be followed by a YOS Café Soirée, where participants can then mingle and get to know each other over some drinks and food.

JOHANNESSON G

2771 17:00 Show me the money - funding opportunities for fellowships
BARBOSA BREDA J - Porto

2772 17:30 Choosing your fellowship and getting the most out of it - advice from Fellows
SOUSA C, Barbosa Breda J - Porto

2773 18:00 Choosing your fellowship and getting the most out of it - advice from Fellows
LUKIC M - London
<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Presentation</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>SIS</td>
<td>18:30</td>
<td>Objective assessment of the superficial ocular surface and tear film in dry eye</td>
<td>DUA HS - Nottingham</td>
</tr>
<tr>
<td></td>
<td>18:50</td>
<td>Bioprotection in dry eye: pre-clinical evidences</td>
<td>LABETOULLE M - Le Kremlin Bicêtre</td>
</tr>
<tr>
<td></td>
<td>19:10</td>
<td>The effects of Treahalose/sodium hyaluronate eyedrops on biomarkers</td>
<td>VERSURA P - Bologna</td>
</tr>
</tbody>
</table>
A video-guided multiple-case presentation. To begin with, simple canula insertion tips and possible failures of canula insertion and canula displacement will be presented as well as several tricks for young vitreoretinal surgeons. Macular surgery will follow. This symposium is to introduce new advances in macular hole surgery, as the inverted ILM flap technique. Additionally new advances in macular oedema surgery, as subretinal fluid injection will be shown. Several tricks will be presented in proliferative vitreoretinopathy, retinal detachment surgery, endophthalmitis and giant retinal tear. Moreover, the session includes tips and tricks in pediatric vitreoretinal surgery.

MICHALEWSKA Z, OZDEK SO

3111 8:30 Tips and tricks in open globe injuries (management of intraocular foreign bodies)
DURUKAN H - Ankara

3112 8:48 Tips and tricks in pediatric retina surgery
OZDEK SO - Ankara

3113 9:06 Tips and tricks in macula surgery
MICHALEWSKA Z, Nawrocki J - Lodz

3114 9:24 Retinectomy and silicone oil in PVR surgery-pearls and tricks
ACAR N - Istanbul

3115 9:42 Advanced vitreoretinal surgery
KOCH P - Bruxelles

---

The cornea is the most densely innervated tissue in human body. Corneal innervation is part of the lachrymal functional unit and is of utmost importance for the physiology of the ocular surface. Corneal nerves are affected by ocular surface pathologies and chronic treatments such as glaucoma medications. Besides, corneal nerve imaging using IVCM is useful for early detection and assessment of the progression of systemic diseases with peripheral neuropathies. It is considered as a surrogate marker in the evaluation of small fiber peripheral neuropathy, such as diabetic neuropathy or other rarer causes of SFN.

Corneal nerve imaging using IVCM is now able to provide qualitative and quantitative evaluation of corneal innervation. This symposium will in one hand explore the latest technical developments used to assess corneal innervation, such as automation of image analysis, and mosaicking the sub-basal nerve plexus, and in the other hand give some examples of clinical application in the field of glaucoma and ocular surface diseases and in polyneuropathies.

ROUSSEAU A, MALIK R

3121 8:30 Automatic tool for quantification of nerve fibres in corneal confocal microscopy images
MALIK R - Doha

3122 8:52 Mosaicking the subbasal nerve plexus
ALLGEIER S, Reichert KM, Stachs O, Köhler B - Eggenstein-Leopoldshafen

3123 9:14 Corneal nerves as a biomarker of peripheral neuropathy: the example of transthyretin amyloidosis

3124 9:36 The corneal nerves in glaucoma and ocular surface diseases
LABBE A, Liang H, Baudouin C - Paris
The SIS will first present briefly the different OCT modalities in ophthalmology and the related technology and terminology behind B scan OCT and angiography OCT (OCTA) necessary in clinical practice. Then the role of Bscan OCT and or OCTA will be addressed in many different subspecialties in ophthalmology. All expert speakers will specially address where OCT may help in diagnosis or / or change a therapeutical decision in daily clinic.

**AMBRESIN A, POURNARAS J**

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>3131</td>
<td>8:30</td>
<td>OCT and OCTA: new technology, new terminology</td>
<td>AMBRESIN A - Lausanne</td>
</tr>
<tr>
<td>3132</td>
<td>8:45</td>
<td>The role of OCT algorithms and OCT A in glaucoma care</td>
<td>MANSOURI K - Lausanne</td>
</tr>
<tr>
<td>3133</td>
<td>9:00</td>
<td>OCT and vitreomacular interface</td>
<td>POURNARAS JA - Lausanne</td>
</tr>
<tr>
<td>3134</td>
<td>9:15</td>
<td>OCT and retinal ganglion cell layer</td>
<td>BORRUAT FX - Lausanne</td>
</tr>
<tr>
<td>3135</td>
<td>9:30</td>
<td>OCT in age related macular degeneration</td>
<td>MANTEL I - Lausanne</td>
</tr>
<tr>
<td>3136</td>
<td>9:45</td>
<td>OCT in retinal and choroidal inflammatory disease</td>
<td>VAUDAUX J - Lausanne</td>
</tr>
</tbody>
</table>

This SIS will discuss aspects influencing tissue integrity and inflammation in the anterior and posterior segment.

**FUCHSLUGERT, STEFANSSON E**

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>3141</td>
<td>8:30</td>
<td>Activity in eye surface sensory neurons is disturbed by inflammation, and vice versa</td>
<td>GALLAR J, Acosta MC - San Juan de Alicante</td>
</tr>
<tr>
<td>3143</td>
<td>9:06</td>
<td>Novel concepts in corneal reconstruction</td>
<td>FUCHSLUGERT, Stafiej P, Florian K, Schubert D - Erlangen</td>
</tr>
<tr>
<td>3144</td>
<td>9:24</td>
<td>Nanoparticle eye drops: A new generation of corticosteroid eye drops</td>
<td>STEFANSSON E - Reykjavik</td>
</tr>
<tr>
<td>3145</td>
<td>9:42</td>
<td>The role of IL-6 and IL-6-blockade in the pathogenesis and treatment of uveitic macular edema</td>
<td>MESQUIDA M - Barcelona</td>
</tr>
</tbody>
</table>
The Course will address the use of electrophysiology and imaging in the diagnosis and management of patients with retinal disease. The importance of using standardised electrophysiological protocols, as recommended by the International Society for Clinical Electrophysiology of Vision will be stressed. Lectures on inherited and acquired disease will follow an introduction to the tests and their interpretation, and the session will conclude with a lecture on paediatric applications.

**HOLDER G, LEROY BP**

3151  8:30  An introduction to the tests and clinical interpretation  
HOLDER G - London

3152  8:52  Inherited retinal disease  
LEROY BP - Ghent

3153  9:14  Acquired retinal disease  
HOLDER G - London

3154  9:36  Paediatric applications  
THOMPSON D - London

**BARRAQUER RI, MICHAEL R**

3161  8:30  How to handle the posterior lens capsule in children  
BARRAQUER RI - Barcelona

3162  8:48  Anterior vitreo-lenticular interface in children  
TASSIGNON MJ - Edegem

3163  9:06  Genetic anomalies in congenital cataract  
Bremond-Gignac D, Burin des Roziers C, Beugnet C, Fourrage C, Moriniere V, Robert M, VALLEIX S - Paris

3164  9:24  Protein analysis of the plaques in congenital cataracts  

3165  9:42  Contact lens service in pseudophakic and aphakic children  
ROSENSVARD A - Stockholm
As a group, inherited optic neuropathies represent an important cause of severe irreversible visual loss among children and young adults. The pathological hallmark is the preferential loss of retinal ganglion cells (RGCs) within the inner retina, which results in progressive optic nerve dysfunction and the onset of visual symptoms. This session will review new insights into the molecular genetic basis of three classical inherited optic neuropathies, namely Leber hereditary optic neuropathy (LHON), autosomal dominant optic atrophy (DOA) and Wolfram syndrome. Although management remains largely supportive, major advances in disease modelling and genetic engineering are paving the way for innovative therapeutic strategies that could help minimise RGC loss and improve the visual prognosis.

**LISKOVA P, YU-WAI-MAN P**

**3171**  8:30  Cracking the nuclear-mitochondrial code in Leber hereditary optic neuropathy

**CARELLI V** - Bologna

**3172**  8:48  Novel pathophysiological mechanisms in dominant optic atrophy beyond the mitochondrial dynamics equilibrium


**3173**  9:06  Antisense oligonucleotide therapy for splicing defects in OPA1-related dominant optic atrophy

**WISSINGER B, Synofzik M, Schölß L, Bonifert T** - Tuebingen

**3174**  9:24  Advances in gene therapy for Wolfram syndrome

**Hamel C, Jagodzinska J, Bonner-Wersinger D, Koks S, Seveno M, DELETTRE C** - Montpellier

**3175**  9:42  Clinical trials for inherited optic neuropathies

**KARANJIA R, Poincenot L, Sadun AA** - Ottawa

---

**NERI P, HERBORT JR. CP**

**3181**  8:30  Ocular inflammatory diseases in ebola survivors

**HERETH E, Resnikoff S, Fardeau C, Bah MO, Sagno IC, March L, Izard S, Lama PL, Ouedeno NA, Delaporte E** - Lille

**3182**  8:42  Endophthalmitis: what role does vitrectomy play?


**3183**  8:54  Surgical management of Acute Retinal Necrosis (ARN): Timing and outcomes

**MORA P, Tagliavini V, Tedesco S, Forlini M, Carta A, Gandolfi S** - Parma

**3184**  9:06  Case series and literature review: Is there a role for antiviral prophylaxis in patients who have had herpetic encephalitis?


**3185**  9:18  Inflammatory markers but not symptoms are a strong predictor of temporal artery biopsy outcome – the Portsmouth experience

**MEREDITH PR, Sepetis A, Balendra S, Jawed M, Lockwood AJ, Maclean H** - Portsmouth

**3186**  9:24  Portuguese prescription patterns of topical antibiotics in Ophthalmology: a yearlong analysis

**SOUSA DC, Leal I, Nascimento N, Abegão Pinto L, Marques-Neves C** - Lisboa
Why do eyes become myopic?

Refractive errors are the most common eye disorders worldwide and the largest source of visual impairment. In particular, high myopia is associated with a significant risk of visual complications, such as myopic macular degeneration, glaucoma, and retinal detachment. The absolute risk of severe visual impairment increases significantly with each diopter of myopic refractive error, ranging from 3% to 5% in individuals with errors of -6.00 D to more than 40% in those with -15.00 D or more. Reports have shown that the prevalence of myopia is on the rise worldwide with the highest prevalence in Asia. This figure is dramatic and demand effective counteractions. The lecture will address the main question “Why do eyes become myopic?” from various perspectives including epidemiological data (genetics, environmental factors, etc.) and animal studies.

Award presentation of the EVER Certificate of Honour

Biography of Caroline KLAVER

Caroline Klaver is professor of epidemiology and genetics of eye diseases at Erasmus MC Rotterdam. She is a retinal specialist who trained as a fellow at University of Iowa and at Columbia University and at Vitreous-Retina-Macula Consultants in New York and currently has her clinic at Radboud UMC, Nijmegen. Her research focuses on genetic-epidemiologic studies of various complex (myopia, age-related macular degeneration (AMD), glaucoma) and Mendelian eye disorders (retinal dystrophies). She is the principal investigator of ophthalmologic studies in 7 large epidemiologic cohorts from Rotterdam. Recently, her interest has shifted towards functional studies as her ultimate ambition is to find targets for intervention and diminish patient load.
New advances in transconjunctival pars plana vitrectomy systems have provided tremendous benefits for the management of vitreoretinal disorders. New instruments have been developed as 27 Gauge vitrectomy. 3D ultra-digital visualization systems are now currently available. Intra-operative OCT may now be added to help surgeons during peeling procedures. Combined surgery remained still questionable and will be discussed, as the update options for submacular hemorrhage management.

POURNARAS J-A, STANGOS A

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>3311</td>
<td>11:00</td>
<td>27 Gauge vitrectomy (pros &amp; cons)</td>
<td>STANGOS A - Geneva</td>
</tr>
<tr>
<td>3312</td>
<td>11:18</td>
<td>3D visualization systems</td>
<td>POURNARAS JA - Lausanne</td>
</tr>
<tr>
<td>3313</td>
<td>11:36</td>
<td>Intra-operative OCT</td>
<td>GUALINO V - Montauban</td>
</tr>
<tr>
<td>3314</td>
<td>11:54</td>
<td>Combined procedures</td>
<td>PAPPAS G - Heraklion</td>
</tr>
<tr>
<td>3315</td>
<td>12:12</td>
<td>Submacular hemorrhage management</td>
<td>POURNARAS C - Genève</td>
</tr>
</tbody>
</table>

This SIS focuses on the state of corneal nerves in health and disease. Pathologies arising from diseased nerves are presented – as well as their conservative and surgical management.

DUA HS, SAID D

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>3321</td>
<td>11:00</td>
<td>Normal and abnormal corneal innervation</td>
<td>DUA HS, Al-Aqaba M - Nottingham</td>
</tr>
<tr>
<td>3322</td>
<td>11:22</td>
<td>Neurotrophic Keratitis: Definition, clinical presentation and diagnosis</td>
<td>SAID D, Dua H - Cairo</td>
</tr>
<tr>
<td>3323</td>
<td>11:44</td>
<td>Medical management of neurotrophic keratitis</td>
<td>RAMA P - Milano</td>
</tr>
<tr>
<td>3324</td>
<td>12:06</td>
<td>Surgical management of Neurotrophic keratitis</td>
<td>SHORTT A - London</td>
</tr>
</tbody>
</table>
**FRIDAY, SEPT 29 - SECOND MORNING SESSION**

### 11:00 - 12:30 | RHODES 2

#### EOVS - Age, vision and retina

<table>
<thead>
<tr>
<th>ID</th>
<th>Time</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>3331</td>
<td>11:00</td>
<td>Measurement of oculomotor parameters and visual processing times without eye-tracking</td>
<td>BARBUR JL, Llapashtica E, Connolly D, Sadler J - London</td>
</tr>
<tr>
<td>3332</td>
<td>11:12</td>
<td>Normal upper age-limits for photopic and mesopic visual acuity and functional contrast sensitivity</td>
<td>KEUKEN A, Subramanian A, Barbur JL - Utrecht</td>
</tr>
<tr>
<td>3333</td>
<td>11:24</td>
<td>Changes in axial length in adult eyes</td>
<td>ROZEMA J, Zakaria N, NI Dhubhghaili S - Edegem</td>
</tr>
<tr>
<td>3334</td>
<td>11:36</td>
<td>Retinal vascular fractal dimension and cerebral blood flow, the CRESCENDO study</td>
<td>NADAL J, Deverdun J, Menjot De Champfleur N, Villain M, Creuzot Garcher C, Le Bars E, Daien V - Nimes</td>
</tr>
<tr>
<td>3335</td>
<td>11:48</td>
<td>How to explain “flat” electroretinograms when patients with Leber’s congenital amaurosis aren’t blind</td>
<td>PARSA C, Taylor A - Paris</td>
</tr>
</tbody>
</table>

#### 12:00 | Proteomics study: Relevance and interest for screening, follow-up, etiopathogenesis of AMD

- **GONZALEZ C** - Toulouse

### 11:00 - 12:30 | RHODES 3

#### PO - Conjunctiva and others

<table>
<thead>
<tr>
<th>ID</th>
<th>Time</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>3342</td>
<td>11:12</td>
<td>β-catenin activation in conjunctival melanocytic proliferations</td>
<td>LARIVE E, Nicolas M, Schalenbourg A, Zografos L, Moulin A - Lausanne</td>
</tr>
<tr>
<td>3343</td>
<td>11:24</td>
<td>Comparing anterior segment optical coherence tomography and ultrasound biomicroscopy with histopathology in measurement of corneal and bulbar conjunctival tumors depth</td>
<td>LAUWERS N, Janssens K, Mertens M, Mathysen D, De Keizer RJW, De Groot V - Edegem</td>
</tr>
<tr>
<td>3346</td>
<td>12:00</td>
<td>Primary human choroidal melanocytes express functional Toll-Like Receptors (TLRs)</td>
<td>CIOANCA V A, McCluskey P J, Madigan M C - Sydney NSW</td>
</tr>
</tbody>
</table>
Although the use of multifocal intraocular lenses (mIOLs) has become increasingly popular because of their good reading-distance VA and their option of variably adding power for near vision, some patients, even those with healthy eyes, complain of hazy vision, which might be the result of reduced contrast. Therefore, it is known that careful consideration must be taken when deciding whether to implant mIOLs in elderly patients over 80 years of age or in patients with other concomitant ocular diseases. Unlike with monofocal IOL implantation in such subclinical handicapped cases, mIOL implantation can result in a decrease in the patient’s visual function because of the precision of the lens. This symposium will debate on whether or not to implant mIOLs in interdisciplinary cases such as patients with retinal disorders, early-stage glaucoma, high myopia with good corrected VA, or mild keratoconus.

**GRZYBOWSKI A, ASCASO F**

<table>
<thead>
<tr>
<th>Session</th>
<th>Topic</th>
<th>Presenter/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>3361</td>
<td>Vitreo-retinal pathology and multifocal IOLs</td>
<td>ASCASO FJ - Zaragoza</td>
</tr>
<tr>
<td>3362</td>
<td>Indications and limits of the implantation of diffractive and refractive intraocular lenses in patients with ocular comorbidities</td>
<td>GATINEL D - Paris</td>
</tr>
<tr>
<td>3363</td>
<td>Ocular motility, do we know what is the dominant eye?</td>
<td>SHAH S - Birmingham</td>
</tr>
<tr>
<td>3364</td>
<td>Varifocal intraocular lenses, how to play with different optical profiles for a better outcome or Trifocal IOLs: results of a randomized clinical study</td>
<td>ALIO SANZ J - Alicante</td>
</tr>
<tr>
<td>3365</td>
<td>Limits for the indication of multifocal lenses based on the contrast sensitivity function</td>
<td>GRZYBOWSKI A - Olsztyn</td>
</tr>
</tbody>
</table>
FRIDAY, SEPT 29 - SECOND MORNING SESSION

11:00 - 12:30 | GALLIENI 4
MBGE/COS - Advances in the genetics and targeted therapies of corneal disorders

Relative immune privilege, transparency and easy accessibility make cornea an exceptional tissue for translational research. Recent and ongoing advances in our understanding of the biological mechanisms underlying corneal disorders provide promise for the development of effective molecular therapies. The special interest symposium will focus on recent molecular discoveries made in the field of corneal disorders and their possible implications for treatment.

LISKOVA P, FUCHSLUGER T

3371 11:00 Exploring molecular mechanisms underlying Fuchs endothelial corneal dystrophy and their relevance to therapeutic interventions
DAVIDSON A - London

3372 11:22 Posterior polymorphous corneal dystrophy; novel clinical and molecular genetic insights
LISKOVA P - Prague

3373 11:44 Novel tissue-targeted localized corneal gene therapy
MOHAN R - Columbia

3374 12:06 Viral and non-viral vectors for cell and gene therapy of the corneal endothelium
FUCHSLUGER T, Grünert A, Mahajan S, Czugala M - Erlangen

11:00 - 12:30 | GALLIENI 5
Roundtable Discussion by Women in EVER (WIE)

The session will consist of three early career scientists/ophthalmologists, discussing their career path to date including their previous and current ambitions/reservations/issues, with exchanges also with the 3 moderators. Audience participation is expected and attendance ranging from students to departmental heads/chairs encouraged.

CREUZOT C, KAWASAKI A, CORDEIRO MF

3381 11:00 Promoting women career through changes of societal stereotypes and academic efficiency indicators
AMBRESIN A - Lausanne

3382 11:30 Life as a junior postdoc in ophthalmology and neurobiology research: challenges and opportunities
DE GROEF L - Leuven

3383 12:00 Seeing the light: A perspective from a junior scientist on her journey from psychology to physics to ophthalmic research
IRSCH K - Paris
Agenda

1. President's address by Andrew Dick
3. Report of the Secretary General, Catherine Creuzot
4. Report of the Programme Secretary, Francesca Cordeiro
5. Report of the Treasurer, Steffen Heegaard:
   • approval of the accounts 2016
   • discharge to the directors
   • approval budget for 2017
6. Results of the elections
7. Presentation of the board 2018
8. Future congresses
9. Miscellanea
10. Handover of chain of office
13:30 - 15:00 | HERMES
RV - Surgery of macular disorders

This session will cover the modern surgical technique for macular disorders such as macular hole, epimacular gliosis, etc, using novel intraoperative diagnostic techniques, as well as to modern developing approaches in treatment of macular degenerations using stem cell therapy. The speakers are world known experts in their field. All the speakers confirmed their participation in EVER 2017.

LYTVYNCHUK L, MICHALEWSKA Z
3511 13:30 Swept Source OCT Angiography after retinal detachment treatment with different techniques
MICHALEWSKA Z, Nawrocki J - Lodz

3512 13:48 Endoculocer OCT assisted epimacular surgery with preliminary vitreoretinal adhesions mapping
STOLIARENKO G, Doroshenko D, Ledeneva M, Salakhutdinov V, Savostianova N - Moscow

3513 14:06 Surgical treatment of traumatic macular hole
RUBAN A - Kyiv

3514 14:24 Intraoperative OCT for inverted ILM flap technique
LYTVYNCHUK L - Giessen

3515 14:42 Nanofibrous carrier for transplantation of retinal pigment epithelial cells

13:30 - 15:00 | RHODES 1
G - Obergurgl EVER optic-nerve-conference symposium 2016: repair, replacement, and regeneration of the optic nerve

The Obergurgl optic-nerve-conference brings together clinicians and basic scientists from different fields and will highlight translational research providing a platform for networking and stimulating discussions, which are a highlight of the meeting. The topic of the Obergurgl conference 2016 was: “repair, replacement, and regeneration of the optic nerve”. In this symposium, a few selected talks from the Obergurgl conference will present interesting topics in this area.

GRUS F, CROWSTON J
3521 13:30 Changing the fate of retinal ganglion cells following retinal ischemia: is autophagy the way?

3522 13:48 Neurotrophins involved in neuroprotective antibody effect
BELL K, Wilding C, Beck S, Pfeiffer N, Grus FH - Mainz

3523 14:06 Role of GSK3 activity in optic nerve regeneration
FISCHER D - Düsseldorf

3524 14:24 siRNA and regeneration
LOGAN A - Birmingham

3525 14:42 Remyelination of regenerating axons
In the modern ophthalmology, the introduction of new technologies and the better knowledge on uveitis pathophysiology have helped in understanding the different clinical characteristics of most of the intraocular inflammatory diseases. Consequently, several old concepts were revised and new ones were introduced. The trend at this point is to create the conditions for a better strategy both for the diagnostic procedures and for the treatment choices by using appropriately all the available tools. For such reasons, the multimodal imaging procedures, systemic tests and even biopsies of ocular tissues are part of the daily practice of a uveitis specialist.

In this special interest symposium the main uveitis subsets will be discussed by addressing the critical points for the diagnostic assessment and bringing new concepts on the uveitis classification and the treatment methodology.

NERI P, HERBORT JR. CP

**3531** 13:30 Multiple evanescent white dot syndrome
PAPADIA M - Genova

**3532** 13:48 Primary stromal choroiditis
HERBORT CP - Lausanne

**3533** 14:06 Tuberculosis
KHAIRALLAH M, Khochtali S, Mahmoud A, Ben Amor H - Monastir

**3534** 14:24 Sarcoidosis
EL AMEEN A - Evian

**3535** 14:42 Idiopathic multifocal choroiditis
NERI P, Pirani V, Lassandro N, Nicolai M - Agugliano

---

**13:30 - 15:00 | RHODES 3**

**PO/NSPH - Optic disc in ocular oncology**

Diagnosis and management of tumors and pseudo-tumors located close to the optic disk and tumors covering or invading the optic is often challenging. All these tumors can damage the visual function because of their position or following the side effects of the treatment. In addition, some of these tumors and specially retinoblastomas can invade the optic disk and progress to the central nervous system. Consequently the aim of the diagnostic approaches is not only to identify the tumor but also to define the anatomical and functional changes in order to allow the best therapeutic approaches.

The aim of this SIS is to bring a multidisciplinary, ophthalmo-oncological and neuro-ophthalmological approach to this complex problem. The various melanocytic, vascular and lymphoproliferative tumors as well as tumors originated from the optic nerve and the epithelium are presented and the side effect of the irradiation treatment of the optic disk is described.

ZOGRAFOS L, KAWASAKI A

**3541** 13:30 Optic disk melanocytoma and juxtapapillary melanoma. Diagnosis and management
SHIELDS C - Lausanne

**3542** 13:45 Juxtapapillary tumors and pseudo-tumors of the retinal pigmented epithelium
KIVELA T - Helsinki

**3543** 14:00 Vascular tumors and malformation of the optic disk
DE LAEY JJ - Gent

**3544** 14:15 Irradiation induced optic neuropathy
ZOGRAFOS L - Lausanne

**3545** 14:30 Optic nerve sheath tumors
KAWASAKI A - Lausanne

**3546** 14:45 Optic disk invasion in SNC lymphoma
CASSOUX N - Paris
This SIS discussed etiologies and treatments of microbial keratitis.

**FUCHSLUGER T, KESTELYN P**

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>3552</td>
<td>13:48</td>
<td>Latest in diagnosis and management of fungal keratitis</td>
<td>KESTELYN P - Gent</td>
</tr>
<tr>
<td>3553</td>
<td>14:06</td>
<td>Acanthamoeba keratitis – pKP versus conservative treatment in a 20-year follow-up study</td>
<td>FUCHSLUGER T, Scheumann A, Roth A, Klammann A, Geerling G - Erlangen</td>
</tr>
<tr>
<td>3554</td>
<td>14:24</td>
<td>Corneal crosslinking in microbial keratitis</td>
<td>SZENTMARY N - Budapest</td>
</tr>
<tr>
<td>3555</td>
<td>14:42</td>
<td>Imaging of the ocular surface in corneal inflammation</td>
<td>GICQUEL JJ - Saint Jean d’Angély</td>
</tr>
</tbody>
</table>

**BRON A, RATNARAJAN G**

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>3561</td>
<td>13:30</td>
<td>Systematic laser suturolysis in post-operative management in trabeculectomy – early results from pilot study</td>
<td>MANO S, Nuno PF, Marques RE, Abegao Pinto L - Lisbon</td>
</tr>
<tr>
<td>3562</td>
<td>13:42</td>
<td>High-intensity focused ultrasound cyclo-coagulation: a prospective study from a tertiary center</td>
<td>SOUSA DC, Pinto Ferreira N, Marques-Neves C, Abegao Pinto L - Lisboa</td>
</tr>
<tr>
<td>3563</td>
<td>13:54</td>
<td>Socioeconomic deprivation status of patients undergoing Trabeculectomy surgery. A 9-year review at Queen Alexandra Hospital, Portsmouth</td>
<td>SEPETIS A, Balendra S, Meredith P, Kirwan J, Lockwood A - Portsmouth</td>
</tr>
<tr>
<td>3564</td>
<td>14:06</td>
<td>Iatrogenic intraocular pressure elevation after repeated intravitreal injection, a prospective cohort study</td>
<td>LEREUIL T, Agard E, Elchehab H, Dot C - Lyon</td>
</tr>
<tr>
<td>3567</td>
<td>14:30</td>
<td>Supraciliary Micro-Stent (CyPass®) is associated with lack of disease progression and minimum usage of IOP lowering medications in patients with POAG 2-Years Post-Implantation</td>
<td>UZUNOV R, lanchulev T, Dickerson J - Cointrin - Geneva</td>
</tr>
<tr>
<td>3568</td>
<td>14:36</td>
<td>Follow-up of non-complicated filtering surgeries under ambulatory care with no control at Day 1</td>
<td>JEANCOLAS AL, Conart JB, Trechot F, Berrod JP, Angioi-Duprez K, Maalouf T - Vandoeuvre les Nancy</td>
</tr>
</tbody>
</table>
Contact lenses have achieved an amazingly wide circulation and usage. The main type of contact lenses soft ones because they appear to be fitted easy and can be worn without a distinct adaption period. Therefore, they appear as the ideal choice for fitter and patient as well - in many countries soft contact lenses can be obtained over the counter without any medical or paramedical advice and supervision. The patient thereby transforms into a mere customer - sometimes addressed as a "customer-patient". Still, contact lenses can lead to severe ocular surface pathology. If the necessary critical care is neglected and if the user is not aware of the minimal cleaning and wearing necessities. Apart from acute wounding mainly chronic pathology of the cornea and conjunctiva occurs and, most alerting, severe ocular surface infections can occur that may require immediate critical clinical care often including surgical reconstruction of the ocular surface.

**KNOP E, ASOKLIS R**

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Speaker(s)</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>3571</td>
<td>Contact lens and ocular surface - After all, its still a foreign body</td>
<td>KNOP E - Berlin</td>
<td></td>
</tr>
<tr>
<td>3572</td>
<td>Results of the Scleral Lens in Current Ophthalmic Practice (SCOPE) survey</td>
<td>NAU A - Boston</td>
<td></td>
</tr>
<tr>
<td>3573</td>
<td>Contact lens related corneal infections</td>
<td>ASOKLIS R - Vilnius</td>
<td></td>
</tr>
<tr>
<td>3574</td>
<td>How to deal with Keratokonus – are there contact lens related problems in sclerals?</td>
<td>NAU C, Shorter E, Nau A, Harthan J, Fogt J, Schornack M - Minnesota</td>
<td></td>
</tr>
<tr>
<td>3575</td>
<td>Ocular surface reconstruction in severe contact lens associated pathology</td>
<td>WYLEGALA E, Dobrowolski D, Wylegala A - Katowice</td>
<td></td>
</tr>
</tbody>
</table>

**LOFGREN S, TASSIGNON MJ**

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Speaker(s)</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>3581</td>
<td>Toric lens implantation in cataract surgery : risk factors of post-operative lens rotation, analysis of 50 cases</td>
<td>LORIA O, Raucau M, Agard E, El Chehab H, Lereuil T, Dot C - Lyon</td>
<td></td>
</tr>
<tr>
<td>3582</td>
<td>Optical properties shape visual cortical population receptive fields after cataract surgery independently from subjective quality of vision</td>
<td>Rosa A, Miranda A, Miguel P, Harvey B M, Silva F, CASTELO-BRANCO M - Coimbra</td>
<td></td>
</tr>
<tr>
<td>3583</td>
<td>Prevention of selenite-induced cataractogenesis by sildenafil in rats</td>
<td>ATALAY HT, Uçgül AY, Ozel Türkçü U, Ozymen MC, Yılmaz NS, Bilgihan A - Ankara</td>
<td></td>
</tr>
<tr>
<td>3584 rf</td>
<td>Visualization of the light field of multifocal intraocular lenses using a dual wavelength approach</td>
<td>EPPIG T, Rubly K, Schröder S, Rawer A, Langenbucher A - Homburg/Saar</td>
<td></td>
</tr>
<tr>
<td>3585 rf</td>
<td>Robotic surgery - a new way to perform cataract surgery</td>
<td>CHAMMAS J, Sauer A, Bourcier T - Strasbourg</td>
<td></td>
</tr>
</tbody>
</table>
POSTER AREA
MBGE: Molecular Biology/Genetics/Epidemiology

Poster F001-F021

DAVIDSON A, KOZMIK Z

F001

Falls re-audit

F002

Ocular traumas in the Finnish elderly-Helsinki Ocular Trauma (HOT) Study
SAHRARAVAND A, Haavisto AK, Holopainen JM, Leivo T - Helsinki

F003

The effect of caffeine on retinal vessel diameters in the Inter99 eye study

F004

Genetic evidence for the role of ultraviolet radiation in the pathogenesis of uveal melanoma
Goh A, RAMLOGAN-STEEL C, Jayachandran A, Steel J, Layton C - Brisbane

F005

Directed migration of retinal astrocytes by PDGF signaling
TAO C, Zhang X - New York

F006

Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency and age-related macular degeneration in a Sardinian male population, Italy
PINNA A, Porcu T, D’Amico-Ricci G, Boscia F, Carru C - Sassari

F007

Prevalence of refractive errors and visual impairment in university students

F008

The prevalence of asthenopia and its determinants in a population of university students

F009

Genetic causes of deaf-blindness in sixteen Czech families
KOUSAL B, Dudakova L, Bujakowska K, Liskova P - Praha

F010

Motile activity and cytoskeleton changes in uveal melanoma after proton beam radiation
ROMANOWSKA DIXON B, Jasinska-Konior K, Sarna M, Urbanska K, Oliko P, Elas M - Krakow

F011

SS - OCT angiography in retinal dystrophies with macular edema or cysts
EL MATRI L, Falfoul Y, Hassaïria A, El Matri K, Nafa A, Chebil A - Tunis

F012

SS - OCT angiography in macular dystrophies
EL MATRI H, Falfoul Y, El Matri K, Hassaïria A, Maamouri R, Chebil A - Tunis

F013

Clinical and genetic study of a new mutation in the choroideremia gene

F014

High resolution imaging analysis of female carriers and patients of Choroideremia with CHM gene mutation
GOCHO K, Akeo K, Kubota D, Katagiri S, Kikuchi S, Hayashi T, Yamaki K, Takahashi H, Kameya S - Inzai

F015

Optical coherence tomography angiography in retinitis pigmentosa
HASSAÏRIA A, Falfoul Y, Matri K, Ben Lassoued O, Chebil A, El Matri L - Tunis

F016

The important role of OCT in the diagnosis of Oculocutaneous albinism

F017

X-linked juvenile retinoschisis: different mutations – same phenotype

F018

Adaptive optics retinal imaging in patients with GNAT2 mutations
GEORGIOU M, Kalitzeos A, Michaelides M - London
### Poster F01-F021

**DAVIDSON A, KOZMIK Z**

| F019  | RF  | Recurrent corneal erosions dystrophy (ERED) in a Finnish family is caused by a COL17A1 splice-altering mutation  
  | TURUNEN J, Tuisku I, Reetta-Stiina J, Kivelä T - Helsinki |
|-------|-----|------------------------------------------------------------------|
| F020  |     | CTG181 trinucleotide repeat expansion in Polish patients with Fuchs endothelial corneal dystrophy  
  | UDZIELA M, Ozieblo D, Sarosiak A, Oldak M, Szaflik JP - Warsaw |
| F021  |     | Familial foveal aplasia                                           
  | MURPHY R, Keegan D, Flitcroft I - Dublin |
**Poster F022-F062**

**ZOGRAFOS L, POURNARAS C**

**F022**  
Poster F022-F062  
ZOGRAFOS L, POURNARAS C  
**F022**  
Popper associated maculopathy – Case report and literary synthesis  
MURPHY R, James M, Cullinane A - Dublin

**F024**  
Is the age a prognostic factor for the outcome after treatment of myopic CNV?  

**F025**  
Intravitreal bevacizumab administration for complicated retinal arterial macroaneurysm in a young male patient  
POPA CHERECHEANU A, Pirvulescu R, Dide C, Ianuc R - Bucharest

**F026**  
Long-term outcome following ranibizumab treatment for CNV related to ND:YAG-Laser macular injury  
BATSOS G, Parikakis E, Christodoulou E, Karagiannis D, Stefaniotou M - Athens

**F027**  
Dexamethasone intravitreal implant combined with anti-VEGF in patients with neovascular age related macular degeneration resistant to anti-VEGF alone  

**F028**  
The development and performance of a new patient derived tool to measure Dimensions in Treatment of Age-related Macular Degeneration (DITAMD)  
JELIN E, Wisløff T, Moe MC, Heiberg T - Oslo

**F029**  
Bevacizumab-treated diabetic macular edema: a pilot yearlong analysis of anatomic and functional outcomes from a referral center in Portugal  
Leitão P, Bettencourt S, Trincão F, Santos P, SOUSA DC, Genro V, Abegão Pinto L, Raposo J - Lisboa

**F030**  
Refractive changes after anti-VEGF injections for diabetic macular edema  
CHATZIRALLI I, Chatzipantelis A, Dimitriou E, Mpourouki E, Saitakis G, Theodossiadis P - Athens

**F031**  
Treatment of diabetic macular edema with micropulse laser therapy  
EL MATRI K, Chebbi Z, Falfoul Y, Kortli M, Hassairi A, Chebil A, El Matri L - Tunis

**F032**  
Changes in retinal vessel diameters after intravitreal aflibercept in patients with diabetic macular edema  
BLINDBÆK SL, Peto T, Grauslund J - Odense C

**F033**  
Vascular macular capillary plexus in patient with Type 1 diabetes with no retinopathy are correlated with OCT volume changes  
ORDUNA HOSPITAL E, Lopez Galvez MI, Perdices Royo L, Acha J, Idoipe M, Sanchez-Cano Al, Abecia E, Pinilla I - Zaragoza

**F034**  
Types of diabetic retinopathy studied by wide field angiography  

**F035**  
Cost-effectiveness of intravitreal therapy with both anti-VEGF and Dexamethasone implant in patients with Diabetic Macular Edema  
D’AMICO RICCI G, Bouzios D, Boscia F, Lupino M, Pinna A - Sassari

**F036**  
Topical betamethasone sodium phosphate, tetracycline hydrochloride and nonsteroidal anti-inflammatory drugs in the treatment of diabetic macular edema: a case report  
D’AMICO RICCI G, Bouzios D, Boscia F, Pinna A - Sassari

**F037**  
OCT Angiography in angioid streaks without neovascular complications  
EL MATRI K, Falfoul Y, Hassairi A, Chebil A, Ammari M, El Matri L - Tunis

**F038**  
Cross-sectional static retinal vessel analysis in routine optometric practice  
FRENCH C, Heitmar R - Birmingham
Ophthalmoscopic and video OCT methods to detect spontaneous venous pulsation in individuals with apparently normal intracranial pressure: the rebirth of the SVP

JENKINS KS, Layton CJ, Adams MKM - Brisbane

Inner retina changes in hydroxychloroquine patients

BARATA A, Leal I, Sousa F, Teixeira F, Pinto F - Lisboa

Idiopathic retinal vasculitis, arteriolar macroaneurysms and neuroretinitis (IRVAN): Case series of three patients with multimodal imaging

YU JEAT C, Logeswaran A, Damato E - Birmingham

Choroidal vascular abnormalities by UWF ICGA in central serous chorioretinopathy

SAGONG M, Noh D, Van Hemert J, Lee J - Daegu

Clinical significance of subretinal hyper-reflective material in retinal angiomatous proliferation patients

KIM JM, Lee KB, Jung JJ, Han JI - Birmingham

Long-term reproducibility of axial length in eyes undergoing combined phacovitrectomy for macular-sparing rhegmatogenous retinal detachment

KANG TS, Shin YI, Kim JY - Daejeon

Acute macular neuroretinopathy type 2: an unusual case

CELLINI M, Sebastiani S, Campos E - Bologna

The impact of epiretinal membrane on neovascular age-related macular degeneration treatment: A spectral-domain optical coherence tomography study


Intra- and inter-grader agreement in grading of coverage of panretinal photocoagulation by ultra-wide field color fundus images

TORP TL, Jakobsen DB, Grauslund J - Odense C

Multimodal imaging of combined hamartoma of the retina and retinal pigment epithelium

BOBAT H, Kaprinis K, De Salvo G - Southampton

Changes in axial length before and after recovery in patients with idiopathic central serous chorioretinopathy with serous retinal detachment

SHIN YI, Shin KS, Jo YJ, Kim JY - Daejeon

Relationship between macular thickness and mesopic visual acuity in older subjects without retinal disease


Clinical application of enhanced retinal vasculature visualization using hemoglobin absorbance

KIM YT - Seoul

Ocular manifestations associated with takayasu arteritis: a multimodal imaging study

CHOTARD G, Diwo E, Coscas F, Saadoun D, Domont F, Le Hoang P, Bodhagi B - Paris

Associations between individual retinal layer thicknesses and diabetic peripheral neuropathy using retinal layer segmentation analysis


Relation between cardiovascular conditions and macular and retinal nerve fiber layer thickness evaluated with Spectral-Domain OCT

OBIS J, Garcia-Martin E, Orduna E, Vilades E, Cipres M, Rodrigo MJ, Satue M - Zaragoza
Photostimulation with subthreshold yellow micropulsed laser for chronic residual subfoveal rhegmatogenous retinal detachment after surgery
ESPOSTI G, Esposti PL, Fruschelli M, Hadjistilianou T - Siena

Evaluation of efficacy and safety of dexamethasone intravitreal implants between vitrectomized and non-vitrectomized eyes in a real-life study
REZKALLAH A, Malcles A, Dot C, Voirin N, Agard E, Vie AL, Denis P, Kodjikian L - Lyon

Enzymatic vitreolysis with ocriplasmin for symptomatic vitreomacular traction syndrome

Efficacy and safety of primary posterior capsulotomy in combined phaco-vitrectomy in patients with rhegmatogenous retinal detachment
KIM JY, Shin YI, Kang TS - Daejeon

Eccentric macular hole after pars plana vitrectomy for epiretinal membrane without internal limiting membrane peeling

The effect of internal limiting membrane peeling in surgical treatment of combined hamartoma and epiretinal membrane
PARK JM, Soo Jung L, Ji Hyun P, Myung In Y - Busan

Retinal diseases of patients without discomfort associated with retinal abnormalities
LEE S - Seoul

Evolution of foveal detachment in dome-shaped macula after treatment by mineralocorticoids: report of three cases
GARHOFER G, OSBORNE N

F063 Effects of dexamethasone implant on macular morphology and visual function in patients with different diseases

F064 Neural degeneration mechanisms in diabetic retinopathy: The role of apoptosis and autophagy
AMATO R, Dal Monte M, Cervia D, Catalani E, Cammalleri M, Casini G - Pisa

F065 Functionalized magnetic nanoparticles as a novel strategy for the treatment of diabetic retinopathy
AMATO R, Dal Monte M, Lulli M, Cammalleri M, Raffa V, Casini G - Pisa

F066 The SRPK1 inhibitor SPHINX31 prevents increased retinal permeability in a rodent model of diabetes
ALLEN C, Horton K, Malhi N, Batson J, Bates D - Nottingham

F067 Resveratrol diminishes oxidative stress in lenses of rats with streptozotocin-induced type 1 diabetes
SEDLAK I, Wojnar W, Kaczmarsczyk-Sedlak I, Zych M, Wygledowska-Promienska D - Katowice

F068 Retinal vessel geometry and oxygen saturation in patients suffering from diabetes mellitus and/or cardiovascular disease
HEITMAR R, Blann A - Birmingham

F069 Microelectrode penetration of the wall of porcine retinal arterioles in vitro results in recordings from several cell types
KUDRYAVTSEVA O, Aalkjaer C, Bek T - Aarhus

F070 Involved in peroxisome proliferator-activated receptor activators in the photoprotective activity of the di-apos-1,3-carotenoids norbixin on RPE cells

F071 Effects of plasma kallikrein inhibitors in an in vitro RPE oxidative stress model

F072 Regenerative therapies with combined axoprotectants in AGE-exposed retinas
OSHITARI T, Bikbova G, Baba T, Yamamoto S - Chiba

F073 Melatonin and epigallocatechin gallate reduce the loss of visual function in an animal model of retinal degeneration: P23H rat

F074 Effect of AVS Retina in a rodent model of retinal ischemia-reperfusion
SANTONOCITO M, La Rosa LR, Zappulla C, Viola S, Mazzone MG, Giuliano F - Ac S. Antonio (CT)

F075 THR-687, a potent small molecule integrin antagonist, holds promise as a therapeutic approach for back-of-the-eye vascular pathologies
VAN HOVE I, Vanhove M, Porcu M, Barbeaux P, Feyen JHM, Vermassen E - Evere

F076 FluoroGold-labeled organotypic retinal explant culture (FLOREC) for neurodegeneration and neurotoxicity screening studies

F077 Effect of intravitreal bevacizumab and aflibercept on retrobulbar blood flow in injected and uninjected sound eyes of patients with neovascular age-related macular degeneration
Changes in retinal arteriolar oxygen saturation predict disease activity in patients treated with aflibercept for neovascular age-related macular degeneration
JAKOBSEN DB, Torp T L, Stefánsson E, Peto T, Grauslund J - Odense C

Intraocular expression of microfibrillar-associated protein 4 (MFAP4) in patients with neovascular age-related macular degeneration (nAMD)

Bilateral tacrolimus-associated optic neuropathy after kidney transplant

Optimisation of potent topical SRPK1 inhibitors with improved retinal pharmacokinetics through ex vivo trans-scleral permeability modelling

Aerobic exercise causes changes in choroidal thickness in young adults
PERDICES L, Orduna E, Insá G, Segura FJ, Idoate A, Sánchez Al, Pinilla I - Zaragoza

The changing sphingolipidome of retinal ganglion cells in response to stress
TRZECIECKA AM, Piqueras MC, Bhattacharya SK - Miami

Nebivolol acts as a beta3-adrenergic receptor agonist in a mouse model of oxygen-induced retinopathy
DAL MONTE M, Amato R, Locri F, Cammalleri M - Pisa

Modulation of iris sphincter and ciliary muscles by Urocortin 2

Alzheimer’s disease: can the retina be a window to the brain?
NEVES AC, Chiquita S, Carecho R, Campos E, Moreira P, Baptista F, Ambrósio F - Coimbra

Electrical direct current stimulation affects retinal vessel diameter and vasodilation in healthy subjects
FREITAG S, Klee S, Haueisen J - Ilmenau

Influence of metabolic control in patients with refractory diabetic macular edema treated with Ozurdex
Agenda

1. Report of the chair of section
2. Report of the programme secretary
3. Next year’s meeting:
   • Nomination of the 2018 section programme secretary (different from the section chair)
   • Proposals of 2018 Special Interest Symposia (SIS)
   • Proposals of 2018 Courses
   • Proposals for 2019 Keynote speakers
4. Comment on the EVER activities
5. Other business

In addition to the agenda, the sections LC and RV will nominate at least 2 candidates for section chair 2018 - 2022
LEROY BP

Cases with retinal imaging are presented and discussed with a panel. Each case presentation lasts for 10 minutes with 5 minutes for discussion. This session is open to all eVer delegates. Presenters at this session are welcome to bring a powerpoint presentation of a single interesting case on a USB memory key and load it up in the speakers room.

www.fan-int.org

16:20 - 17:50 | RHODES 1

G - Microglia in retinal neurodegenerative diseases: friend or foe?

Microglia play an important role in the pathology of many neurodegenerative disorders, yet there remains significant uncertainty about their neuroprotective and/or degenerative role in disease. Indeed, whereas the inflammatory response was classically considered a harmful process, it is increasingly clear that both blood-borne and resident inflammatory cells also contribute to CNS repair processes, including the promotion of neuronal survival and axonal regeneration. As a result, therapeutic interventions increasingly seek to modulate rather than simply suppress neuroinflammation.

In this SIS, we explore the involvement of microglia in retinal degeneration. Incorporating recent developments in retinal imaging, histological and bio-image informatics approaches to assess microglial behaviour, we will evaluate the potential of microglia as valuable indicators of disease progression. Furthermore, their changing behaviour in the aging retina/visual system will be discussed, along with its implications for optic nerve repair.

DE GROEF L, DAVIS B

3621  16:20 Contribution of microglia and complement activation to glaucoma progression


3622  16:38 Contribution of microglia-mediated neuroinflammation to retinal degenerative diseases

Boia R, Madeira MH, Aires ID, Neves CR, Ambrósio AF, SANTIAGO AR - Coimbra

3623  16:56 Characterizing microglia activation: a spatial statistics approach to maximize information extraction


3624  17:14 Ocular inflammation as a motor for axonal regeneration in the optic nerve

FISCHER D - Düsseldorf

3625  17:32 “Inflammaging” in the zebrafish visual system

High resolution imaging of the eye has become critical to improving the diagnosis, assessment of severity, and evaluation of treatment of eye diseases. In this SIS, we will see the interest in our everyday practice, through practical example; of the newest technologies in ocular imaging that are now becoming more easily accessible.

**GICQUEL J, PISELLA PJ**

**3631** 16:20 Why should you buy a Shack-Hartman aberrometer for your everyday practice?
*GICQUEL JJ - Saint Jean d’Angély*

**3633** 17:04 Emerging applications of adaptive optics retinal imaging
*VABRE L, Chateau N - Orsay*

**3634** 17:26 High resolution anterior segment OCT and lamellar corneal surgery
*NUBILE M - Chieti*

---

**KIVELAT , KILIC E**

**3641** 16:20 Small fatal choroidal melanomas: A survey by the European Ophthalmic Oncology Group

**3642** 16:32 miRNA profiling of uveal melanoma exosomes as a metastatic risk biomarker

**3643** 16:44 Absence of nuclear Programmed cell death 4 as an indicator of poor prognosis in uveal melanoma patients
*AHMED I, Kalirai H, Angi M, Coupland S - Liverpool*

**3644** 16:56 Nestin expression in primary and metastatic uveal melanoma
*DJIRACKOR L, Shakir D, Kalirai H, Petrovksi G, Coupland S - Liverpool*

**3645** 17:08 Protein kinase inhibitors for targeting tumor-initiating cells in uveal melanoma
*CABRE ESTIVILL E, Pereira E, Vinyals A, Lorenzo D, Varela M, Piulats JM, Caminal JM, Fabra A - L’Hospitalet de Llobregat*

**3646** 17:14 Macular features assessed by optical coherence tomography-angiography after proton beam therapy for choroidal melanoma
*LUMBROSO L, Sellam A, Coscas F, Dendale R, Levy C, Coscas G, Desjardins L, Cassoux N - Paris*
### Mitochondrial disorders and the eye

Based on the latest epidemiological data, mitochondrial diseases affect at least 1 in 5,000 people in the general population. Remarkably, ocular involvement occurs in at least half of all patients with confirmed mitochondrial disease and the two most common phenotypes are visual loss associated with primary retinal ganglion cell loss and optic atrophy and extraocular muscle pathology leading to progressive ophthalmoplegia and ptosis. Visual impairment can also arise due to outer retinal degeneration. This session will provide a clinically relevant overview of mitochondrial eye diseases and the multisystemic complications that can be associated with this group of disorders.

**YU-WAI-MAN P, VOTRUBA M**

<table>
<thead>
<tr>
<th>Code</th>
<th>Time</th>
<th>Title</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>3651</td>
<td>16:20</td>
<td>Primary mitochondrial optic neuropathies</td>
<td>BARBONI P - Bologna</td>
</tr>
<tr>
<td>3652</td>
<td>16:38</td>
<td>Retinal involvement in mitochondrial diseases</td>
<td>LEROY BP - Ghent</td>
</tr>
<tr>
<td>3653</td>
<td>16:56</td>
<td>Chronic progressive external ophthalmoplegia</td>
<td>YU-WAI-MAN P - Cambridge</td>
</tr>
</tbody>
</table>

### Noninvasive morphological and functional imaging in the eye

The aim of this course is to introduce and review different optical technologies allowing the non-invasive imaging of both morphological features and functional parameters in the anterior and posterior part of the eye. The speakers will present the physical concepts of the imaging modalities, discuss the limitations and will demonstrate their application for preclinical and clinical imaging.

**WERKMEISTER R, LEITGEB RA**

<table>
<thead>
<tr>
<th>Code</th>
<th>Time</th>
<th>Title</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>3661</td>
<td>16:20</td>
<td>Anatomy and physiology of the anterior eye segment</td>
<td>WERKMEISTER R - Vienna</td>
</tr>
<tr>
<td>3662</td>
<td>16:38</td>
<td>Doppler OCT - functional imaging in the retina</td>
<td>ASCHINGER G - Vienna</td>
</tr>
<tr>
<td>3663</td>
<td>16:56</td>
<td>OCT Angiography</td>
<td>LEITGEB RA - Vienna</td>
</tr>
<tr>
<td>3664</td>
<td>17:14</td>
<td>Multifunctional OCT for preclinical imaging</td>
<td>BAUMANN B - Vienna</td>
</tr>
<tr>
<td>3665</td>
<td>17:32</td>
<td>Photoacoustic imaging and its preclinical application in ophthalmology</td>
<td>LIU M - Vienna</td>
</tr>
</tbody>
</table>
Vision had to start somewhere and well-preserved Cambrian fossils reveal the evolution of vision through the world’s oldest eyes. Likewise, eye has been an ancient symbol of protection, royal power and good health, with the Egyptian Eye of Horus as an example. Furthermore, it has been the subject of conflicting interpretations since antiquity. Many ancient physicians and philosophers, such as Plato, Aristotle, Galen, Leonardo and Kepler, made the eye a subset of special study. Finally, eyes play an important role in the history of visual Arts, including painting, sculpture, drawing, design, etc. We will take a look at topics, which show the importance of ancient eyes along the history.

**GRZYBOWSKI A, ASCASO F**

**3671**
16:20 The earliest eyes on Earth

**ASCASO FJ - Zaragoza**

**3672**
16:38 Eye of Horus

**GRZYBOWSKI A - Olsztyn**

**3673**
16:56 The eye according to Byzantines medical writers

**TROMPOUKIS C - Chios**

**3674**
17:14 Artistic depictions of the eyes and blindness throughout history

**BULLOCK J - Kettering**

**3675**
17:32 The evolution of oculoplastic operations

**PAPADAKIS M - Wuppertal**

---

The lens of the eye is discussed to be more radiosensitive than previously thought but, despite a substantial reduction in occupational dose limits based on recent epidemiological information and reanalyses, the mechanisms of low dose radiation cataract induction are still unclear. Since it is an important current public health issue, this SIS brings together experts to discuss a number of key research questions on this topic, including: how does low dose radiation cause cataracts; is there a dose rate effect, and how does genetic background influence cataract development after radiation exposure. The speakers will demonstrate various mouse models as well as cellular studies in investigating the mechanistic chain of events from the initial radiation insult and biological responses through to formation of lens opacities.

**GRAW J, AINSBURY L**

**3681**
16:20 Lifetime Study in mice: radiation-induced cataract


**3682**
16:42 Radiation-induced cataracts

BARNARD S, Moquet J, Lloyd S, Ellender M, Ainsbury E, Quinlan R - Didcot

**3683**
17:04 The role of the Shh signaling pathway in radio-induced cataractogenesis


**3684**
17:26 Radiation-induced cataracts

The pre-Descemets corneal layer (Dua's layer): Controversy and clinical applications

DUA HS - Nottingham
INVITATION

EVER 20\textsuperscript{th} Anniversary

in Acropolis Convention Center

\textbf{Walking dinner}

Friday 29 September 2017

From 19:00 to 22:00
The proposed special interest symposium aims to tackle topics of controversy in the management of macular disease. These controversies follow the introduction of new treatments for particular macular pathology entities or involve management options whose efficacy or safety have yielded contradictory results in the clinical practice or literature.

The proposed format of the symposium is in the form of three debates with a panel of known experts supporting or not the management option in question.

**PAPASTEFANOU V, XIROU T**

**4111**  8:30 Surgical management of diabetic macular edema - For  
  **POURNARAS JA** - Lausanne

**4112**  8:45 Surgical management of diabetic macular edema - Against  
  **CHATZIRALLI I** - Athens

**4113**  9:00 Ocriplasmin in the treatment of vitreomacular traction - For  
  **XIROU T, Chatziralli I** - Glyfada

**4114**  9:15 Ocriplasmin in the treatment of vitreomacular traction - Against  
  **ZAMBARAKJI H** - London

**4115**  9:30 Anti-VEGF intravitreal injections in the management of radiation maculopathy - For  
  **KIVELÄ T** - Helsinki

**4116**  9:45 Anti-VEGF intravitreal injections in the management of radiation maculopathy - Against  
  **PAPASTEFANOU V** - London

**NORMANDO EM, ROUSSEAU A**

**4121**  8:30 Effects of docosahexaenoic acid on the viability of human tenon's fibroblasts  
  **DE LAZZER A, Acar N, Bretillon L, Bron AM, Creuzot Garcher C** - Dijon

**4122**  8:42 Effects of Caveolin-1 ablation in the inner retina under healthy and experimental glaucoma conditions  

**4123**  8:54 Global histone modifications predict the outcome of glaucoma surgery  
  **JEON S, Park HY L, Kim JH, Jung Y, Park CK** - Seoul

**4124**  9:06 Inflammatory changes in aqueous induced by diabetes in open angle glaucoma patients  
  **PANTALON A, Constantinescu D, Feraru C** - Iasi

**rf**  9:18 Early signs of microglial activation in mice retinas contralateral to experimental glaucoma: quantitative analysis of cells number, processes retraction and reorientation  

**rf**  9:24 Qualitative early signs of microglial activation in mice retinas contralateral to experimental glaucoma  

**rf**  9:30 Aqueous inflammatory proteasome in open angle glaucoma in Caucasian patients  
  **PANTALON A, Feraru C, Constantinescu D** - Iasi

**rf**  9:36 Association of apolipoprotein E with a risk of primary open-angle glaucoma  
### SATURDAY, SEPT 30 - FIRST MORNING SESSION

#### RHODES 2

**COS - Science and practice of crosslinking**

Topo- and tomographical indices in keratoconus and in case of progression - as indication for crosslinking - are summarized. The effect of crosslinking on parameters of Ocular Response Analyser are described. The effect of crosslinking on human corneal cells, microorganisms and on viral, bacterial, mycotic and acanthamoeba keratitis is summarized.

**SZENTMARY N**

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>4131</td>
<td>8:30</td>
<td>Topo- and tomographical keratoconus indices in case of progression</td>
<td>LANGENBUCHER A, Szentmary N, Eppig T - Homburg</td>
</tr>
<tr>
<td>4132</td>
<td>8:48</td>
<td>Application of OCT in diagnosis and treatment of keratoconus patients</td>
<td>WYLEGALA E, Dobrowolski D, Wylegala A - Katowice</td>
</tr>
<tr>
<td>4134</td>
<td>9:24</td>
<td>Crosslinking in infectious corneal ulcers and Terrien marginal degeneration</td>
<td>BARRAQUER RI, Alvarez de Toledo J, Lamarca J - Barcelona</td>
</tr>
<tr>
<td>4135</td>
<td>9:42</td>
<td>Crosslinking in infectious keratitis - experimental and clinical data</td>
<td>Szentmary N - Budapest</td>
</tr>
</tbody>
</table>

#### RHODES 3

**PO: OOG Ocular Oncology Group II**

**HADJISTILIANOUT, DESJARDINS L**

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>4141</td>
<td>8:30</td>
<td>Preliminary results: Comprehensive national retinoblastoma cohort in Finland - RB1 mutation spectrum</td>
<td>NUMMI K, Kivelä T - Helsinki</td>
</tr>
<tr>
<td>4142</td>
<td>8:36</td>
<td>Outcome of Retinoblastoma Patients Treated According to the University Hospital of Siena Guidelines</td>
<td>CORIOLANI G, Galimberti D, Guglielmucci DF, Caini M, De Francesco S, Esposito G, Bracco S, Galluzzi P, Toti P, Pinto AM, Favre C, Grosso S, Hadjistilianou T - Siena</td>
</tr>
<tr>
<td>4144</td>
<td>9:00</td>
<td>Orbital recurrence of uveal melanoma after 45 years from enucleation</td>
<td>HADJISTILIANOUT, Galluzzi P, Toti P, Menicacci F, Menicacci C, Daini R, Pica A, Zografos L - Siena</td>
</tr>
<tr>
<td>4146</td>
<td>9:24</td>
<td>Adult orbital precursor B-lymphoblastic lymphoma with involvement of the extraocular muscles</td>
<td>MIKKELSEN LH, Ejstrup R, Clasen-Linde E, Andersen MK, Gjerdrum MLR, Heegaard S - Copenhagen</td>
</tr>
</tbody>
</table>
SATURDAY, SEPT 30 - FIRST MORNING SESSION

TASSIGNON MJ, CASPERS L

**4151 8:30** CLP-PEG scaffold development: towards conjunctival tissue engineering
VAN ACKER S - Wilrijk

**4152 8:42** Corneal mesenchymal stem cell derived exosomes: new therapeutic option for corneal wound healing
VAN DEN BOGERD B - Wilrijk

**4153 8:54** Corneal thinning post crosslinking: fact or fiction? Solving the mystery by in-vivo measurements of corneal refractive index
CONSEJO A - Antwerpen

**4154 9:06** Discovering and elucidating the role of non-coding defects in the CHM region in the pathogenesis of choroideremia
VAN DE SOMPELE S - Gent

**4155 9:18** Evaluation of blood retinal barrier breakdown in non-infectious uveitis through an endothelium transcriptomic approach
FOUCART V - Bruxelles

**4156 9:30** Exploring the role of cis-acting non-coding variation in inherited blindness: the ABCA4 gene in Stargardt disease as a model
BAUWENS M - Ghent

**4157 9:42** Immunomodulatory capacity of corneal derived MSCs and keratocytes
MATHYSSEN S - Edegem

**4158 9:54** Incretins, a new target for neuroprotection in glaucoma therapy?
LEMMENS S - Leuven

**4159 10:06** Inhibition of a hyperactive kinase signaling hub as a novel and integrative therapy for diabetic retinopathy
SERGEYS J - Leuven

---

RV - OCT-angiography for the evaluation and management of macular pathologies

OCT angiography (OCT-A) as a new non-invasive imaging technology that enables the monitoring of the macular retinal and choroidal circulation. OCT-A allows a detailed detection either of the macular retinal capillaries plexus as well as the subretinal choroidal neovascularisation. The correlation of OCT-A with OCT longitudinal or “en face” sections resulted to a better understanding of the pathologic features of the macular degenerative or vascular pathologies. OCT-A became a useful imaging modality in the evaluation and management of macular hemodynamic changes observed during the evolution of the retinal ischemic microneangiopathies, age related maculopathies related to a subretinal neovascularisation as well as the vitreoretinal interface surgical pathologies. The aim of this course is to present the most recent findings for the evaluation of macular pathologies and to have an interactive session.

**COSCAS G, POURNARAS C**

**1311 08:30** Principles and techniques; pearls and pitfalls
LUPIDI M, Coscas G, Coscas F - Perugia

**1312 08:42** OCT-A et critères d’activité
COSCAS G, Lupidi M, Coscas F - Creteil

**1313 08:54** OCTA and assessment of CNV retreatment
COSCAS F, Coscas G, Souied EH - Creteil

**1314 09:06** OCT-A A in CSC and in MacTel type 2
MAUGET-FAYSSE M, Wolf B, Vasseur V, De Bats F - Paris

**1315 09:18** OCTA in ocular oncology
ZOGRAFOS L - Lausanne

**1316 09:30** OCT-A: Diagnosis and management of surgical macular pathologies
POURNARAS C - Genève

**1317 09:42** OCT-A and Diabetic maculopathy; automated assessment
LUPIDI M, Cagini C, Coscas F, Coscas G - Perugia
10:20 - 10:50 | HERMES
Ophthalmic Research Lecture by Hendrik SCHOLL

**EMERGING THERAPIES FOR RETINAL AND MACULAR DYSTROPHIES**

Hendrik SCHOLL - Bonn

10:20 Introduction by Francesca M. CORDEIRO

10:25 Emerging therapies for retinal and macular dystrophies

Inherited retinal degenerative diseases, a genetically and phenotypically heterogeneous group of disorders, affect the function of photoreceptor cells and are among the leading causes of blindness. Recent advances in molecular genetics and cell biology are elucidating the pathophysiological mechanisms underlying these disorders and are helping to identify new therapeutic approaches, such as gene therapy, stem cell therapy, and optogenetics. Several of these approaches have entered the clinical phase of development. Artificial replacement of dying photoreceptor cells using retinal prostheses has received regulatory approval. Precise retinal imaging and testing of visual function are facilitating more efficient clinical trial design. In individual patients, disease stage will determine whether the therapeutic strategy should comprise photoreceptor cell rescue to delay or arrest vision loss or retinal replacement for vision restoration.

10:50 Award presentation of the Certificate of Honour

Biography of Prof. Hendrik SCHOLL:

Hendrik P.N. Scholl, M.D., M.A. is Professor and Chairman of the Department of Ophthalmology, University of Basel, and Adjunct Professor of Ophthalmology at the Wilmer Eye Institute, Johns Hopkins University. He received his M.D. from the Eberhard Karls University of Tuebingen, Germany, and did his residency at the Centre for Ophthalmology, University of Tuebingen. He did a clinical research fellowship at Moorfields Eye Hospital, London, UK. In 2004, he was awarded a Heisenberg-Fellowship of the German Research Foundation for his achievements in the field of macular degeneration and subsequently joined the faculty at the Dept. of Ophthalmology, University of Bonn for 5 years until he was recruited to the Wilmer Eye Institute in 2010 where was leading the retinal degeneration clinic and the Visual Neurophysiology Service of the Johns Hopkins Hospital until 2016.

Dr. Scholl specializes in medical and surgical management of retinal diseases such as age-related macular degeneration and diabetic retinopathy. He has a specific expertise in inherited retinal and macular degenerations. He has published more than 100 peer-reviewed original and review articles, inside and outside the eye literature in such journals as Nature, Nature Genetics, Journal of Immunology, American Journal of Human Genetics, Human Molecular Genetics and PLoS ONE. His group is working on outcome measures for clinical trials in retinal degenerative diseases.

Dr. Scholl is member of the steering committee and coordinator of the Expert Committee on Retinal Dystrophies, European Vision Institute Clinical Research Network (EVICR.net). He is Associate Editor (Genetics) of Ophthalmic Research and member of the editorial board of Translational Vision Science & Technology (TVST), JAMA Ophthalmology and Ophthalmologica.

Dr. Scholl has received numerous awards including the European Vision Award in 2008, the Wynn-Gund Translational Research Award by the Foundation Fighting Blindness and the Macular Degeneration Research Award by the American Health Assistance Foundation in 2010, the Visionary Award from the Foundation Fighting Blindness and the ARVO Foundation/Pfizer Ophthalmics Carl Camras Translational Research Award in 2014, and the President's Award from the American Society of Retina Specialists in 2015.
10:50 - 12:00 | POSTER AREA
COS: Cornea/Ocular Surface

**Poster S001-S038**

**SZENTMARY N , WYLEGALA E**

**S001**  
In vivo evaluation of voriconazole eye drops efficacy in a rat Acanthamoeba polyphaga keratitis model  

**S002**  
Hydrops: Not that bad!  
MEKKI MB , Said Y , Okba T , Taibi A - Algiers

**S003**  
Two photon microscopic findings of sonoporation-assisted enhancement of corneal penetration of fluoroquinolone antibiotics  
LEE JA , Jeong H , Kim JY , Teah H , Kim KH , Kim MJ - Seoul

**S004**  
Efficacy of a RAR selective agonist eye drop formulation on improvement of tear production and corneal fluorescein staining in the BTX-B mouse model of dry eye disease  
LEMIRE I , Harvey M , Grogan D , Desjardins C - Montreal

**S005**  
Graft blues: case report  

**S006**  
Comparison between over-glasses patching and conventional patching for children with moderate amblyopia : a prospective randomized clinical trial  
KIM SJ , Lee SU , Lee JE - Changwon-si

**S007**  
Micro-instillation of fluorescein with an inoculation loop for ocular surface staining in dry eye syndrome.  

**S008**  
Does femtosecond laser assisted penetrating keratoplasty lead to less astigmatism in keratoconus patients, compared with conventional penetrating keratoplasty?  
STEN LGB , Råen M , Brevik T B , Drolsum L - Oslo

**S009**  
Corneal confocal microscopy assessment in contact lens discomfort  

**S010**  
Effects of trypan blue on corneal endothelial cell viability :Optimal time of Trypan Blue Dye Application to DMEK donor tissue  
KIM EY , Kim SY - Uijeongbu-Si

**S011**  
Use of sodium hyaluronate in combination with a blood derivative in the re-epithelialization of rabbit corneas  

**S012**  
Evaluation of visual quality parameters after Descemet membrane endothelial keratoplasty (DMEK)  

**S013**  
Interference ofTRPA1 function affects background activity of corneal cold thermoreceptors in ageing mice  
GALLAR J , Rincón-Frutos L , Luna C , Velasco E , Aracil A , Diaz-Tahoces A , Acosta MC - San Juan de Alicante

**S014**  
Femtolaser-assisted vs manual anterior lamellar keratoplasty in patients with keratoconus  
KAZAKBAEV R , Bikbov M , Usubov E , Kazakbaeva G - Ufa

**S015**  
Progressive changes in visual function after Descemet membrane endothelial keratoplasty  
<table>
<thead>
<tr>
<th>Poster S001-S038</th>
</tr>
</thead>
</table>

### Szentmary N, Wylegala E

**S016**  
Ocular cicatricial pemphigoid secondary to intravitreal implant of ranibizumab: a case report  
LOPEZ SANGROS I, Marco Monzón S, Bartolomé Sensé I, Berniolles Alcaide J, Sanchez Marin JI, Idoate Domenech A, Ascaso Puyuelo J, Del Buey Sallas MA - Zaragoza

**S017**  
Assessment of endothelial quality of pre-stripped DMEK grafts prepared using the Muraine technique  

**S018**  
Discomfort self-perception in contact lens wearers  
Pastor-Zaplana JA, Morales-Villellas M, GALLAR J, Acosta MC - San Juan de Alicante

**S019**  
Bioactive sphingolipid mediators promote corneal epithelial homeostasis and wound healing  
TRZECIECKA AM, Piqueras MC, Bhattacharya SK - Miami

**S020**  
Corneal haze in juvenile and adult keratoconus patients after corneal cross-linking  

**S021**  
The use of corneal scrubbing associated with matrix therapy in the treatment of chronic ulcers  
LAZREG S, Christophe B - Blida

**S022**  
Refractive Lenticule Transplantation (RLT) for correction of iatrogenic hyperopia and high astigmatism after LASIK  
LAZARIDIS A, Reinstein DZ, Archer TJ, Schulze S, Sekundo W - Abu Dhabi

**S023**  
The efficacy of heating devices to warm the lids  
ALMUTAIRI R, Hagan S, Madden LC, Pearce E - Glasgow

**S024**  
Corneal melting and perforation under topical moxifloxacin and tobramycin: case report  
CASPERS S, Noi L, Le A, Janssens X, Willermain F, Caspers L - Brussels

**S025**  
Mushroom keratoplasty  
NAHAS S, Silvana M - Southend

**S026**  
Confocal characterization of recurrent corneal erosion syndrome suspects  
SMEDOWSKI A, Mazur R, Tarnawska D, Wylegala E - Katowice

**S027**  
Mean shape of the human sclera  
CONSEJO A, Iskander RD, Rozema JJ - Antwerpen

**S028**  
The impact of daily disposable soft contact lens wear on tear film surface quality over a three month period  
MOUSAVI M, Garaszzuk IK, Jesus DA, Szczesna-Iskander D, Iskander DR - Wroclaw

**S029**  
Exploratory ocular surface distribution studies of Azithromycin formulations based on semifluorinated alkanes  
FISCHER K, Grillenberger R, Amr T, Krösser S - Heidelberg

**S030**  
Softacort®, preservative-free Hydrocortisone 0.335% drops: A new anti-inflammatory drop with minimal effects on intraocular pressure  
SHORTT A, Rolando M - London

**S031**  
Association of incidental epithelialization of corneal endothelium with endothelial barrier impairment  
Smedowski A, Mazur R, Tarnawska D, WYLEGALA E - Katowice

**S032**  
Femtosecond assisted intracorneal segments implantation for mild to moderate keratoconus: long term results  
KONTADAKIS G, Parikakis E, Kaprinis K, Stoupaki M, Nikas S, Konstantinidou V, Peponis V - Athens

**S033**  
Complete corneal ring (MyoRing) implantation combined with corneal collagen crosslinking in keratoconus treatment  
EMIN U, Mukharram B, Gyulli K, Guzel B - Ufa
<table>
<thead>
<tr>
<th>Poster S001-S038</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>S034</strong> Corneal clarity measurements in patients with myopia undergoing laser assisted in situ keratomileusis and laser assisted sub-epithelial keratectomy</td>
</tr>
<tr>
<td>ALZAHIRANI K, Din N, Brahma A, Carley F, Hillarby MC - Manchester</td>
</tr>
<tr>
<td><strong>S035</strong> Recombinant human heat shock protein 27 can inhibit ultraviolet B-induced differentiation in pterygial-derived fibroblast</td>
</tr>
<tr>
<td>KIM JY, Moon CH, Shin JA, Kang SS, Kim ES, Tchah H - Seoul</td>
</tr>
<tr>
<td><strong>S036</strong> Corneal clarity after Descemet membrane endothelial keratoplasty versus Descemet stripping endothelial keratoplasty: Two-year outcomes</td>
</tr>
<tr>
<td><strong>S037</strong> Short-term in vivo morphologic changes of amniotic membrane after fibrin glue-assisted pterygium surgery on anterior segment optical coherence tomography: a case series</td>
</tr>
<tr>
<td>LIM S - Daegu</td>
</tr>
<tr>
<td><strong>S038</strong> Ultrastructural analysis of human pre-Descemet's tissue</td>
</tr>
</tbody>
</table>
ABEGAO PINTO L, BONO V

**S039**

**rf** Early signs of microglial activation in mice retinas contralateral to experimental glaucoma: quantitative analysis of cells number, processes retraction and reorientation


**S040**

Comparative study of retinal nerve fiber layer and ganglion cell complex thickness between Korean patients with unilateral exfoliation syndrome and normal control

LIM S - Daegu

**S041**

Efficacy and safety of the pars plana clip in the Ahmed valve device in patients with refractory glaucoma


**S042**

Three year results of iStent + Phacoemulsification cataract surgery for glaucoma


**S043**

Supraciliary Micro-Stent (CyPass®) is associated with lack of disease progression and minimum usage of IOP lowering medications in patients with POAG 2-Years Post-Implantation

UZUNOV R, Landry T, Dickerson J - Cointin - Geneva

**S044**

Follow-up of non-complicated filtering surgeries under ambulatory care with no control at Day 1

JEANCOLAS AL, Conart JB, Trechot F, Berrod JP, Angioli-Duprez K, Maalouf T - Vandoeuvre les Nancy

**S045**

IOP-lowering efficacy of prostaglandin analogues adjunctive to a Supraciliary Micro-Stent (CyPass®)

UZUNOV R, Landry T, Dickerson J - Cointin - Geneva

**S046**

Ultrasound ciliary plasty to treat glaucoma: efficacy and safety results on 152 patients

APTEL F, Rouland JF - Meylan

**S047**

Computational fluid dynamics simulations of aqueous flow through the CyPass® Micro-Stent

VIDAL AROCA F, Vera LF, Missel P, Sarangapani R - Milan

**S048**

Trabeculectomy: evaluation of the area exposed to mitomycin C

PINTO FERREIRA N, Sousa D, Mano S, Medeiros Pinto J, Barata A, Abegao Pinto L - Lisbon

**S049**

Clinical manifestations of reverse pupillary block after scleral-fixed intraocular lens implantation: Pre- and post-laser peripheral iridotomy

KIM JM, Lee KB, Han JI, Jung JJ - Seoul

**S050**

Positional and shape changes of lamina cribrosa after trabeculectomy in pseudoexfoliative and primary open angle glaucoma

KADZIAUSKIENE A, Strelkauskait E, Asoklis R, Girard MJA, Schmetterer L - Vilnius

**S051**

Interest of analysis of circumpapillary retinal nerve fibers layer thickness at different measurement diameters

EL CHEHAB H, Agard E, Loria O, Theo L, Dot C - Lyon

**S052**

Screening for glaucoma progression by using non-parametric tests

PANTALON A, Chiseilta D, Feraru C - Iasi

**S053**

Prospective comparison of global visual field indices and cluster progression in glaucoma and their relationship to structural changes

BONO V, Normando EM, Davis B, Cordeiro MF - Avellino

**S054**

Reproducibility of angle metrics in children using hand-held spectral domain optical coherence tomography: intra-observer and inter-observer variability

PANTALON A, Chiseilta D, Feraru C - Iasi
ABEGAO PINTO L, BONO V
EDAWAJI B, Shah S, Proudlock F, Gottlob I - Leicester

**S055**
UBM evaluation of mechanisms that drive intraocular pressure (IOP) decrease after ultrasound ciliary plasty (UCP) with high intensity focused ultrasound (HIFU), towards a new explanation of the role of uveoscleral pathway outflow
ROQUANCOURT T, Aptel F, Rouland JF - Lille

**S056**
Modifications in corneal biomechanics and intraocular pressure after deep sclerectomy

**S057**
Glaucoma in screening of diabetic retinopathy programme
SUMMANEN P, Kivelä T, Sipilä V, Uhlenius N, Von Wendt G - Helsinki

**S058**
Analysis of changes in individual retinal layer thickness after cataract surgery using spectral-domain optical coherence tomography
KWAK AY, Park SK, Kim CY - Seoul

**S059**
Application of 3D-ASL technique in observation on cerebral blood flow changes in early and mid-stage primary open angle glaucoma
QING Z - Guangzhou

**S060**
ISNT rule applicability based on optical coherence tomography parameters in a normal Portuguese population
BARATA A, Teixeira F, Pinto F - Lisboa

**S061**
Macular thickness after intraocular pressure reduction following trabeculectomy
DRUKTEINIENE E, Streitkauškaitė E, Kudziauskienė A, Asoklis R, Schmetterer L - Vilnius

**S062**
First real-life data of use of the new PF-MD glaucoma device (EasyGrip®): Results of the ISY study from Spain and France
DENIS P, Duch S - Lyon

**S064**
Wait before extrapolating rather than wait between two eyedrops! ... The 1974 Chrai et al.’s study on the albino rabbit may not apply to humans
BAILLEUL H, Beraud G, Denion E - Caen

**S065**
Prescription pattern of ocular hypotensive drugs in Portugal and its comparison with the European guidelines – PEM Study
PIMENTA G, Sousa DC, Leal I, Marques-Neves C, Abegao Pinto L - Lisbon

**S066**
Missed opportunities of optimizing glaucoma medical therapy – A nationwide cross-sectional analysis of glaucoma topical therapy in Portugal (PEM Study)
PIMENTA G, Sousa DC, Leal I, Barata A, Marques-Neves C, Abegao Pinto L - Lisbon

**S067**
Enzymatic Activity of CYP1B1 in primary congenital glaucoma goniodysgenesis and its relation with histological alterations

**S068**
Qualitative early signs of microglial activation in mice retinas contralateral to experimental glaucoma

**S069**
Aqueous inflammatory proteasome in open angle glaucoma in Caucasian patients
PANTALON A, Feraru C, Constantinescu D - Iasi

**S070**
Association of apolipoprotein E with a risk of primary open-angle glaucoma

**S071**
Glaucoma assessment tools used by clinicians: old or gold?
Poster S072-S078

**ANDJELIC S, LORIA O**

**S072** Calcium signaling in human lens epithelial cells after mechanical stimulation  
**ANDJELIC S, Gosak M, Gojic D, Hawlina M - Ljubljana**

**S073** Effects of short oxidative stress exposure on lens epithelial cells  
**D'ANTIN JC, Barraquer RI, Michael R - Barcelona**

**S074** Changes in the X-ray diffraction pattern of porcine lens before and after simulated accommodation  
**AL-ATAWI S, Albon J, Meek K, Hayes S, Bell J, Regini J - Cardiff**

**S075** Intraocular implant calculation based on the fellow eye measurements  
**KALEMAKI M - Heraklion**

**S076** Persistent pupillary membrane associated with cataract  

**S077** Visualization of the light field of multifocal intraocular lenses using a dual wavelength approach  
**EPPIG T, Rubly K, Schröder S, Rawer A, Langenbucher A - Homburg/Saar**

**S078** Robotic surgery - a new way to perform cataract surgery  
**CHAMMAS J, Sauer A, Bourcier T - Strasbourg**
### Poster Session 3: Pathology/Oncology

**Poster Area**

**10:50 - 12:00 | POSTER AREA**

**PO: Pathology/Oncology**

<table>
<thead>
<tr>
<th>Poster</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>S079</td>
<td>Usefulness of Ret-Cam imaging in diagnosis, treatment and monitoring of retinoblastoma</td>
<td>Romanowska Dixon B, Morawski K - Krakow</td>
</tr>
<tr>
<td>S080</td>
<td>Preliminary results: Comprehensive national retinoblastoma cohort in Finland - RB1 mutation spectrum</td>
<td>Nummi K, Kivelä T - Helsinki</td>
</tr>
<tr>
<td>S082</td>
<td>Case of IgG4-related eye disease requiring differentiation from carotid-cavernous fistula</td>
<td>Yamagishi A, Oshitari T, Tawada A, Yamamoto S - Chiba</td>
</tr>
<tr>
<td>S083</td>
<td>Protein kinase inhibitors for targeting tumor-initiating cells in uveal melanoma</td>
<td>Cabre Estivill E, Pereira E, Vinyals A, Lorenzo D, Varela M, Piulats JM, Caminal JM, Fabra A - L’Hospitalet de Llobregat</td>
</tr>
</tbody>
</table>
Chair: Alain BRON, President EVER 2018

Introduction of the Award Ceremony by Francesca M. Cordeiro, Programme Secretary
- Travel awards presentation by the section chairs
- Poster prize presentations by the section chairs

Presentation and report of the scientific sections meetings

Conclusion of the congress by the President 2018 Alain Bron
SATURDAY, SEPT 30 - FIRST AFTERNOON SESSION

13:00 - 14:30 | HERMES
RV/PO - Surgery of pediatric vitreoretinal disorders

This session will cover the modern surgical techniques for pediatric vitreoretinal diseases such as ROP, PFV etc, as well as to modern developing approaches in treatment of macular degenerations using gene therapy. The speakers are world known experts in their field.

LYTVYNCHUK L, LORENZ B

4411  13:00  Transpupillary laser versus intravitreal Anti-VEGF for the management of acute ROP: where do we stand?
LORENZ B - Giessen

4412  13:18  Endoscopic vitrectomy for stage 4 ROP
WONG SC - London

4413  13:36  Surgery in ROP, when is not too late?
FLORES-AGUILAR M - Celaya

4414  13:54  Novel gene based therapies for inherited retinal dystrophies in pediatric patients
STIEGER K - Giessen

4415  14:12  Surgical treatment of Persistent Fetal Vasculature (PFV)
LYTVYNCHUK L, Lorenz B - Giessen

13:00 - 14:30 | RHODES 1
G - A glaucoma surgery start-up guide - tips and tricks for your first 20 cases

Glaucoma surgery has undergone a renaissance over the last decade with refinement of traditional procedures such as trabeculectomy, deep sclerectomy & tube surgery and the introduction of novel techniques such as ab interno Schlemm's canal surgery (i-Stent, Hydrus, Kahook), sub-conjunctival devices (Xen, InnFocus) & endoscopic Sx (ECP).

Many glaucoma sub-specialists undergo intense fellowship training before embarking on independent practice but no experience specifically prepares you for the first months of your solo career. This SIS is aimed at residents & fellows aiming to become leading glaucoma specialists in the future.

It will provide expert tips & genuine advice from young glaucoma consultants across Europe who will share their expertise on how to prepare for that very first consultant post and what lessons & pitfalls to expect during the first months of independent glaucoma surgery, including handling complex cases and teaching your very own residents and fellows.

The speakers will talk about trabeculectomy, deep sclerectomy, tube surgery, i-Stent, Hydrus, Kahook blade, Xen, InnFocus and ECP with interactive videos and live discussions between the speakers and with the audience.

MERCIECA K, AU L

4421  13:00  Trabeculectomy - what I learned from my first 20 cases
ABEGAO PINTO L - Lisbon

4422  13:18  Glaucoma Drainage Device (tube) surgery - what I learned from my first 20 cases
ANAND N - Cheltenham

4423  13:36  XEN implant and UC3 - what I learned from my first 20 cases
VANDEWALLE E - Leuven

4424  13:54  Ab interno glaucoma surgery - what I learned from my first 20 cases
AU L - Manchester

4425  14:12  Deep Sclerectomy - what I learned from my first 20 cases
MERCIECA K - Manchester
GALLAR J, SZEVRNARY N

13:00 - 14:30 | RHODES 2
COS - Corneal injury & wound healing

13:00 The suppression of local cytokine production in experimental models of injured cornea after stem cell treatment
KOSSL J, HERVANKOVA B, JAVORKOVA E, BOHACOVA P, ZAJICOVA A, HOLAN V - Prague

13:18 Method for assessing the impact of residual roughness after corneal ablation in perception and vision
VERMA S, HESSER J, ARBA-MOSQUERA S - Kleinostheim

13:30 Optical control of corneal nerve activity using chemical photoswitches
GALLAR J, AREZ-SUAREZ D, QUIRCE S, ACOSTA MC, BELMONTE C, MESEGUER V - San Juan de Alicante

13:42 In vivo evaluation of voriconazole eye drops efficacy in a rat Acanthamoeba polyphaga keratitis model
<table>
<thead>
<tr>
<th>Paper</th>
<th>Time</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>4451</td>
<td>13:00</td>
<td>Interventional controlled cross-sectional study assessing the correlation between optic nerve vessels anomalies, serum angiogenic factors and renal anomalies in children with Down syndrome</td>
<td>POSTOLACHE L - Brussels</td>
</tr>
<tr>
<td>4452</td>
<td>13:12</td>
<td>Metabolomics in surgical ophthalmological patients (MISO study)</td>
<td>BARBOSA BREA J - Leuven</td>
</tr>
<tr>
<td>4453</td>
<td>13:24</td>
<td>Modulating synaptogenesis in mouse iPS derived 3D retinal cultures: a strategy to enhance neural circuit reconstruction post-transplantation</td>
<td>GEORGES A - Liège</td>
</tr>
<tr>
<td>4454</td>
<td>13:36</td>
<td>Neuroinflammation to rebuild neural circuits: unraveling the underlying molecular players</td>
<td>BOLLAERTS I - Leuven</td>
</tr>
<tr>
<td>4455</td>
<td>13:48</td>
<td>Ophthalmological screening and follow up of children with neurofibromatosis type 1</td>
<td>CASSIMAN C - Leuven</td>
</tr>
<tr>
<td>4456</td>
<td>14:00</td>
<td>Pathophysiological changes of the ocular surface as a result of scleral contact lens wear</td>
<td>BEHAEGEL J - Brussels</td>
</tr>
<tr>
<td>4457</td>
<td>14:12</td>
<td>Peroxisomes and vision: exploring the importance of peroxisomal beta-oxidation for retinal integrity</td>
<td>DAS Y - Leuven</td>
</tr>
<tr>
<td>4458</td>
<td>14:24</td>
<td>The eye as a miRror: targeting inflammatory miRNAs in age-related ocular diseases</td>
<td>ROBLAIN Q - Liège</td>
</tr>
</tbody>
</table>
Awardees of the EVERf Research Fellowships 2016

- Dr Mahajan DEEPTI, India
  host institute : Vision Lab, Cardiff Centre for Vision Sciences, Cardiff University, UK

- Dr Narine ADZHEMIAN, Russia
  host institute : Medical University of Vienna, Austria
was used.

After topical ophthalmic administration is lower than for systemic administration. Due to beta-adrenergic component, timolol, the acidosis.

Indicated in the treatment of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or pseudoexfoliative glaucoma. The dose is one drop of DUOKOPT in the (conjunctival sac of the) affected eye(s) two times daily.

Posology:

The dose is one drop of DUOKOPT in the (conjunctival sac of the) affected eye(s) two times daily.

Contraindications:

- Hypersensitivity to one of or to both active substances or to any of the excipients.
- Reactive airway disease, including bronchial asthma, or severe chronic obstructive pulmonary disease; Sinus bradycardia, sick sinus syndrome, sino-atrial block, second or third degree atrioventricular block not controlled with pacemaker, overt cardiac failure, heart disease.

The dose is one drop of DUOKOPT in the (conjunctival sac of the) affected eye(s) two times daily.

Indications:

- Treatment of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or pseudoexfoliative glaucoma.

Undesirable effects:

- Signs and symptoms of systemic allergic reactions, including angioedema, urticaria, pruritus, rash, anaphylaxis.
- Systemic adverse reactions, including hypotension, bradycardia, respiratory distress (bronchoconstriction).

Special warnings and precautions for use:

- Although topically applied, timolol is absorbed systemically. Due to beta-adrenergic component, timolol, the acidosis.
- Should be used with caution in patients with mild/moderate chronic obstructive pulmonary disease; Sinus bradycardia, sick sinus syndrome, sino-atrial block, second or third degree atrioventricular block not controlled with pacemaker, overt cardiac failure, heart disease.

Breast-feeding:

If treatment with DUOKOPT is required, then lactation should not be used during pregnancy.

Pregnancy:

DUOKOPT should not be used during pregnancy.

Interactions:

- Concomitantly with the following systemic treatments without evidence of adverse interactions: ACE-inhibitors, calcium channel blockers, diuretics, non-steroidal anti-inflammatory drugs (NSAIDs). See the most accessed articles for the year.

Marketing authorisation holder:

BLERIOT - 63017 CLERMONT-FERRAND CEDEX 2 France.

Pack sizes: 1 box of one 5 ml bottle, 1 box of one 10 ml bottle, 1 box of two 10 ml bottles, 1 box of three 5 ml bottles, 1 box of five 5 ml bottles. Not all pack sizes may be marketed.

Marketing authorisation holder:

Marketing authorisation holder:

The European Association for Vision and Eye Research

The Nordic and Dutch Ophthalmological Societies

Acta Ophthalmologica (formerly Acta Ophthalmologica Scandinavica) publishes clinical and experimental original articles, reviews, editorials, educational photo essays (Diagnosis and Therapy in Ophthalmology), case reports and case series, letters to the editor and doctoral theses.

Members of EVER receive FREE online access to Acta Ophthalmologica as part of your membership.
EBOD Exam 2018

The EBOD Exam 2018 will take place between the 4th and 5th of May 2018 in the Palais des Congres, Paris

www.ebo-online.org/ebo-exam/exam-information
Lucentis®, un traitement efficace sur tous les néovaisseaux choroïdiens quelle que soit leur étiologie

Lucentis® est indiqué chez les adultes :

- Dans le traitement de la baisse visuelle due à une néovascularisation choroidienne (NVC) Non remboursable et non agréé aux collectivités à la date de janvier 2017 (demande d’admission à l’étude).

Exemples d’étiologies de NVC : Stries angioïdes, chorioretinopathie séreuse centrale, chorioretinopathie idiopathique, chorioretinopathie post-inflammatoire, étiologies diverses

- En 1ère intention dans le traitement de la baisse visuelle due à une néovascularisation choroidienne (NVC) secondaire à une myopie forte (MF)

- En 1ère intention dans le traitement de la forme néovasculaire (humide) rétrofovéolaire de la dégénérescence maculaire liée à l’âge (DMLA)

- En 1ère intention dans le traitement de la baisse visuelle inférieure ou égale à 5/10 due à l’œdème maculaire diabétique (OMD), réservé aux formes diffuses et aux formes impliquant le centre de la macula après une prise en charge optimale du diabète et des facteurs de risque associés à l’OMD

- En 1ère intention dans le traitement de la baisse visuelle due à l’œdème maculaire secondaire à une occlusion de branche veineuse rétinienne (OBVR) ou de la veine centrale de la rétine (OVR)

Avant de prescrire, consultez la place dans la stratégie thérapeutique sur www.has-sante.fr

Lucentis® est un médicament d’exception : la prescription doit être accompagnée d’une ordonnance de médicament d’exception et ne peut avoir lieu que dans le respect de la Fiche d’Information Thérapeutique (FIT).

Les mentions légales sont disponibles sur la base de données publique des médicaments (http://base-donnees-publique.medicaments.gouv.fr)

* Autre que la baisse visuelle due à une néovascularisation choroidienne (NVC) secondaire à une myopie forte et à une DMLA.
* Photo non représentative de la taille réelle.
1. Résumé des Caractéristiques du Produit Lucentis®. 2. HAS. Avis de la Commission de la Transparence Lucentis®, 20/05/2015. 3. HAS. Avis de la Commission de la Transparence Lucentis®, 17/06/2015. 4. HAS. Avis de la Commission de la Transparence Lucentis®, 02/12/2015.
Ophthalmology Is Our Singular Focus

We Are Constantly Exploring New Possibilities in Eye Care

With a singular focus on eye care, all our efforts go into advancing the ocular health of patients. That’s the Santen Way.

Discover more at www.santen.com
Stand Strong for Science: Stand for Strong Vision Science

In a rapidly changing world, eye and vision researchers are emerging from the lab and the clinic to engage the public, patients and policymakers regarding the sight-saving work that we do and the benefits it brings to our societies. Our passion for our work and commitment to evidence-based science and medicine empower these conversations as they occur around the world.

We invite you to join us for the ARVO 2018 Annual Meeting in Honolulu, Hawaii, where 11,000 international basic and clinical researchers will share the latest breakthroughs in vision research. Engage with your colleagues as we work to advance our science and expand its support within our communities and governments.

arvo.org/am

Research training for all

ARVO’s Online Education — designed by vision researchers for vision researchers — offers essential training and career development for clinicians, scientists and students at all career levels. Self-paced modules are free to members. Not a member? Join as an online-only member for as little as $40 USD at arvo.org/dues.
New Karger Publications in Ophthalmology

Developments in Ophthalmology, Vol. 60
Management of Diabetic Retinopathy
Editors: Bandello, F. (Milan); Zarbin, M.A. (Newark, N.J.); Lattanzio, R.; Zucchiatti, I. (Milan)
X + 194 p., 77 fig., 64 in color, 30 tab., 2017, hard cover
CHF 198.00 / EUR 185.00 / USD 233.00

Developments in Ophthalmology, Vol. 59
Glaucoma Surgery
2nd, revised and extended edition
Editors: Bettin, P. (Milan); Khaw, P.T. (London)
XII + 196 p., 79 fig., 69 in color, 11 tab., 2017, hard cover
CHF 198.00 / EUR 185.00 / USD 233.00

Developments in Ophthalmology, Vol. 58
Macular Edema
2nd, revised and extended edition
Editors: Coscas, G. (Créteil); Loewenstein, A. (Tel Aviv); Cunha-Vaz, J. (Coimbra); Soubrane, G. (Crétteil, Paris)
XII + 244 p., 127 fig., 89 in color, 9 tab., 2017, hard cover
CHF 189.00 / EUR 177.00 / USD 222.00
www.karger.com/deoph

ESASO Course Series, Vol. 9
Medical Retina
Update 2017
Editors: Bandello, F.; Querques, G. (Milan); Loewenstein, A. (Tel Aviv)
VIII + 86 p., 34 fig., 26 in color, 9 tab., 2017, soft cover
CHF 98.00 / EUR 92.00 / USD 115.00
www.karger.com/esaso

www.karger.com
<table>
<thead>
<tr>
<th>Day</th>
<th>Timeslot</th>
<th>Hall</th>
<th>Order in session</th>
<th>Presenting First Authors</th>
</tr>
</thead>
</table>
| ABBASI, M: 4122
ABEGAO PINTO, L: 2625, 4421
ABRAHAMSEN RAVN, L: F079
ACAR, N: 3114
AHMED, F: 2122
AHMED, I: 3643
AJELETI, MO: F076
AL-ATAWI, S: S074
ALBINI, T: 1532, 2632
ALIO SANZ, J: 3364
ALLEN, C: F066
ALLGEIER, S: 3122
ALMUTAIRI, R: S023
ALONSO-ALONSO, ML: F071
ALZAHRAI, K: S020, S034
AMADIO, M: T001
AMARIE, O: 1353
AMATO, R: F064, F065
AMBRESIN, A: 1514, 2111, 3131, 3381
AMIRKAVEI, M: T005
ANAND, N: 4422
ANDJELIC, S: S072
ANDOLLO, N: S011
ANDRE, H: 1343, 1553, T010, T011
ANGI, M: 2732
APTEL, F: S046
ARDAN, T: 3515
ARNOULD, L: 2685
ASCASO, F: T079, T085, 3361, 3671
ASCHINGER, G: 3662
ASOKLIS, R: 3573
ATALAY, HT: 3583
ATILLA, H: 2362, 2663
AU, L: 4424
BABCHIA, N: 1189
BAILLEUL, H: S064
BALEN'TA, S: 3184
BARATA, A: 1517, F040, S060, T025
BARBONI, P: 2321, 3651
BARBOSA BREA, J: 1123, 2771, 4452
BARBURN, JL: 2165, 3331
BARNARD, S: 3662
BARRAQUER, RI: 3161, 4134
BARTOLOMÉ, I: F080, T074
BATES, D: 2611
BATSOS, G: F026
BAUMANN, B: 3664
BAUWENS, M: 4156
BEHAEGEL, J: 4456
BEHAR-COHEN, F: 2141
BEK, T: 1141
BELL, K: 3522
BEN ABDERRAHIM, K: 1183, 1193
BENNEDJAI, A: S081
BERNARDES, R: 1173, 1513
BERNIOLLES, J: F016, T060
BEUERMAN, R: 1151, 2762
BHATTACHARYA, SS: 2511
BIRD, AC: 1611
BIRKELDH, U: T027
BITOUN, P: 2781
BLINDBÆK, SL: F032
BLOOM, P: 2123
BOBAT, H: F048
BODAGHI, B: 1335, 2335
BOLLAERTS, I: 4454
BONO, V: 1127, S053
BORRUAT, F: 3134
BOULADI, M: T088, T089
BOYCHUK, I: T066
BREMONT-GIGNAC, D: 2662, 2753, 3354, T043
BRON, A: 1552, 1583
BULLOCK, J: 3674
BURIN DES ROZIERS, C: 2361
BUSHUYEVA, N: T049
CABRÉ ESTIVILL, E: 3645, S083
CALVAS, P: 2782
CANADAS SUAREZ, P: S009
CARDIGOS, J: 1186, 1541
CARELLI, V: 2322, 3171
CARTA, A: T050
CASPERS, S: S024
CASSIMAN, C: 4455
CASSOUX, N: 2344, 3546
CASTELO-BRANCO, M: 3582, T056
CAJOLLE, JP: 2342
CELLINI, M: F045
CHAMMAS, J: 3585, S078
CHANG, HR: T052
CHARLIER, J: T045
CHATZIRALLI, I: 4112, F030, F046
CHOTARD, G: F052

One letter and three digit numbers refer to posters

X  X  X  X

Day | Order in the postersession

Four digit numbers refer to oral presentations

X  X  X  X

Day | Timeslot  | Hall  | Order in session
<table>
<thead>
<tr>
<th>Author</th>
<th>ID(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>MANSOURI, K</td>
<td>3132</td>
</tr>
<tr>
<td>MANTEL, I</td>
<td>3135</td>
</tr>
<tr>
<td>MANZAR, H</td>
<td>F001</td>
</tr>
<tr>
<td>MARCO MONZON, S</td>
<td>F062</td>
</tr>
<tr>
<td>MARKOMICHELAKIS, N</td>
<td>1132, 1332, 2432</td>
</tr>
<tr>
<td>MARTIN, G</td>
<td>2364</td>
</tr>
<tr>
<td>MATHUR, R</td>
<td>2314</td>
</tr>
<tr>
<td>MATHYSSEN, S</td>
<td>4157</td>
</tr>
<tr>
<td>MAUGET-FAYSSE, M</td>
<td>1314</td>
</tr>
<tr>
<td>MCCARTY, C</td>
<td>2181</td>
</tr>
<tr>
<td>MCCLOSKEY, C</td>
<td>1112</td>
</tr>
<tr>
<td>MCNAUGHT, A</td>
<td>2622</td>
</tr>
<tr>
<td>MEIER-GIBBONS, F</td>
<td>1322</td>
</tr>
<tr>
<td>MEKIKI, MB</td>
<td>2372, 2386, S002, T057</td>
</tr>
<tr>
<td>MENG, W</td>
<td>2182</td>
</tr>
<tr>
<td>MERCIECA, K</td>
<td>2623, 4425</td>
</tr>
<tr>
<td>MEREDITH, P</td>
<td>3185, T072</td>
</tr>
<tr>
<td>MERMOUD, C</td>
<td>2725</td>
</tr>
<tr>
<td>MESQUIDA, M</td>
<td>3145</td>
</tr>
<tr>
<td>MICHALEWSKA, Z</td>
<td>3113, 3511</td>
</tr>
<tr>
<td>MICHON, F</td>
<td>2763</td>
</tr>
<tr>
<td>MIERE, A</td>
<td>1382</td>
</tr>
<tr>
<td>MIKHAILOVA, A</td>
<td>2764</td>
</tr>
<tr>
<td>MIKKESEN, LH</td>
<td>4146</td>
</tr>
<tr>
<td>MOHAN, R</td>
<td>3373</td>
</tr>
<tr>
<td>MOONS, L</td>
<td>3625</td>
</tr>
<tr>
<td>MORA, P</td>
<td>3183</td>
</tr>
<tr>
<td>MORGAN, I</td>
<td>2742</td>
</tr>
<tr>
<td>MOULIN, A</td>
<td>2151, 2155</td>
</tr>
<tr>
<td>MOURIAX, F</td>
<td>2345</td>
</tr>
<tr>
<td>MOUSAVI, M</td>
<td>S028</td>
</tr>
<tr>
<td>MRAZOVAC, D</td>
<td>T014</td>
</tr>
<tr>
<td>MUNK, SAJ</td>
<td>3352</td>
</tr>
<tr>
<td>MURALI, A</td>
<td>1558, T015</td>
</tr>
<tr>
<td>MURPHY, R</td>
<td>1116, 1374, F021, F022</td>
</tr>
<tr>
<td>NADAL, J</td>
<td>3334</td>
</tr>
<tr>
<td>NAGYMIHALY, R</td>
<td>1371</td>
</tr>
<tr>
<td>NAHAS, S</td>
<td>S025</td>
</tr>
<tr>
<td>NANDROT, E</td>
<td>2171</td>
</tr>
<tr>
<td>NÄTTINEN, J</td>
<td>1153</td>
</tr>
<tr>
<td>NAU, A</td>
<td>2374, 3572</td>
</tr>
<tr>
<td>NAU, C</td>
<td>3574</td>
</tr>
<tr>
<td>NAVARRO, R</td>
<td>2744</td>
</tr>
<tr>
<td>NAZARALLI, S</td>
<td>T038</td>
</tr>
<tr>
<td>NERI, P</td>
<td>1133, 1531, 2132, 2634, 2731, 3535</td>
</tr>
<tr>
<td>NEUMANN, B</td>
<td>3525</td>
</tr>
<tr>
<td>NEVES, AC</td>
<td>1564, F086</td>
</tr>
<tr>
<td>NORMANDO, EM</td>
<td>1521, 2325</td>
</tr>
<tr>
<td>NUBILE, M</td>
<td>3634</td>
</tr>
<tr>
<td>NUMMI, K</td>
<td>4141, S080</td>
</tr>
<tr>
<td>NYMARK, S</td>
<td>2172</td>
</tr>
<tr>
<td>OBIS, J</td>
<td>F054, T028</td>
</tr>
<tr>
<td>OHLENDORF, A</td>
<td>2741</td>
</tr>
<tr>
<td>ORDUNA HOSPITAL, E</td>
<td>F033, T024, T031</td>
</tr>
<tr>
<td>OSBORNE, N</td>
<td>1365</td>
</tr>
<tr>
<td>OSHITARI, T</td>
<td>F072</td>
</tr>
<tr>
<td>OZCAN, AA</td>
<td>2433</td>
</tr>
<tr>
<td>OZDEK, SO</td>
<td>2713, 3112</td>
</tr>
<tr>
<td>PANFOLI, I</td>
<td>1556, T008</td>
</tr>
<tr>
<td>PANTALON, A</td>
<td>1126, 4124, 4127, S052, S069</td>
</tr>
<tr>
<td>PAPADAKIS, M</td>
<td>3675</td>
</tr>
<tr>
<td>PAPADIA, M</td>
<td>3531</td>
</tr>
<tr>
<td>PAPASTEFANOU, V</td>
<td>4116</td>
</tr>
<tr>
<td>PAPPAS, G</td>
<td>3314</td>
</tr>
<tr>
<td>PAQUES, M</td>
<td>1384, 2353</td>
</tr>
<tr>
<td>PARK, JM</td>
<td>F060</td>
</tr>
<tr>
<td>PARSA, C</td>
<td>3335</td>
</tr>
<tr>
<td>PATERNO, J</td>
<td>1575, T007</td>
</tr>
<tr>
<td>PERDICES, L</td>
<td>F073, F082</td>
</tr>
<tr>
<td>PEREZ CARRASCO, MJ</td>
<td>T063</td>
</tr>
<tr>
<td>PETROVSKI, G</td>
<td>1573</td>
</tr>
<tr>
<td>PICAUD, S</td>
<td>1363</td>
</tr>
<tr>
<td>PICH, F</td>
<td>1535, 2134, 2633</td>
</tr>
<tr>
<td>PIMENTA, G</td>
<td>S065, S066</td>
</tr>
<tr>
<td>PINNA, A</td>
<td>F006</td>
</tr>
<tr>
<td>PINTO FERREIRA, N</td>
<td>S048</td>
</tr>
<tr>
<td>PINTO PROENÇA, R</td>
<td>3341</td>
</tr>
<tr>
<td>PIRANI, V</td>
<td>3551</td>
</tr>
<tr>
<td>POPA CHERECHEANU, A</td>
<td>1192, F025</td>
</tr>
<tr>
<td>POSTOLACHE, L</td>
<td>4451</td>
</tr>
<tr>
<td>POURNARAS, C</td>
<td>1316, 2114, 3315</td>
</tr>
<tr>
<td>POURNARAS, J-A</td>
<td>2712, 3133, 3312, 4111</td>
</tr>
<tr>
<td>PUELL, M</td>
<td>F050, T067</td>
</tr>
<tr>
<td>QING, Z</td>
<td>S059</td>
</tr>
<tr>
<td>QUINLAN, R</td>
<td>3684</td>
</tr>
<tr>
<td>RAMA, P</td>
<td>3323</td>
</tr>
<tr>
<td>RAMIREZ, AI</td>
<td>S067</td>
</tr>
<tr>
<td>RAMIREZ, JM</td>
<td>4126, S068</td>
</tr>
<tr>
<td>RAMLOGAN-STEEL, C</td>
<td>2787, F004</td>
</tr>
<tr>
<td>RANTA-AHO, S</td>
<td>1376, T004</td>
</tr>
<tr>
<td>RATNARAJAN, G</td>
<td>2724</td>
</tr>
<tr>
<td>RAVESH, Z</td>
<td>2681</td>
</tr>
<tr>
<td>RENAUDT, D</td>
<td>S007</td>
</tr>
<tr>
<td>REZKALLAH, A</td>
<td>1115, F056</td>
</tr>
<tr>
<td>RICHER, S</td>
<td>2164</td>
</tr>
<tr>
<td>RIMPALÄ, A</td>
<td>1562</td>
</tr>
<tr>
<td>ROBLAIN, Q</td>
<td>4458</td>
</tr>
<tr>
<td>ROBSON, A</td>
<td>2162</td>
</tr>
<tr>
<td>ROCHA DE SOUSA, A</td>
<td>3182, F085</td>
</tr>
<tr>
<td>ROJAS LOZANO, MP</td>
<td>T033</td>
</tr>
<tr>
<td>ROMANOWSKA DIXON, B</td>
<td>F010, S079</td>
</tr>
<tr>
<td>ROMERO SANZ, M</td>
<td>S015</td>
</tr>
<tr>
<td>ROQUANCOURT, T</td>
<td>S055</td>
</tr>
<tr>
<td>ROSENBLETT, M</td>
<td>2373, 2375</td>
</tr>
<tr>
<td>ROSENSVÄRD, A</td>
<td>3165</td>
</tr>
<tr>
<td>ROTHSCCHILD, P</td>
<td>2363</td>
</tr>
<tr>
<td>ROUGIER, M</td>
<td>1383</td>
</tr>
<tr>
<td>ROUSSEAU, A</td>
<td>1585, 3123</td>
</tr>
</tbody>
</table>
ROUX, L: 2673
ROUX, M: 1351
ROZEMA, J: 2743, 3333
RUBAN, A: 3513
RUSSO, R: 3521
SADUN, A: 2671
SAGON, M: F042
SAHRARAVAND, A: 2785, F002
SAID, D: 3322
SALOBRAR-GARCIA, E: 4126, T020, T021
SANCHEZ RAMON, A: 1566, F088
SANTIAGO, R: 3622
SANTONOCITO, M: F074
SAROSSY, M: T064
SAUER, A: 2664
SCHAEFFEL, F: 2745
SCHALENBURG, A: 2654, 3541
SCHMETTERER, L: 1581, 2211, 2352
SCHMIDL, D: 1145
SCHOLL, H: 4211
SEBASTIANI, S: F077
SEDLAK, L: F067
SEMINA, E: 1164
SEPETIS, A: 3563
SERDAREVIC, O: 1182
SERGEYS, J: 4159
SERGOUNIOTIS, P: 1355
SHERAWY, T: 2722
SHAH, S: 3363
SHEARDOWN, H: 2142
SHIELDS, C: 1711, 2341, 2652
SHIN, Y: F049
SHORTT, A: 3324, S030
SITIWIN, E: 3345
SJÖSTRAND, J: T055
SMEDOWSKI, A: S026
SODERBERG, P: 1122
SOJKA-LESZCZY_SKA, P: T090
SOUIDED, E: 1111, 1381, 2351
SOUSA, C: 2772
SPENCER, F: 2624
SRIVASTAVA, S: 1534
STACHS, O: 2381
STANGOS, A: 3311
STANISZEWSKI, B: T081
STAPPLER, T: 2714
STEFANSSON, E: 2613, 3144
STEN, LB: S008
STIEGER, K: 4414
STOLIARENKO, G: 3512
STORSBERG, J: T076
STRUPAITE, R: 2686, F017
SUMMANEN, P: S057
SUNARIC MEGEVAND, G: 1321
SZAFLIK, JP: 4128, S070
SZENTMARY, N: 3554, 4135
TAGAMI, M: T046
TAKEISHI, M: T058
TAO, C: 2786, F005
TASSIGNON, MJ: 3162
TEIXEIRA, F: 1121, 4145
THOMPSON, D: 3154
THURET, G: 1341, 1546, S005
TORDT, TL: F047
TOUHAMI, S: 2332
TRANOS, P: 2711
TROMPOUKIS, C: 3673
TRZECIECKA, A: F083, S019
TSAKPINIS, D: 2716
TURUNEN, J: 2788, F019
UDZIELA, M: F020
URTITI, A: 2144
UUSITALO, H: 1154, 1572
UZUNOV, R: 3567, S043, S045
VABRE, L: 3633
VALLEIX, S: 2661, 3163
VAN ACKER, S: 4151
VAN DE SOMPELE, S: 4154
VAN DEN BOGERD, B: 4152
VAN GENTERDEUREN, R: 2152, 2154
VAN HOVE, I: F075
VAN KEER, K: T023
VAN LOOVEREN, J: 3164
VANDEWALLE, E: 4423
VARMA, D: 2723
VAUDAUX, J: 3136
VEIBY, N: F003
VELISSARIS, S: 2684
VERHELST, E: 1190
VERLY, E: T077
VERMA, S: 4433
VERSURA, P: 2833
VETTER, M: 3621
VIDAL AROCA, F: S047
VIDAL-SANZ, M: 1364
VILADES, E: T029, T030, T035, T036
VISBY, E: T062
VITTE, J: 3353
VOTRUBA, M: 2672
WAIZEI, M: T073, T087
WERMKEISTER, R: 3661
WILLERMAIN, F: 1331
WILLSHIRE, C: 1542
WISSINGER, B: 3173
WONG, M: 2312, S019
WONG, SC: 4412
WONG, T: 2356
PRESENTING FIRST AUTHORS

WYLEGALA, E: 3575, 4132, S031
XIROU, T: 2717, 4113, F059
YAMAGISHI, A: S082
YEHEZKEL, O: T054
YEKTA, AA: F007, F008
YU JEAT, C: 1518, F041
YU-WAI-MAN, P: 3653
ZAMBARAKJI, H: 4114
ZHANG, X: 1163
ZOGRAFOS, L: 1315, 2115, 2348, 2651, 3544
All authors of abstracts are listed alphabetically

One letter and three digit numbers refer to posters
Four digit numbers refer to oral presentations
The digit numbers marked in bold indicate a first author abstract

AALKJAER, C: F069
AAPOLA, U: 2174
ABABID, V: 2364
ABBASI, M: 4212
ABELANIA, E: F033
ABEÇÂO, PINTÔ: L: 1121, 2625, 4421, 1123, 3186, 3561, 3562, F029, S048, S065, S066, T023, T084
ABERDAM, D: 2673
ABRAHAMS, RAVIV, L: F079
ABROUG, N: 2133
ACAR, A: 1552, 4211, 3114
ACHA, J: F033
ACOSTA, MC: 3141, 4434, S013, S008
ACQUART, S: 1544, T016
ADAMS, D: 3123
ADAMS, MKM: 1516, F039
ADORNETTO, A: 3521
AFLI, N: 1512
AGARD, E: 1115, 3546, 3581, F056, S051
AGUDO-BARRIOSO, M: 1364
AHMED, F: 2122
AHMED, I: 3643
AINSBURY, E: 3682
AIRES, ID: 3622
AJELETTI, MO: F076
AJOY, D: 4125, 4126, S039, S068
AJKO, K: F014
AL-AQABA, M: 3321
AL-ATAWI, S: S074
ALATAR, S: 1553
ALBERTOS, H: 2173
ALBINI, T: 1532, 2632
ALBON, J: S074
ALBUSSON, E: 2364
ALDIGIERI, R: 2674
ALI, SB: F007, F008
ALJAHMAD, B: T064
ALIO SANZ, J: 3364
ALLEN, C: F066
ALLGEIER, S: 3122
ALMUTAIRI, R: S023
ALONSO-ALONSO, ML: F071
ALUKO, P: 2311
ALVAREZ DE TOLEDO, J: 4134
ALVES-FARIA, P: 3182
ALVES, N: 1541
ALZAHRAHI, K: S020, S034
AMADIO, M: T001
AMAR, T: S029
AMARIE, O: 2783, 1353
AMATI-BONNEAU, P: 3172
AMATO, R: F084, F064, F065
AMBRESIN, A: 1514, 2111, 3131, 3381
AMBRÓSIO, AF: 1564, 3622, F086
AMBROZAITYTE, L: 2686, F017
AMELOOT, F: 1113
AMIOOT, C: 1351
AMIRKAVI, M: T005
AMMAR, M: T039
AMMARI, M: F037
ANAND, N: 4422
ANANIKAS, K: F046
ANDERSEN, MK: 4146
ANDERSON, K: 2671
ANDERSON, S: 3621
ANDJELIC, S: S072
ANDOLLO, N: S011
ANDRÉ, H: 1343, 1553, T010, T011, 1555, T012
ANDREIA, P: T056
ANDREZZO, G: 3155, 2883, T015
ANGI, M: 3643, 2732
ANGIOI-DUPRÉZ, K: 3568, S044
ANKUDINOV, A: T059
ANSAR, M: 2681
ANSARI, E: 3565, S042
ANTOVOSVA, B: 1152
APTEL, F: S055, S046
ARACIL, A: S013
ARBA-MOSQUIERA, S: 4433
ARCHER, TJ: S022
ARDAN, T: T381
ARES-SUAREZ, D: 4434
ARJOLUD, L: 2685
ARONSSON, M: 1555, T012
ARRoyo-DEL ARROYO, C: S009
ASCHINGER, G: 3662
ASHWORTH, J: 1355
ASOKLIS, R: 3573, 2686, F017, S050, S061
ATALAY, HT: 3583
ATILLA, H: 2362, 2663
ATKINSON, M: 3681
AU, L: 4424
AUGUSTIN, S: 2332
AVISÉS-TRIGUEROS, M: S068
AYALA-AYERBES, M: F050, T063
AZIMI, A: F007
AZIMZADEH, O: 3681
AZUMI, A: T046
BABA, T: F072
BACHBIA, N: 1189
BABINI, G: 3683
BACO DAIAN, D: 2781
BAGETTA, G: 3521
BAGGERMAN, G: 3164
BAH, MO: 3181
BAILLEUL, H: S064
BALDUCCI, C: F070
BALENDRA, S: 3185, 3563, T072, 3184
BAMBÓ RUBIO, MP: T032, T037
BAPTISTA, F: 1564, F086
BARATA, A: 4145, S048, S066, 1517, F040, S060, T025
BARBEAUX, P: F075
BARBONI, P: 2674, 3654, 2321, 3651
BARBOSA-BREA, J: T023, 1123, 2771, 4452, F085
BARBUR, J: 2165
BARBUR, JL: 3332, 3331
BARCELÓS, F: 1541
BARJOU, A: 2361
BARNARD, S: 3682
BÁRÓ, R: 5262
BARRAUER, RL: 4134, S073, 3161
BARTOLOME SÉNÉSÉ, I: S016
BARTOLOME SESE, FI: F013, F062, F063, S076, T079
BARTOLOME SESE, MI: F016, T060
BARTOLOME SESE, S: T085
BARTOLOME, I: 3566, S041, S056, F080, T074
BASILO, A: 1186
BASTIAN, A: 1192
BATA, A: 1145
BATELLIER, L: 3353
BATES, D: F066, F081, 2611
BATES, DO: 2612
BATISTA, S: 1513
BATSON, J: F066, F081, 2612
BATOS, G: F024, F026
BAUDOUIN, C: 3123, 3124
BAUMANN, B: 3664
BAUWENS, M: 4156
BAYE, A: 3353
BEAUJEAU, A: 1555, T012
BECK, S: 3522
BECKERS, A: 3625
BEGUIER, F: 2332
BEHEAEGEL, J: 4456
BEHAR-COHEN, F: 2141
BEIRNE, K: 2672
BEK, T: 1378, F069, T017, 1141, 1142
BELAOUDEM, R: 2372
BELKIN, M: T054
BELL, J: S074
BEL, K: 3522
BELMONTE, C: 4434
BEN ABDEHRAHIM, K: 1183
BEN AMOR, H: 3533
BEN LASSOUED, O: F015
BENABDERRAHIM, K: 1193
BENMALEK, A: 3123
BENNEJAI, S: S081
BENZACKEN, B: 2781
BERAUD, G: S064
BERGANDI, F: T016
BERGIN, C: 1514
BERNARDELLI, M: 2361
BERNADES, R: 1173, 1513
BERROD, JP: 1113, 3568, S044
BERRY, M: 1182
BEGSEN, V: 2383
BETTENCOURT, S: F029
BEUERMAN, R: 2174, 1151, 2762
BEUGNET, C: 2661, 3163
BHATTACHARYA, SK: F083, S019
BHATTACHARYA, SS: 2511
BIANCHI-MARZOLI, S: 2674
BIGNAMI, F: 3142
ALL AUTHORS

WISLOFF, T: F028
WISSINGER, B: 2681, 3173
WITKOWSKA, K: 1145
WOJNAR, W: F007
WOLF, S: 1511, 2323
WOLFF, B: 1314
WONG, C: 3565, S042
WONG, D: 2714
WONG, EY: 2314
WONG, M: 2312, S019
WONG, SC: 4412
WONG, T: 2356
WONG, TY: 2314, S019
WOZNIAK, P: 1145
WROBEL, A: 3344
WURST, W: 3681
WYGLEDOWSKA-PROMIENSKA, D: F067
WYLEGALA, A: 3575, 4132
WYLEGALA, E: 3575, S026, 4132, S031
XIROU, T: F057, 2717, 4113, F059
YAHIAOUI, S: 2372
YAM, R: T054
YAMAGISHI, A: S082
YAMAKI, K: F014
YAMAMOTO, S: F072, S082, T058
YEHEZKEL, O: T054
YEKTA, AA: F007, F008
YILMAZ, NS: 3583
YU JEAT, C: 1518, F041
YU-WAI-MAN, P: 3653
YUBERO, R: T021
YUSUF, A: F001
ZAHAVI, O: T027
ZAJICCOVA, A: 1377, 4431, T013
ZAKARIA, N: 3333
ZAKIR, R: 2684
ZAMBARAKJI, H: 4114
ZAPPULLA, C: F074
ZARZOSA MARTIN, E: 1566, F088
ZASA, G: F027
ZELENTSOV, K: T059
ZELENTSOV, S: T059
ZHANG, J: 2142
ZHANG, X: 2786, F005, 1163
ZHANG, Y: 1557, T009
ZHAO, B: T048
ZHAO, Y: 1165
ZHENG, D: 1165
ZHOU, L: 2762
ZINA, S: 1183
ZINKERNAGEL, MS: 1511, 2323, 2331, T070
ZITZELSBERGER, H: 3681
ZOGRAFOS, L: 2651, 3342, 4144, 1315, 2115, 2348, 3544
ZOLTÁN NAGY, Z: 1184
ZSOLT NAGY, Z: 1185
ZYCH, M: F067
<table>
<thead>
<tr>
<th>Country</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALGERIA</td>
<td>2</td>
</tr>
<tr>
<td>AUSTRALIA</td>
<td>11</td>
</tr>
<tr>
<td>AUSTRIA</td>
<td>8</td>
</tr>
<tr>
<td>BELGIUM</td>
<td>24</td>
</tr>
<tr>
<td>CANADA</td>
<td>8</td>
</tr>
<tr>
<td>CHINA</td>
<td>3</td>
</tr>
<tr>
<td>CROATIA</td>
<td>2</td>
</tr>
<tr>
<td>CZECH REPUBLIC</td>
<td>6</td>
</tr>
<tr>
<td>DENMARK</td>
<td>14</td>
</tr>
<tr>
<td>EGYPT</td>
<td>1</td>
</tr>
<tr>
<td>FINLAND</td>
<td>24</td>
</tr>
<tr>
<td>FRANCE</td>
<td>72</td>
</tr>
<tr>
<td>GERMANY</td>
<td>25</td>
</tr>
<tr>
<td>GREECE</td>
<td>11</td>
</tr>
<tr>
<td>HUNGARY</td>
<td>2</td>
</tr>
<tr>
<td>ICELAND</td>
<td>1</td>
</tr>
<tr>
<td>INDIA</td>
<td>1</td>
</tr>
<tr>
<td>IRAN</td>
<td>2</td>
</tr>
<tr>
<td>IRELAND</td>
<td>2</td>
</tr>
<tr>
<td>ISRAEL</td>
<td>1</td>
</tr>
<tr>
<td>ITALY</td>
<td>32</td>
</tr>
<tr>
<td>JAPAN</td>
<td>7</td>
</tr>
<tr>
<td>LITHUANIA</td>
<td>4</td>
</tr>
<tr>
<td>MEXICO</td>
<td>1</td>
</tr>
<tr>
<td>NETHERLANDS, THE</td>
<td>3</td>
</tr>
<tr>
<td>NORWAY</td>
<td>4</td>
</tr>
<tr>
<td>POLAND</td>
<td>14</td>
</tr>
<tr>
<td>PORTUGAL</td>
<td>16</td>
</tr>
<tr>
<td>QATAR</td>
<td>1</td>
</tr>
<tr>
<td>ROMANIA</td>
<td>2</td>
</tr>
<tr>
<td>RUSSIA</td>
<td>4</td>
</tr>
<tr>
<td>SINGAPORE</td>
<td>3</td>
</tr>
<tr>
<td>SLOVENIA</td>
<td>1</td>
</tr>
<tr>
<td>SOUTH-KOREA</td>
<td>20</td>
</tr>
<tr>
<td>SPAIN</td>
<td>35</td>
</tr>
<tr>
<td>SWEDEN</td>
<td>9</td>
</tr>
<tr>
<td>SWITZERLAND</td>
<td>24</td>
</tr>
<tr>
<td>THE NETHERLANDS</td>
<td>1</td>
</tr>
<tr>
<td>TUNISIA</td>
<td>6</td>
</tr>
<tr>
<td>TURKEY</td>
<td>5</td>
</tr>
<tr>
<td>UKRAINE</td>
<td>3</td>
</tr>
<tr>
<td>UNITED ARAB EMIRATES</td>
<td>2</td>
</tr>
<tr>
<td>UNITED KINGDOM</td>
<td>67</td>
</tr>
<tr>
<td>UNITED STATES</td>
<td>23</td>
</tr>
</tbody>
</table>
SPONSORS AND EXHIBITORS

GOLD SPONSOR

SILVER SPONSOR

APP SPONSOR

CIS SPONSOR - INDUSTRY SPONSORED SYMPOSIUM

SIS SPONSORS - SPECIAL INTEREST SYMPOSIA

EXHIBITORS

THANK YOU